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8Summary
This report is the fifth national report on the performance of the National Cervical Screening
Program in Australia. Cervical screening services are provided as part of mainstream health
services with general practitioners performing approximately 80% of Pap smears. The
program is funded by Medicare, the Australian Government, and the state and territory
governments.
There is a set of performance monitoring indicators agreed to by the National Advisory
Committee to the program. This report presents statistics on the monitoring undertaken. The
main features of the report are summarised below.
Participation
• The total number of women who participated in cervical screening in 2000–2001 was
3,314,787 of whom 3,244,329 (98%) were in the screening program target age group of
20–69 years. This represented an increase of 16,621 in the number of women screened in
1999–2000.
• Between the periods 1999–2000 and 2000–2001 the proportion of women in the target
population (women aged 20–69 years) participating in cervical screening declined from
62.6% to 61.8%.
• Participation in screening declined in all 5-year age groups within the target population
between 1999–2000 and 2000–2001 except for the youngest (20–24) and oldest (65–69) age
groups which each showed a slight increase. The largest decline was in women in their
thirties —decreasing from 67.0% to 64.9% for women aged 30–34 years and from 68.7% to
67.1% for women aged 35–39 years.
Early re-screening
• The recommended screening interval is 2 years following a negative smear. Of a cohort of
women screened in February 2000 who had a negative Pap smear result, 32% screened
again within 21 months. It is not known what proportion of this early re-screening is
justified on clinical grounds.
Detection of abnormalities
• A low-grade abnormality includes atypia, warty atypia, possible cervical intraepithelial
neoplasia (CIN), equivocal CIN, and CIN 1, and a high-grade abnormality is defined to
include CIN 1/2, CIN 2 and CIN 3 or adenocarcinoma in situ. The ratio of histologically
confirmed low-grade abnormalities to high-grade abnormalities was 1.3 for Australia in
2001, the same as in 2000. The 2001 ratio did not include data for the Northern Territory.
• In 2001, the National Cervical Screening Program detected 13,555 women in the target
age group 20–69 years with high-grade abnormalities. The number of high-grade
abnormalities was highest in the younger age groups. For women under 35 years of age,
the rate of high-grade abnormalities was over 10 per 1,000 women screened whereas it
was less than 2 per 1,000 women aged 50 years and over.
9Incidence and mortality
• The number of new cases of cervical cancer in Australia has continued to decline. There
were 745 new cases in Australia in 2000 compared with 1,072 detected in 1989.
• Cervical cancer is the 15th most common cause of cancer mortality in women, accounting
for 262 deaths in 2001. Although there was some fluctuation from year to year, the age-
standardised mortality rate from cervical cancer declined. For all women aged 20 years
and over there was a decline of 5.9 per 100,000 women in 1982 to 2.8 per 100,000 in 2001.
During the same period, for women in the target age group of 20–69 years the rate
declined from 5.1 per 100,000 to 2.4 per 100,000. The mortality rate also declined for
women aged 70 years and over from 2.7 per 100,000 in 1982 to 1.1 per 100,000 in 2001.
• Women in the target age group from remote locations experienced a relatively high
mortality rate from cervical cancer—3.0 deaths per 100,000 compared with
2.3 deaths per 100,000 women in metropolitan areas. However, between the periods
1994–1997 and 1998–2001, the age-standardised cervical cancer mortality rate declined in
all regions (metropolitan, rural and remote).
• Prior to 1998, only Western Australia, South Australia and the Northern Territory had
Indigenous mortality registration data of sufficient quality to be publishable. In 1998,
Queensland’s coverage of Indigenous deaths reached an acceptable level to be included
in the analysis of Indigenous mortality data. For these jurisdictions, in the period
1998–2001 there were 20 deaths from cervical cancer among Indigenous women in the
target age group (an age-standardised mortality rate of 11.4 per 100,000 women). This is
more than four times the corresponding rate in non-Indigenous women (2.5 per 100,000).
Compared with the 1996–1999 mortality rate for Indigenous women in the target age
group, which was 9.8 per 100,000, there was an increase in mortality in the 1998–2001
period. However, these rates are based on relatively small numbers of cases and may be
subject to large variability. Despite the relatively large size of the apparent increase in the
rate, it is still within the range of variation that would be expected due to chance.
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National cervical screening
monitoring indicators
This report monitors the performance of the National Cervical Screening Program using 10
indicators which measure program activity, performance and outcome. They help measure
changes in disease patterns and examine the contribution health interventions may have in
preventing or reducing deaths. They can also be used to help evaluate screening or other
health interventions.
Screening indicators for the National Cervical Screening Program cover the areas of
participation, early re-screening, low- and high-grade abnormality detection, incidence and
mortality. These have been endorsed by the National Advisory Committee and state and
territory cervical screening programs. Indicators are reviewed annually and, in this report,
definitions of Indicators 2 and 5 have been changed compared with the definitions used in
previous reports.
A listing of the 10 indicators and their definitions follows. The target age group for the
National Cervical Screening Program is 20 to 69 years.
Indicator 1: Participation rate for cervical screening
Percentage of women screened in a 24-month period by 5-year age groups (20–24, 25–29,
30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69), for all ages (20–80+) and the target
age group (20–69 years).
Indicator 2: Early re-screening
Proportion of women re-screened by number of re-screens during a 21-month period
following a negative smear.
Indicator 3: Low-grade abnormality detection
Number of women with a histologically verified low-grade intraepithelial abnormality
detected in a 12-month period as a ratio of the number of women with a histologically
verified high-grade intraepithelial abnormality detected in the same period.
Indicator 4: High-grade abnormality detection
Detection rate for histologically verified high-grade intraepithelial abnormalities per 1,000
women screened in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39,
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age
group (20–69 years, age-standardised).
Indicator 5: Incidence of micro-invasive squamous cell carcinoma
Incidence rate of micro-invasive squamous cell carcinoma per 100,000 estimated resident
female population in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39,
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age
group (20–69 years, age-standardised).
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Indicator 6: Incidence of squamous, adenocarcinoma, adeno-squamous and
other cervical cancer
Incidence rate of squamous, adenocarcinoma, adeno-squamous and other cervical cancers
per 100,000 estimated resident female population in a 12-month period by 5-year age groups
(20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+)
and for the target age group (20–69 years, age-standardised).
Indicator 7: Mortality
Death rate from cervical cancer per 100,000 estimated resident female population in a
12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years, age-
standardised).
Periodic indicators
Periodic indicators have been developed to report on issues that are of importance in
monitoring the outcomes of the cervical screening program over a longer period of time than
1 year. This longer period allows for a greater aggregation of information on issues that are
subject to wide annual fluctuations and for a more confident and meaningful estimate of the
outcomes. The periodic indicators presented in this report are based on a reporting period of
4 years.
Periodic incidence and mortality indicators by location
Indicator 8: Incidence by location
Incidence rate of cervical cancer per 100,000 estimated resident female population in a 4-year
period by location and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years, age-
standardised).
Indicator 9: Mortality by location
Death rate from cervical cancer per 100,000 estimated resident female population in a 4-year
period by location  and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years, age-
standardised).
Postcode and statistical local area information for incidence and mortality are routinely
collected at the point of diagnosis or death. These data have been classified using the Rural,
Remote and Metropolitan Areas classification (RRMA). This classification was developed in
1994 by the then Department of Primary Industries and Energy and the then Department of
Human Services and Health as a framework by which various data sources could be
analysed for metropolitan, rural and remote zones. The RRMA groups are classified
according to Statistical Local Area based on the Australian Standard Geographical
Classification (ASGC) version 2.1 (DPIE & DHSH 1994). Concordance algorithms have been
developed to convert statistical local area information coded according to earlier and later
ASGC versions into rural, remote and metropolitan area groupings.
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Table 1: Structure of the Rural, Remote and Metropolitan Areas classification
Zone Category
Metropolitan zone Capital cities
Other metropolitan areas (urban centre population > 100,000)
Rural zone Large rural centres (urban centre population 25,000–99,999)
Small rural centres (urban centre population 10,000–24,999)
Other rural areas (urban centre population < 10,000)
Remote zone Remote centres (urban centre population > 5,000)
Other remote area (urban centre population < 5,000)
Source: DPIE & DHSH 1994.
Indicator 10: Indigenous mortality
Death rate from cervical cancer per 100,000 estimated resident female population in a 4-year
period by Indigenous status and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49,
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69
years, age-standardised).
This indicator examines the patterns of mortality among Indigenous women.
Identification of Indigenous status is still very fragmented and generally of poor quality in
health data collections, and cervical screening data are no exception. Of the seven cervical
screening indicators, only one indicator can be stratified by Indigenous status: mortality.
Even for this, coverage is not complete. Only Western Australia, South Australia, the
Northern Territory and Queensland are currently considered to have adequate coverage of
Indigenous deaths in the registration of deaths. Therefore, only mortality data from these
jurisdictions are analysed in this report.
Confidence intervals
Where indicators include a comparison between states and territories, between time periods,
between geographic locations or between Indigenous and non-Indigenous women, a 95%
confidence interval is presented with the rates. This is because the observed value of a rate
may vary due to chance even where there is no variation in the underlying value of the rate.
The 95% confidence interval represents a range over which variation in the observed rate is
consistent with this chance variation. These confidence intervals can be used as an
approximate test of whether changes in a particular rate are consistent with chance variation.
Where the confidence intervals do not overlap, the change in a rate is greater than that which
could be explained by chance. Where the intervals do overlap, then changes in the rate may
be taken as approximately consistent with variability due to chance.
For example, the participation rate for Victoria in 1999–2000 was 66.2% with a confidence
interval of 66.1% to 66.3%. The corresponding rate for 2000–2001 was 65.3% with a
confidence interval of 65.2% to 65.4%. These two intervals do not overlap, so the difference
between the 1999–2000 and 2000–2001 rates is larger than we would expect due to chance
alone.
Another example is the comparison between cervical cancer mortality rates for women living
in rural and remote areas. In the period 1997–2000 there were 2.4 cervical cancer deaths per
100,000 women living in rural areas. This rate had a confidence interval of 2.1 to 2.8. The
corresponding rate for women in remote areas was 3.7 per 100,000, with a confidence interval
of 2.2 to 5.4. These confidence intervals overlap, so despite the relatively large difference
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between the two observed rates they are still consistent with chance variation. This arises
from the fact that remote areas of Australia have small populations, which leads to small
numbers of deaths from any specific cause, and these death rates may fluctuate from year to
year over time. This in turn leads to relatively wide confidence intervals for an observed
death rate.
It is important to note that this result does not imply that the difference between the two
rates is definitely due to chance. Instead, an overlapping confidence interval represents a
difference in rates which is too small to differentiate between a real difference and one which
is due to chance variation.
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Participation
The major objective of the National Cervical Screening Program is to reduce morbidity and
deaths from cervical cancer by detecting treatable pre-cancerous lesions before their
progression to cancer. Through increased participation, more women with pre-cancerous
abnormalities can be detected and treated before progression to cervical cancer, thus
reducing morbidity. In addition, increased participation will lead to the detection of more
women with early stages of cancer where treatment can reduce mortality.
The program, through a variety of recruitment initiatives, actively targets women in the age
group 20–69 years. The recommended screening interval for women in this target age group
who have been sexually active at any stage in their lives is 2 years. Pap smears may cease at
the age of 70 years for women who have had two normal Pap smears within the previous
5 years. Women over 70 years who have never had a Pap smear, or who request a Pap smear,
are screened.
Some women in the target population are unlikely to require screening. They include:
• those who have had a total hysterectomy with their cervix removed;
• those who have never been sexually active;
• women with a previously diagnosed gynaecological cancer.
Participation rate calculations should, in principle, exclude all three groups from the data. In
practice, the data are adjusted to remove women who have had a hysterectomy but the latter
two groups cannot be excluded due to the lack of reliable data.
State and territory programs have strategic plans in place to increase participation of women
in cervical screening. Such strategies include targeting priority population groups including
Indigenous women, rural and remote women, and women from culturally and linguistically
diverse backgrounds.
The objectives and usefulness of participation as an indicator are outlined below:
• The participation indicator measures the proportion of the target population covered by
the cervical screening program and the current screening policy of a 2-year interval.
• The indicator is important in assessing the contribution of the cervical screening program
to changes in incidence and mortality.
• The indicator can be used as a means of evaluating recruitment practices, particularly if
participation rates are analysed by demographic characteristics.
• When this indicator is used in conjunction with others, it can be used to support analysis
relating to target groups and screening intervals.
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State and territory-specific issues
• Except for Victoria, Western Australia and the Australian Capital Territory, the
participation rates are based on all women who were screened in a state or territory. This
may lead to a small error in the estimation of numbers of women screened because of
double counting of some women between states, difficulty in identifying state of
residence for women in border areas, and inclusion of women resident overseas.
• Victorian rates for the two periods are not comparable because data provided for the
1999–2000 period include non-resident women; in the 2000–2001 period women were
excluded if they were not Victorian residents.
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Indicator 1: Participation rate for cervical screening
Percentage of women screened in a 24-month period by 5-year age groups (20–24, 25–29,
30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the
target age group (20–69 years).
The graphs and tables below refer to the data for the target age group only. For detailed data
refer to Tables 1b and 2b (pages 48 and 50).
Notes
1. Participation rates have been adjusted for the estimated proportion of women who have had a
hysterectomy.
2. These data exclude women who have opted not to be on the register.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 1: Participation rates in the National Cervical Screening Program
by age group, Australia, 1999–2000 and 2000–2001
Age group
2-year
period 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69
(Per cent)
1999–2000 49.5 62.4 67.0 68.7 68.8 67.8 71.3 62.5 56.5 44.2 62.6
2000–2001 50.3 61.4 64.9 67.1 68.1 67.4 70.2 62.1 55.7 45.3 61.8
Note: Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
• The proportion of women in the target age group (20–69 years) participating in cervical
screening fell from 62.6% in 1999–2000 to 61.8% in 2000–2001, a decline that is statistically
significant (Table 2b, page 50).
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• The total number of women screened by the National Cervical Screening Program in
2000–2001 was 3,331,408, an increase of 16,621 (0.5%) over the 1999–2000 reporting period
for all ages. Of the total number screened in 2000–2001, 98% were from the target age
group of 20–69 years (Table 2a, page 49).
• The age-specific participation rate was lower in 2000–2001 than in 1999–2000 in all age
groups with the exception of the youngest and oldest age groups, 20–24 and 65–69
respectively (Tables 1b and 2b, pages 48 and 50).
• The age-specific participation rate was highest in the 50–54 age group with 70.2% of
women screened compared with 45.3% in the 65–69 age group. As in the 1999–2000
reporting period, participation is highest in the age groups 35–39 to 50–54 but declines
sharply thereafter as age increases (Tables 1b and 2b, pages 48 and 50).
• The age group with the largest difference in participation rates between the two periods
was the 30–34 age group where the participation rate was 2.1 percentage points lower in
2000–2001 than in 1999–2000. Conversely, the age groups that experienced the least
change in participation rates were the 45–49 and 55–59 age groups where there was only
a  difference of 0.4 percentage points in both groups (Tables 1a and 2a, pages 47 and 49).
19
Notes
1. Rates are expressed as the percentage of the eligible female population and age-standardised to the
Australian 1991 population.
2. Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
3. Bars on graphs represent 95% confidence intervals.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 2: Participation (age-standardised) in the National Cervical Screening Program
by women aged 20–69 years, states and territories, 1999–2000 and 2000–2001
2-year period/
rate NSW Vic(b) Qld(a) WA(b) SA Tas ACT(b) NT Australia
1999–2000
AS rate 60.2 66.2 59.5 62.8 66.2 65.5 65.1 65.6 62.6
95% CI 60.1–60.3 66.1–66.3 59.3–59.6 62.6–63.1 66.0–66.5 65.0–65.9 64.6–65.7 64.9–66.4 62.5–62.6
2000–2001
AS rate 59.8 65.3 58.1 62.5 66.0 66.6 63.2 62.1 61.8
95% CI 59.7–59.9 65.2–65.4 57.9–58.2 62.3–62.7 65.8–66.3 66.1–67.0 62.6–63.7 61.4–62.7 61.8–61.9
(a) Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
(b) The Vic, WA and ACT registries register women with only a Vic, WA or ACT address respectively.
• The age-standardised participation rate for women screened in the target age group of
20–69 years in 2000–2001 ranged from 58.1% in Queensland to a high of 66.6% in
Tasmania (Table 2b, page 50).
• When compared with the 1999–2000 rates, the rates are lower in all jurisdictions except
Tasmania where there was a statistically significant increase from 65.5% to 66.6% in
2000–2001 (Tables 1b and 2b, pages 48 and 50). The rise in Tasmania was due, at least
partially, to a television advertising campaign.
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Early re-screening
The National Cervical Screening Program seeks to maximise reductions in incidence and
mortality for cervical cancer. The design of the screening program defines two key
parameters for achieving these objectives—target populations and screening intervals.
Compliance with these parameters is crucial to maintaining the effectiveness of the program
and cost efficiency in order that resources may be used to increase population coverage. For
most women who have a negative smear, the recommended interval before their next screen
is 2 years.
This indicator is defined as the repeating of a Pap smear within 21 months of a negative
smear report. Reasons for the choice of 21 months as the time line for reporting are discussed
under ‘Data issues’ below.
This indicator:
• tracks over a period of 21 months a cohort of women from all states and territories who
had a negative smear result in February 2000 to determine the extent of early re-screening
within the National Cervical Screening Program. The exception to this is Queensland
where the index month is March. February was selected as the index month nationally
because it has been shown to be a relatively stable month in terms of the number of
women who are screened. This pattern has been consistent over a number of years, partly
because fewer women take holidays at this time;
• measures the compliance with the recommended screening interval following a negative
smear; and
• is important in assessing screening coverage around the recommended interval, as
significant differences may reduce program effectiveness.
This indicator should be interpreted with caution as some early re-screening after a negative
Pap smear report is appropriate and in accordance with the National Health and Medical
Research Council (NHMRC) guidelines. Specifically, if a woman has a history of
histologically proven high-grade abnormality, then annual screening is recommended. If a
woman is being monitored after treatment or during the resolution phase of a low-grade
abnormality, it is appropriate for her to be screened earlier than the 24 months interval.
Data issues
The data for Indicator 2 published in reports before the Cervical Screening in Australia
1999–2000 report are not directly comparable with the data in this report as this indicator has
been modified to change the follow-up period from 24 months to 21 months. This change has
been made because women often have their Pap smear taken at a time convenient to them
and are likely to have their biennial screening immediately before the 24-month anniversary.
Also for some women, prescriptions for oral contraceptives lapse at 22 months and these
women are then likely to combine their Pap smears with their visit to the GP for renewing
their scripts for contraceptives.
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Indicator 2: Early re-screening
Proportion of women re-screened by number of re-screens during a 21-month period
following a negative Pap smear.
Refer to Table 4 (page 51).
Note: The reference period for this indicator was the 21 months following the index month February 1999
and February 2000.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 3: Proportion of women re-screened by number of screens during the 21-month
period following a negative Pap smear in February 2000, Australia
21-month period 0 screens 1 screen 2 screens 3+ screens
(Per cent)
Feb 1999–Nov 2000 68.0 27.3 3.8 0.9
Feb 2000–Nov 2001 68.1 27.3 3.6 0.9
• A cohort of 168,640 women screened in February 2000 whose smear results were negative
were tracked over a 21-month period to measure the extent of early re-screening. When
compared with the February 1999 cohort, very little difference was observed in the rate of
re-screening women with a negative smear (Tables 3 and 4, page 51).
• Of this cohort, 32% were re-screened (4.5% of these were re-screened more than once)
and 68% did not have any further screens in the 21-month period tracked (Table 4,
page 51).
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Refer to Table 4 (page 51).
Note: The reference period for this indicator was the 21 months following the index month February 2000.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 4: Proportion of women re-screened by number of screens during the 21-month
period following a negative smear in February 2000, states and territories
No. of
screens NSW Vic Qld WA SA Tas ACT NT Australia
(Per cent)
0 screens 68.5 65.0 69.5 67.7 73.9 69.9 70.4 76.2 68.1
1 screen 27.6 29.4 25.6 28.6 22.4 26.4 25.3 18.9 27.3
2 or more 3.9 5.6 4.9 3.7 3.7 3.7 4.4 4.9 4.5
• Of the cohort of women screened in February 2000, over 70% of women whose smear
results were negative in the Northern Territory, South Australia and the Australian
Capital Territory did not have any further screens during the follow-up 21-month period
(Table 4, page 51).
• The proportion of women having additional screens varied among the states and
territories. For example, the Northern Territory experienced the lowest proportion of
re-screens (23.8%) and the highest proportion was in Victoria (35.0%).
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Low-grade abnormalities
The Pap smear test is able to identify a range of abnormalities in cervical cells. Some of these
abnormalities have a greater chance of becoming malignant (the so-called high-grade
abnormalities), and are therefore treated aggressively. The chance of low-grade
abnormalities progressing to malignant change is very much less.
In this report a low-grade intraepithelial abnormality includes:
• atypia;
• warty atypia (human papilloma virus (HPV) effect);
• possible cervical intraepithelial neoplasia (CIN) (see glossary);
• equivocal CIN;
• CIN 1; and
• endocervical dysplasia not otherwise specified (NOS).
The indicator is measured as the ratio of low-grade to high-grade intraepithelial
abnormalities, all histologically verified.
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Indicator 3: Low-grade abnormality detection
Ratio of number of women with a histologically verified low-grade intraepithelial
abnormality detected in a 12-month period to the number of women with a histologically
verified high-grade intraepithelial abnormality detected in the same period.
Refer to Tables 5a and 5b (page 52).
Note: Northern Territory data are not available for 2000–2001.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 5: Ratio of low- to high-grade abnormalities by women aged 20–69 years, states
and territories, 2000 and 2001
Year NSW Vic Qld WA SA Tas ACT NT Australia
(Ratio)
2000 1.4 1.2 1.6 1.7 1.5 1.4 1.2 1.1 1.4
2001 1.4 1.1 1.4 1.5 1.4 1.3 1.2 .. 1.3
.. not available.
• In 2001, the ratio of histologically confirmed low-grade intraepithelial abnormalities to
high-grade intraepithelial abnormalities was lower in all states and territories than in
2000. A comparison cannot be made for the Northern Territory because data for 2001 are
unavailable. (When the Northern Territory data were excluded from the all-Australia
2000 data for comparison purposes, the 2000 national ratio increased from 1.4 to 1.5)
(Tables 5a and 5b, page 52).
• The ratio of low-grade to high-grade abnormalities in 2001 ranged from 1.1 in Victoria to
1.5 in Western Australia.
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High-grade abnormalities
High-grade lesions have a greater probability of progressing to invasive cancer than do low-
grade lesions. Therefore, one of the aims of the National Cervical Screening Program is to set
a screening interval that detects most of these lesions before they progress and become
invasive. This indicator measures the frequency of this type of abnormality in the screened
community. A high-grade intraepithelial abnormality is defined in this report as CIN 1/2,
CIN 2, CIN 3 or adenocarcinoma in situ.
The National Health and Medical Research Council has produced guidelines to assist in the
management of women who have low- and high-grade intraepithelial abnormalities (DHSH
1994b). These are summarised in Appendix F.
State- and territory-specific issues
• The reference period for Indicator 4 was 12 months from January to December 2001 for
all states and territories.
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Indicator 4: High-grade abnormality detection
Detection rate for histologically verified high-grade intraepithelial abnormalities per 1,000
women screened in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39,
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age
group (20–69 years, age-standardised).
The graph and table below refer to the data for the target age group only. For detailed data
refer to Tables 6a and 6b (pages 53 and 54).
Notes
1. Northern Territory data are not available for 2001.
2. The reference period for this indicator is from January to December 2001.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 6: High-grade abnormalities per 1,000 women by age group,
Australia, 2000 and 2001
Age group
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69
(Number per 1,000 women)
2000 16.3 15.5 10.3 6.5 4.5 3.0 1.9 1.5 1.5 1.7 7.4
2001 16.3 15.6 10.1 6.6 4.4 3.0 1.8 1.5 1.5 1.6 7.3
Note: Northern Territory data are not available for 2001.
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• The age-standardised rate of high-grade abnormalities per 1,000 women screened in the
target age group (20–69 years) declined from 7.4 in 2000 to 7.3 in 2001 (Tables 6a and 6b,
pages 53 and 54). Northern Territory data are not available for 2001. However, when the
Northern Territory data are excluded from the 2000 national data there is no change to
the all-Australia rate from 2000 to 2001.
• In 2001, approximately 0.7% of the 1,875,006 women screened in the target age group
(20–69 years) were found to have high-grade abnormalities (Tables 7b and 8b, pages 56
and 58).
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Refer to Tables 9a and 9b (page 59).
Notes
1. The reference period for this indicator is from January to December 2001.
2. Rates are standardised to the 1991 Australian total population.
3. Northern Territory data are not available for 2001.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 7: Age-standardised rate of high-grade abnormalities per 1,000 women
screened aged 20–69 years, states and territories, 2000 and 2001
AS rate NSW Vic Qld WA SA Tas ACT NT Australia
2000 7.6 6.2 9.4 6.5 7.2 10.6 6.8 12.9 7.5
95% CI 7.4–7.8 6.0–6.4 9.0–9.7 6.1–6.9 6.8–7.6 9.7–11.6 5.9–7.7 11.4–14.4 7.4–7.6
2001 7.8 5.9 8.9 8.1 6.8 10.3 7.3 .. 7.5
95% CI 7.6–8.1 5.7–6.1 8.6–9.3 7.7–8.5 6.4–7.3 9.4–11.3 6.4–8.2 .. 7.4–7.6
.. not available.
• In 2001 the age-standardised rate of high-grade abnormalities increased in New South
Wales, Western Australia and the Australian Capital Territory and declined in all other
jurisdictions—the all-Australia rate did not change between 2000 and 2001 (Tables 9a and
9b, page 59).
• In Western Australia the increase between the two reporting periods from 6.5 to 8.1 per
1,000 women screened is statistically significant (Tables 9a and 9b, page 59).
• There are considerable variations in the age-standardised rates of high-grade
abnormalities between the states and territories. They ranged from 5.9 per 1,000 women
in Victoria to 10.3 per 1,000 women in Tasmania.
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Incidence
A major objective of the National Cervical Screening Program is to minimise the incidence of
cervical cancer by detecting treatable pre-cancerous lesions before their progression to
cancer. However, where these pre-cancerous lesions cannot be detected, diagnosis of cancer
at its earliest stage, the micro-invasive stage, is the most desirable alternative. The next two
indicators measure the incidence rates of micro-invasive and all cervical cancers in the
community.
In 1994 the International Federation of Gynaecology and Obstetrics endorsed the following
definition of micro-invasive carcinoma of the cervix:
Stage 1a1. Measured invasion of stroma no greater than 3 mm in depth and no wider than
7 mm.
Stage 1a2. Measured invasion of stroma between 3 mm and 5 mm in depth and no wider
than 7 mm. The depth of invasion should be measured from the base of the
epithelium, either surface or glandular, from which it originates. Vascular space
involvement, either venous or lymphatic, should not alter the staging (Ostor &
Mulvany 1996).
Micro-invasive squamous cell carcinoma makes up the largest share of the micro-invasive
cancers reported in Indicator 5. There are also other forms of micro-invasive cancers such as
adenocarcinoma and adeno-squamous cell carcinoma for which data are not available for
inclusion in this indicator.
In interpreting cervical cancer incidence statistics, note that cervical screening has been
available on an ad hoc basis since the 1960s, but it is only since the late 1980s and early 1990s
that there has been an organised national approach to screening at a population level. The
introduction of cervical screening programs which achieve higher participation rates may
result in the paradox whereby in the short term the number of new cases of micro-invasive
cancer increases because cancers are found earlier than they would have been without
screening, with the rate of more advanced cancers decreasing in the longer term.
For this report the most recent national data available on incidence are for 2000, in contrast to
screening data which are available for 2001. This time lag in availability of incidence data is
expected to reduce over the next 2 years.
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Indicator 5: Incidence of micro-invasive cervical
cancer
Incidence rates of micro-invasive squamous cell carcinoma per 100,000 estimated resident
female population in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39,
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age
group (20–69 years, age-standardised).
The graphs and tables below refer to the data for the target age group only. For detailed data
refer to Table 11 (page 61).
1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
New cases per 100,000
Approximate commencement of the National Cervical
Screening Program
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 8: Age-standardised incidence rates for micro-invasive squamous cell
cancer, women aged 20–69 years, Australia, 1989–2000
1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
(Number per 100,000 women)
AS rate 1.8 2.8 2.9 2.8 2.5 3.0 3.1 2.5 2.0 2.0 1.5 1.4
• The age-standardised incidence rate of micro-invasive cervical cancer was 1.4 per 100,000
women in 2000 for women in the target age group of 20–69 years and 0.9 per 100,000 for
women of all ages (Table 11, page 61). The rates have been declining rapidly since 1995.
• In 2000 there were 89 new cases of micro-invasive cervical cancers for all women and 86
new cases in women aged 20–69 years (Table 10, page 60).
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Note: Rates are expressed per 100,000 women.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 9: Age-specific incidence rates of micro-invasive squamous cell cancer, women
aged 20–69 years, Australia, 1999 and 2000
Age group
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69*
1999 0.3 1.9 2.0 2.6 2.1 1.1 1.2 1.8 0.5 0.9 1.5 (1.2–1.8)
2000 0.2 1.7 3.5 1.9 1.0 2.2 0.8 0.8 0.8 0.0 1.4 (1.1–1.7)
*Age-standardised rates (standardised to the Australian 1991 population) with 95% confidence intervals.
• The age-standardised incidence rate of micro-invasive squamous cell cancer was 1.4 per
100,000 women aged 20–69 years in 2000; this was statistically no different from the 1.5
per 100,000 in 1999. Hence none of the differences between 1999 and 2000 for any 5-year
age group can be regarded as significant (Tables 10 and 11, pages 60 and 61).
• The highest detection rates for micro-invasive squamous cell cancer were for women in
the 25–29 to 45–49 age groups.
32
Indicator 6: Incidence of squamous,
adenocarcinoma, adeno-squamous and other
cervical cancers
Incidence rates of squamous, adenocarcinoma, adeno-squamous and other cervical cancer
per 100,000 estimated resident female population in a 12-month period by 5-year age
groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79,
80–84, 85+) and for the target age group (20–69 years, age-standardised).
Refer to Table 13 (page 54).
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 10: Age-standardised incidence rates of cervical cancer, Australia, 1989–2000
Age 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
(Number per 100,000 women)
All ages 12.7 12.4 12.3 11.4 11.0 12.1 10.0 9.5 8.0 8.4 7.8 7.1
20–69 years 17.4 17.0 16.6 15.4 15.1 16.3 13.4 12.8 10.8 11.2 10.6 9.3
• In 2000, there were 745 new cases of cervical cancer diagnosed in Australia, of these 578
were women in the target age group 20–69 years (Table 12, page 62). All but two cases of
the remaining 167 were in women aged 70 years and over.
• The incidence rate of all cervical cancers declined to 7.1 per 100,000 women for all women
in Australia, and to 9.3 per 100,000 women in the target group.
• Between 1989 and 2000 the age-standardised incidence rate for cervical cancer for women
of all ages declined by 43.9%, and in the target age group by 56.9% (Table 13, page 63).
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Refer to Table 13 (page 63).
Note: Rates are expressed per 100,000 women.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 11: Age-specific incidence rates of cervical cancer, Australia, 1999 and 2000
Age group
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69
(Number per 100,000 women)
1999 1.2 7.5 10.4 13.5 14.6 11.4 11.0 10.8 16.4 15.6 10.6
2000 1.1 5.5 11.6 9.0 10.8 10.7 9.3 12.0 15.9 14.8 9.3
• The age-specific rate of cervical cancer incidence rose rapidly in women from age 20–24
through to age 30–34 years in 2000, and stabilised through to the 50–54 age group before
rising again.
• In 2000, the age-specific rates of cervical cancer incidence were lower than in 1999 in all
5-year age groups ranging from 20–69, except in the 30–34 and 55–59 age groups.
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Refer to Tables 14b and 15b (pages 65 and 67).
Notes
1. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
2. Bars on graphs represent 95% confidence intervals.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 12: Age-standardised cervical cancer incidence rates by women aged
20–69 years, states and territories, 1996–1999 and 1997–2000
NSW Vic Qld WA SA Tas ACT NT Australia
1996–1999 11.5 10.3 13.7 10.6 9.1 14.1 9.1 18.6 11.4
95% CI 10.8–12.2 9.5–11.1 12.6–14.7 9.2–11.9 7.8–10.5 11.1–17.4 6.2–12.3 12.5–24.9 10.9–11.8
1997–2000 11.0 9.0 12.6 9.6 9.1 13.1 8.7 13.6 10.5
95% CI 10.2–11.7 8.3–9.8 11.6–13.7 8.4–11.0 7.8–10.5 10.2–16.2 5.7–11.7 8.8–19.4 10.1–10.9
• In the period 1997–2000, the Australian Capital Territory had the lowest incidence at 8.0
per 100,000 women and the Northern Territory had the highest rate of cervical cancer
incidence of 13.6 per 100,000 women. Queensland (12.6) was significantly above the
national average (10.5) and Victoria (9.0) was significantly below.
• The incidence rate declined in all states and territories between the two periods
1996–1999 and 1997–2000 (Tables 14b and 15b, pages 65 and 67.)
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Refer to Table 16b (page 68).
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 13: Age-standardised incidence rates of cervical cancer by histological type,
women aged 20–69 years, Australia, 1989–2000
Histological type 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Squamous 13.2 12.1 11.9 11.1 10.7 11.1 9.5 9.0 7.5 8.0 7.6 6.4
Adenocarcinoma 2.2 2.8 2.6 2.6 2.5 3.4 2.6 2.5 2.1 2.3 2.1 1.9
Adeno-squamous 0.9 0.9 0.8 0.9 0.8 0.7 0.6 0.7 0.5 0.5 0.4 0.5
Other 1.1 1.2 1.1 0.8 1.1 1.1 0.8 0.7 0.6 0.5 0.6 0.5
• In 2001, squamous cell carcinomas of the cervix accounted for 69.2% of all new cases of
cervical cancer in women aged 20–69 years, adenocarcinomas 20.3%, adeno-squamous
5.3%, and the remaining 5.2% comprised a range of other mixed and unknown
histologies (Table 16a, page 68).
• The trend from 1989 to 2000 for all histological types has been a decrease in the age-
standardised rates of cervical cancer per 100,000 in women aged 20–69 years. However,
this trend is not statistically significant for adenocarcinoma.
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Indicator 8: Incidence by location
Incidence rates of cervical cancer per 100,000 estimated resident female population in a
3-year period by location by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49,
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69
years, age-standardised).
The graph and table below refer to the data for the target age group only. For detailed data
refer to Table 19 (page 71).
Notes
1. The age-standardised rates are presented as 4-year rolling blocks of data.
2. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
3. Bars on graphs represent 95% confidence intervals.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 14: Age-standardised incidence rates of cervical cancer by location by
women aged 20–69 years, Australia, 1993–1996 and 1997–2000
Metropolitan Rural Remote
1993–1996 1997–2000 1993–1996 1997–2000 1993–1996 1997–2000
AS rate 14.2 10.6 14.4 10.2 20.7 11.9
95% CI 13.7–14.8 10.1–11.1 13.4–15.3 9.3–11.0 17.0–24.8 9.4–14.9
• There were 2,327 new cases (72.9% of all new cases) of cervical cancer in metropolitan
locations in the 4-year period 1997–2000, 778 new cases (24.4% of all new cases) in rural
locations and 88 new cases (2.4% of all new cases) in remote locations (Table 18, page 70).
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• Age-standardised cervical cancer incidence rates in the period 1997–2000, for women in
the target age group 20–69 years, were higher in remote locations (11.9 per 100,000
women) than in rural (10.2) and metropolitan (10.6) locations. This difference was not
statistically significant (Table 19, page 71).
Age-specific features
(Table 19, page 71)
• Very few cervical cancers occur in women under the age of 20. The incidence rate of
cervical cancer increases with age.
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Mortality
Cancer of the cervix is one of the few cancers for which there is an efficacious screening test
for detection of precursors of the disease. Most deaths due to cervical cancer are potentially
avoidable (Marcus & Crane 1998). The objective of the National Cervical Screening Program
is to reduce this mortality rate.
The three mortality indicators are mortality (by age and state), mortality by location
(metropolitan, rural and remote), and Indigenous mortality (Indigenous and Non-
Indigenous). These indicators measure the level of mortality from cervical cancer in the total
female population by age and other demographic characteristics. The mortality indicators are
important because from them an assessment can be made of changes in mortality in different
age groups and particular target groups over time. However, note that changes in the
mortality rates may not be evident for a number of years following an improvement in the
participation rate. Therefore, the effectiveness of this measure needs to be viewed in the
longer rather than the shorter term.
Data issues
• Two major changes that have occurred in the classification and processing of Australian
mortality data require some caution when interpreting mortality data over time. They
are:
1. the introduction of the tenth revision of the International Classification of Diseases
(ICD–10) for classifying deaths registered from 1 January 1999; and
2. the introduction by the Australian Bureau of Statistics (ABS) of the Automated
Coding System (ACS) for processing deaths registered from 1 January 1997.
• As a result of this there is now a break in the mortality data series. In order to make
mortality data coded using ICD–9 and ICD–10 comparable, the ABS has derived
comparability factors to adjust data based on ICD–9. These comparability factors are
derived from the movements in the underlying causes of death coded in ICD–9
compared with ICD–10 (ABS 2000).
• For cervical cancer deaths, the comparability factor is 0.98, and the pre-1997 mortality
data presented in this report have been adjusted accordingly. The effect of this is that the
pre-1997 number of deaths appearing in this report are different from figures in previous
Cervical Screening in Australia reports.
• Prior to 1998, only South Australia, Western Australia and the Northern Territory had a
relatively high coverage of Indigenous status identification in the deaths data. In 1998
Queensland’s coverage of Indigenous deaths reached an acceptable level following the
introduction of a new Death Information Form in 1996–97 which included a question on
Indigenous status (ABS 1999). Therefore, in this report, cervical cancer deaths for
Indigenous Australians include data from Queensland (for 1998 to 2000), South Australia,
Western Australia and the Northern Territory.
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Indicator 7: Mortality
Death rate from cervical cancer per 100,000 estimated resident female population in a
12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years,
age-standardised).
Approx. commencement of the
National Cervical Screening Program
Refer to Table 21 (page 73).
Notes
1. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
2. Deaths were derived from place of usual residence and by year of registration
3. Rates for all ages are based on data for women aged 15 years and over.
Source: AIHW Mortality Database.
Figure 15: Age-standardised death rates from cervical cancer, Australia, 1982–2001
’82 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ’01
All ages 5.9 5.5 5.4 5.7 5.4 5.0 5.1 5.2 4.9 4.5 4.3 4.1 4.3 4.2 3.7 3.5 3.1 2.5 3.0 2.8
20–69 years 5.2 5.0 4.7 4.9 4.8 4.4 4.4 4.6 4.4 4.0 3.6 3.6 3.8 3.7 3.1 3.0 2.7 2.2 2.7 2.5
• Cervical cancer was the 15th most common cause of cancer deaths in Australian women
in 2001, accounting for 262 deaths.
• The age-standardised death rate for women of all ages fell to 2.8 per 100,000 in 2001.
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Notes
1. Rates are expressed per 100,000 women.
2. Deaths were derived from place of usual residence and by year of registration.
Source: AIHW Mortality Database.
Figure 16: Age-specific cervical cancer death rates by age group, Australia, 1988–1991
and 1998–2001
Age group
Period 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
1988–1991 0.2 0.7 2.1 3.4 4.2 6.6 5.3 7.7 9.6 12.6 13.4 14.7 15.9 22.7
1998–2001 0.2 0.5 1.0 1.9 2.3 3.6 3.3 3.9 5.7 6.9 9.9 9.7 12.7 16.0
• In both 1988–1991 and 1998–2001 the rates of cervical cancer mortality increased with
increasing age.
• The mortality between the two reference periods declined in all age groups except for the
age group 20–24 years where there was no difference.
• In the period 1998–2001 the mortality in the target age group was 0.2 deaths per 100,000
women in the 20–24 years age group and rose with each successive age group to 6.9 in
the 65–69 age group.
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Refer to Tables 23 and 25 (pages 75 and 77).
Notes
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the
smaller states and territories.
2. Deaths derived from place of usual residence and by year of registration.
3. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW Mortality Database.
Figure 17: Age-standardised cervical cancer death rates by women aged 20–69
years, states and territories, 1994–1997 and 1998–2001
NSW Vic Qld WA SA Tas ACT NT Australia
Rate 1994–1997 3.7 2.8 3.2 3.9 1.9 5.7 4.0 11.0 3.4
95% CI 3.4–4.0 2.5–3.2 2.8–3.6 3.3–4.6 1.5–2.3 4.2–7.3 2.3–5.7 5.8–16.2 3.2–3.6
Rate 1998–2001 2.4 2.0 2.9 2.7 2.1 2.6 1.8 6.2 2.4
95% CI 2.0–2.7 1.7–2.4 2.4–3.4 2.1–3.4 1.5–2.8 1.4–3.9 0.6–3.1 2.2–10.3 2.2–2.6
• In 1998–2001 there were 1,046 deaths from cervical cancer in all states and territories
compared with 1,273 in 1994–1997.
• The age-standardised mortality rate varied from 1.8 per 100,000 women in the Australian
Capital Territory to 6.2 in the Northern Territory.
• The age-standardised death rates decreased in all jurisdictions between the two periods
except in South Australia. The declines were significantly different in New South Wales,
Victoria and Tasmania. Although the Northern Territory rate decreased sharply between
the two periods, the rates are based on very small numbers and are subject to
considerable variation.
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Indicator 9: Mortality by location
Death rate from cervical cancer per 100,000 estimated resident female population in a
4-year period by location and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49,
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69
years, age-standardised).
The graph and table below refer to the data for the target age group only. For additional data
refer to Table 27 (page 79).
Notes
1. Age-standardised rates are presented as 4-year rolling blocks of data.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW Mortality Database.
Figure 18: Age-standardised cervical cancer death rates by location, women aged
20–69 years, 1994–1997 and 1998–2001
Metropolitan Rural Remote
1994–1997 1998–2001 1994–1997 1998–2001 1994–1997 1998–2001
Rate 3.1 2.3 3.4 2.7 6.6 3.0
95% CI 2.8–3.4 2.1-2.5 2.9-3.8 2.3-3.1 4.3–8.8 1.7–4.6
• During the 4-year period 1998–2001, there were 709 deaths (70% of all cervical cancer
deaths in that period) in metropolitan areas, 270 deaths (27% of all cervical cancer deaths)
in rural areas and 35 deaths (3% of all cervical cancer deaths) in remote areas (Table 26,
page 78).
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• The age-standardised death rate for women in the target age group 20–69 years increased
from metropolitan to rural areas and from rural to remote areas, though none of these
differences were statistically significant.
• In all three regions the age-standardised mortality rates declined between the periods
1994–1997 and 1998–2001; however, only the decline in the metropolitan area was
statistically significant. The largest overall mortality reduction was in remote areas (a
mortality reduction of 55% between 1994–1997 and 1998–2001), but these rates are based
on small numbers and therefore the decline is not statistically significant. Between the
same two periods, in metropolitan areas there was a 26% decline in cervical cancer
mortality, and in rural areas it was 21%.
Age-specific features
(Tables 26 and 27, pages 78 and 79)
• In metropolitan and rural locations, the death rates from cervical cancer increased with
age. In remote locations, although there is a general trend of rising death rates with age,
the specific pattern is less clear because of the small numbers involved in calculating the
rates.
• In metropolitan locations, age-specific cervical cancer mortality increased slightly for
younger ages. In rural locations, age-specific mortality declined in almost all age groups.
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Indicator 10: Indigenous mortality
Death rate from cervical cancer per 100,000 estimated resident female population in a
4-year period by Indigenous status and 5-year age groups (20–24, 25–29, 30–34, 35–39,
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age
group (20–69 years, age-standardised).
The graph and table below refer to the data for the target age group only. For detailed data
refer to Table 29 (page 81).
Notes
1. Age-standardised rates are presented as 4-year rolling blocks of data.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
4. Only Queensland (from 1998), South Australia, Western Australia and the Northern Territory have
Indigenous death registration data considered to be of a publishable standard.
5. Bars on graphs represent 95% confidence intervals.
Source: AIHW Mortality Database.
Figure 19: Age-standardised cervical cancer mortality rates by Indigenous status,
women aged 20–69 years (Qld, WA, SA and NT), 1996–1999, 1997–2000 and 1998–2001
Indigenous Non-Indigenous
1996–1999 1997–2000 1998–2001 1996–1999 1997–2000 1998–2001
AS Rate (A) 9.8 11.3 11.4 1.9 2.1 2.5
95% CI 4.6–16.1 6.2–17.1 6.3–17.6 1.6–2.3 1.7–2.4 2.2–2.8
Note: Indigenous and non-Indigenous deaths from Queensland for 1998, 1999, 2000 and 2001 are included in the above table.
Excluding Queensland
AS Rate (A) 7.9 7.2 5.5 1.8 1.9 2.0
95% CI 2.3–14.1 2.6–12.9 1.4–11.0 1.4–2.2 1.2–2.2 1.6–2.4
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• Due to the difficulties of Indigenous identification in health data collections, only
Indigenous mortality data from Queensland (from 1998), Western Australia, South
Australia and the Northern Territory are considered to be of publishable standard.
Therefore, all cervical cancer mortality data for both Indigenous women and non-
Indigenous women used in this analysis are confined to these jurisdictions.
• The age-standardised mortality rate attributable to cervical cancer among Indigenous
women in the target age group in the 1998–2001 period was 11.4 per 100,000 women and
was considerably higher than the mortality rate for non-Indigenous women in the same
age range (2.5 per 100,000 women) (Tables 28 and 29, pages 80 and 81).
• The Indigenous cervical cancer mortality rate among women in the target age group was
higher in 1998–2001 than in 1996–1999. However, these figures are not directly
comparable because data from Queensland was available only from 1998. Queensland
accounts for almost half of the Indigenous population when the four jurisdictions are
combined. If we exclude Queensland, then death rates among Indigenous people fell
between 1996–1999 and 1998–2001. Death rates for Indigenous women are based on
relatively small numbers of cases and may be subject to large variability. This is reflected
in the wide confidence intervals associated with the mortality rates. (Table 29, page 81).
Age-specific features
(Tables 28 and 29, pages 80 and 81)
• The numbers of deaths among Indigenous women in Queensland, Western Australia,
South Australia and the Northern Territory are either very small or none in many age
groups and care is needed in interpreting the rates.
• Mortality rates generally increased with increasing age in both Indigenous and non-
Indigenous women.
• Compared with non-Indigenous women, Indigenous women experienced high rates of
mortality in every age group.
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Tables
Indicator 1: Participation
Table 1a: Number of women participating in the National Cervical Screening Program by age,
states and territories, 1999–2000
Age group NSW Vic Qld WA(a) SA(b) Tas ACT(a) NT Australia
20–24 99,812 83,943 64,583 34,401 25,727 8,939 6,354 4,587 328,346
25–29 147,289 120,835 82,879 44,631 33,896 10,398 8,083 6,067 454,078
30–34 151,934 125,001 81,147 46,230 36,101 11,047 8,072 5,782 465,314
35–39 156,192 124,293 83,093 47,573 38,032 11,999 7,964 4,941 474,087
40–44 137,205 110,095 73,124 42,825 35,019 10,864 7,369 4,170 420,671
45–49 115,982 94,509 61,746 35,698 30,326 9,101 6,706 3,490 357,558
50–54 95,632 78,785 50,876 27,795 25,564 7,582 5,848 2,491 294,573
55–59 64,864 53,943 33,397 17,857 17,313 5,123 3,485 1,444 197,426
60–64 48,312 41,339 23,470 13,451 13,827 3,822 2,243 719 147,183
65–69 34,003 30,654 16,317 9,346 10,135 2,849 1,388 401 105,093
70–74 14,487 11,283 7,955 3,583 6,517 788 491 147 45,251
75–79 5,487 4,233 3,228 1,230 n.a. 321 168 79 14,746
80+ 2,113 1,946 1,423 542 n.a. 140 58 20 6,242
Not stated 3,720 27 408 0 24 4 15 21 4,219
All ages 1,077,032 880,886 583,646 325,162 272,481 82,977 58,244 34,359 3,314,787
Ages 20–69
years 1,051,225 863,397 570,632 319,807 265,940 81,724 57,512 34,092 3,244,329
(a) The WA and ACT registers only register women with a WA or ACT address respectively.
(b) South Australia has grouped women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes
1. These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas; however, the likely impact of double counting is probably very small.
2. Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Table 1b: Proportion of women participating in the National Cervical Screening Program by age,
states and territories, 1999–2000
Age group NSW Vic Qld WA(a) SA(b) Tas ACT(a) NT Australia
(Per cent)
20–24 45.6 50.0 51.7 50.6 53.5 61.3 48.8 58.8 49.5
25–29 59.6 65.5 61.2 62.9 65.8 66.3 62.1 64.9 62.4
30–34 65.3 69.9 64.0 67.9 69.9 70.1 67.7 67.6 67.0
35–39 67.2 72.3 64.8 69.5 71.5 71.2 69.2 66.6 68.7
40–44 67.0 72.5 64.8 69.5 72.6 70.7 69.7 69.7 68.8
45–49 66.1 72.1 63.2 67.3 71.3 68.4 70.2 72.4 67.8
50–54 69.3 76.4 65.9 70.3 75.1 72.2 79.9 75.2 71.3
55–59 60.2 68.3 57.1 60.7 66.3 62.0 71.7 70.0 62.5
60–64 53.7 62.2 51.0 56.4 62.3 54.6 65.3 58.6 56.5
65–69 40.8 49.7 39.9 44.5 48.6 43.9 49.9 48.3 44.2
All ages
Crude rate 55.2 60.4 55.4 58.5 59.5 58.9 61.4 65.3 57.5
AS rate 55.0 60.4 54.5 57.4 60.4 59.4 59.5 60.7 57.2
95% CI 54.9–55.1 60.3–60.6 54.4–54.7 57.2–57.6 60.2–60.6 59.0–59.8 58.9-60.0 60.0–61.4 57.1-57.2
Ages 20–69 years
Crude rate 60.7 66.6 60.2 63.5 66.7 66.0 65.3 66.4 63.1
AS rate 60.2 66.2 59.5 62.8 66.2 65.5 65.1 65.6 62.6
95% CI 60.1–60.3 66.1–66.3 59.3–59.6 62.6–63.1 66.0–66.5 65.0–65.9 64.6-65.7 64.9–66.4 62.5-62.6
(a) The WA and ACT registers only register women with a WA or ACT address respectively.
(b) South Australia has grouped women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes
1. These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas; however, the likely impact of double counting is probably very small.
2. Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
3. Rates are standardised to the 1991 Australian total population.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Table 2a: Number of women participating in the National Cervical Screening Program by age,
states and territories, 2000–2001
Age group NSW Vic(a) Qld WA(a) SA(b) Tas ACT(a) NT Australia
20–24 98,410 81,673 62,480 33,698 25,410 8,804 6,193 4,595 321,263
25–29 143,840 114,693 79,515 43,183 32,306 10,127 7,845 5,898 437,407
30–34 153,836 125,139 81,104 46,448 36,257 10,994 8,158 5,827 467,763
35–39 154,920 121,537 80,964 47,090 37,436 11,924 7,976 5,043 466,890
40–44 140,924 112,399 74,268 43,390 35,941 11,193 7,474 4,188 429,777
45–49 118,907 95,793 62,383 36,619 30,829 9,475 6,708 3,464 364,178
50–54 99,838 82,150 52,047 29,221 26,386 8,081 6,059 2,509 306,291
55–59 68,905 56,506 35,118 18,729 18,311 5,505 3,665 1,375 208,114
60–64 50,567 42,868 24,336 14,060 14,155 4,106 2,378 766 153,236
65–69 35,430 31,124 16,749 9,621 10,236 2,974 1,519 359 108,012
70–74 14,641 10,486 8,042 3,641 6,495 798 483 149 44,735
75–79 5,341 3,617 3,098 1,173 n.a. 327 168 53 13,777
80+ 2,190 1,584 1,354 542 n.a. 133 46 26 5,875
Not stated 3,720 0 320 0 20 3 9 18 4,090
All ages 1,091,469 879,569 581,778 327,415 273,782 84,444 58,681 34,270 3,331,408
Ages 20–69
years 1,065,577 863,882 568,964 322,059 267,267 83,183 57,975 34,024 3,262,931
(a) The Vic, WA and ACT registers only register women with a Vic, WA or ACT address respectively.
(b) South Australia has grouped women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Note: These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas; however, the likely impact of double counting is probably very small.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Table 2b: Proportion of women participating in the National Cervical Screening Program by age,
states and territories, 2000–2001
Age group NSW Vic(a) Qld WA(a) SA(b) Tas ACT(a) NT Australia
(Per cent)
20–24 46.5 51.1 51.1 53.1 54.9 62.9 47.7 59.1 50.3
25–29 59.2 63.7 59.7 62.8 64.7 67.6 59.3 63.5 61.4
30–34 63.7 67.3 61.5 66.0 68.8 68.8 64.7 65.5 64.9
35–39 65.9 69.9 62.6 68.6 70.7 72.2 67.0 65.9 67.1
40–44 66.3 71.8 63.5 68.8 72.7 71.5 68.2 66.1 68.1
45–49 65.9 71.7 62.4 67.0 71.7 70.3 68.2 66.6 67.4
50–54 68.6 75.8 63.8 69.1 73.8 73.7 76.3 68.2 70.2
55–59 60.2 68.0 55.9 60.1 66.5 63.7 68.8 58.6 62.1
60–64 53.1 61.6 49.2 55.4 61.6 55.9 63.1 54.4 55.7
65–69 42.2 50.6 40.6 45.1 49.9 46.7 52.4 40.0 45.3
All ages
Crude rate 54.7 59.4 54.0 58.2 59.3 60.4 59.3 62.4 57.8
AS rate 54.6 59.5 53.2 57.1 60.2 60.4 57.6 57.2 56.5
95% CI 54.5–54.7 59.4–59.6 53.1–53.4 56.9–57.3 60.0–60.4 60.0–60.8 57.1–58.1 56.6–57.8 56.5–56.6
Target age 20–69 years
Crude rate 60.4 65.8 58.7 63.3 66.6 67.1 63.4 63.6 62.5
AS rate 59.8 65.3 58.1 62.5 66.0 66.6 63.2 62.1 61.8
95% CI 59.7–59.9 65.2–65.4 57.9–58.2 62.3–62.7 65.8–66.3 66.1–67.0 62.6–63.7 61.4–62.7 61.8–61.9
(a) The Vic, WA and ACT registers only register women with a Vic, WA or ACT address respectively.
(b) South Australia has grouped women aged 70 years or more, and for the purpose of this table, they appear in the 70–74 age group.
Notes
1. These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas; however, the likely impact of double counting is probably very small.
2. Rates are standardised to the 1991 Australian total population.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Indicator 2: Early re-screening
Table 3: Number of women with repeat screenings in the 21 months following a negative Pap
smear in February 2000, states and territories, 1999–2000 and 2000–2001
No. of tests NSW Vic(a) Qld WA(a) SA Tas ACT(a) NT
Australia
2000–2001
Australia
1999–2000
Number of women
0 36,316 31,627 20,356 11,376 9,311 2,699 2,021 1,196 114,902 119,556
1 14,626 14,300 7,507 4,803 2,829 1,018 725 297 46,105 47,916
2 1,709 2,045 1,117 536 387 113 114 54 6,075 6,591
3 296 469 254 67 58 27 10 18 1,199 1,310
4 37 134 52 6 14 3 1 4 251 269
5 or more 17 66 16 4 4 0 0 1 108 81
(a) The Vic, WA and ACT registries only register women with a Vic, WA and ACT address respectively.
Note: These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas; however, the likely impact of double counting is probably very small.
Source: State and territory Cervical Cytology Registry data.
Table 4: Percentage of women with repeat screenings in the 21 months following a negative Pap
smear in February 2000, states and territories, 1999–2000 and 2000–2001
No. of tests NSW Vic(a) Qld WA(a) SA Tas ACT(a) NT
Australia
2000–2001
Australia
1999–2000
Per cent of women
0 68.5 65.0 69.5 67.7 73.9 69.9 70.4 76.2 68.1 68.0
1 27.6 29.4 25.6 28.6 22.4 26.4 25.3 18.9 27.3 27.3
2 3.2 4.2 3.8 3.2 3.1 2.9 4.0 3.4 3.6 3.8
3 0.6 1.0 0.9 0.4 0.5 0.7 0.4 1.1 0.7 0.7
4 0.1 0.3 0.2 0.0 0.1 0.1 0.0 0.3 0.1 0.2
5 or more 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0
(a) The Vic, WA and ACT registries only register women with a Vic, WA and ACT address respectively
Note: These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas; however, the likely impact of double counting is probably very small.
Source: State and territory Cervical Cytology Registry data.
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Indicator 3: Low-grade abnormality detection
Table 5a: Number of low- and high-grade abnormalities on histology for women aged 20–69 years,
states and territories, 2000
Abnormalities NSW Vic Qld WA SA Tas ACT NT Australia
Low-grade 6,381 3,701 5,016 2,075 1,541 678 273 320 19,985
High-grade 4,493 2,986 3,105 1,240 1,045 478 220 284 13,851
Ratio 1.42 1.24 1.62 1.67 1.47 1.42 1.24 1.13 1.44
As a percentage of all screens in 2000
Low-grade 1.1 0.7 1.6 1.1 1.0 1.5 0.5 1.6 1.1
High-grade 0.7 0.6 1.0 0.6 0.7 1.0 0.4 1.4 0.7
Note: These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas; however, the likely impact of double counting is probably very small.
Source: State and territory Cervical Cytology Registry data.
Table 5b: Number of low- and high-grade abnormalities on histology for women aged 20–69 years,
states and territories, 2001
Abnormalities NSW Vic Qld WA SA(a) Tas ACT Australia
Low-grade 6,416 3,099 4,086 2,308 1,335 591 291 18,126
High-grade 4,614 2,855 2,890 1,515 961 471 249 13,555
Ratio 1.39 1.09 1.41 1.52 1.39 1.25 1.17 1.34
As a percentage of all screens in 2001
Low-grade 1.1 0.6 1.3 1.2 0.9 1.3 0.5 1.0
High-grade 0.8 0.6 0.9 0.8 0.6 1.0 0.4 0.7
Notes
1. Northern Territory data are unavailable for 2001.
2. These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas; however, the likely impact of double counting is probably very small.
Source: State and territory Cervical Cytology Registry data.
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Indicator 4: High-grade abnormality detection
Table 6a: Rate of histologically confirmed high-grade abnormalities per 1,000 women screened,
states and territories, 2000
Age group NSW Vic Qld WA SA(a) Tas ACT NT Australia
20–24 17.0 13.8 19.0 13.8 13.8 27.0 13.8 24.0 16.3
25–29 15.4 13.1 19.7 14.8 13.8 18.1 9.4 23.7 15.5
30–34 10.3 8.6 12.8 9.1 10.9 12.1 12.1 15.6 10.3
35–39 6.2 5.3 8.6 5.6 6.1 10.9 5.4 12.3 6.5
40–44 5.0 3.4 5.5 3.2 4.9 7.0 3.1 11.5 4.5
45–49 2.8 2.3 4.1 2.2 3.4 4.4 4.8 6.3 3.0
50–54 1.9 1.2 2.6 1.3 2.3 3.4 3.6 1.4 1.9
55–59 1.3 1.0 3.0 1.0 1.8 1.7 2.5 3.6 1.5
60–64 1.4 1.1 1.5 1.7 2.4 1.4 1.6 4.7 1.5
65–69 2.2 1.1 1.6 1.0 2.0 2.6 2.6 9.5 1.7
70–74 3.0 2.0 2.4 n.a. 8.6 2.3 0.0 12.7 3.2
75–79 3.7 2.1 6.0 n.a. n.a. 0.0 50.0 0.0 3.8
80–84 4.8 2.5 9.5 n.a. n.a. 0.0 0.0 0.0 4.3
85+ 6.5 0.0 0.0 n.a. n.a. 0.0 0.0 0.0 3.1
All ages 7.3 5.9 9.5 6.3 7.0 10.2 6.9 14.3 7.3
Ages 20–69
years 7.4 6.0 9.6 6.4 7.0 10.4 6.8 14.3 7.4
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Note: These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas; however, the likely impact of double counting is probably very small.
Source: State and territory Cervical Cytology Registry data.
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Table 6b: Rate of histologically confirmed high-grade abnormalities per 1,000 women screened by
age, states and territories, 2001
Age group NSW Vic Qld WA SA(a) Tas ACT Australia
20–24 18.2 12.6 18.9 17.8 13.7 23.7 2.2 16.3
25–29 16.5 12.7 18.0 17.6 13.3 20.4 13.0 15.6
30–34 10.4 8.1 12.1 11.0 9.4 11.8 11.1 10.1
35–39 6.2 5.2 8.1 7.2 6.4 10.0 11.3 6.6
40–44 4.2 3.5 5.1 4.8 3.9 7.0 9.9 4.4
45–49 3.1 2.0 3.7 3.2 3.6 4.9 5.3 3.0
50–54 1.7 1.3 2.7 1.5 2.2 1.3 1.7 1.8
55–59 1.4 0.9 2.4 1.4 1.5 2.1 2.8 1.5
60–64 1.6 0.9 2.1 1.0 2.2 2.9 3.0 1.5
65–69 1.6 1.2 2.2 1.6 1.8 2.3 4.7 1.6
70–74 1.2 1.4 1.7 3.0 4.8 4.4 11.7 2.1
75–79 3.7 3.9 6.0 1.2 n.a. 0.0 0.0 3.9
80–84 3.4 1.6 10.6 3.6 n.a. 17.9 0.0 4.9
85+ 6.1 0.0 0.0 7.9 n.a. 0.0 0.0 3.2
All ages 7.4 5.6 8.9 7.9 6.5 9.8 7.6 7.2
Ages 20–69
years 7.5 5.7 9.0 8.0 6.5 9.8 7.6 7.3
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes
1. Northern Territory data are unavailable for 2001.
2. These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas, however the likely impact of double counting is probably very small.
Source: State and territory Cervical Cytology Registry data.
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Table 7a: Number of histologically confirmed high-grade abnormalities by age, states and
territories, 2000
Age group NSW Vic Qld WA SA(a) Tas ACT NT Australia
20–24 924 632 665 266 196 131 46 62 2,922
25–29 1,284 880 904 379 260 105 42 83 3,937
30–34 898 619 593 249 224 75 56 53 2,767
35–39 559 373 400 158 131 73 24 36 1,754
40–44 399 217 231 84 97 44 13 28 1,113
45–49 192 128 146 50 58 23 18 13 628
50–54 107 58 75 23 33 15 12 2 325
55–59 49 31 57 11 17 5 5 3 178
60–64 40 28 20 14 18 3 2 2 127
65–69 41 20 14 6 11 4 2 2 100
70–74 24 13 10 3 31 1 0 1 83
75–79 11 5 10 1 0 0 4 0 31
80–84 4 2 5 0 0 0 0 0 11
85+ 2 0 0 1 0 0 0 0 3
Not stated 2 0 1 0 0 0 0 0 3
All ages 4,536 3,006 3,131 1,245 1,076 479 224 285 13,982
Ages 20–69
years 4,493 2,986 3,105 1,240 1,045 478 220 284 13,851
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Note: These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas; however, the likely impact of double counting is probably very small.
Source: State and territory Cervical Cytology Registry data.
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Table 7b: Number of histologically confirmed high-grade abnormalities by age, states and
territories, 2001
Age group NSW Vic Qld WA SA(a) Tas ACT Australia
20–24 1,008 588 652 343 194 116 8 2,909
25–29 1,334 821 786 429 232 116 57 3,775
30–34 929 600 558 297 189 75 51 2,699
35–39 544 366 365 193 130 68 51 1,717
40–44 343 232 218 122 78 45 42 1,080
45–49 216 110 130 70 62 27 20 635
50–54 102 63 82 27 33 6 6 319
55–59 58 32 49 16 16 7 6 184
60–64 48 22 29 9 17 7 4 136
65–69 32 21 21 9 10 4 4 101
70–74 10 8 8 7 16 2 3 54
75–79 11 8 10 1 0 0 0 30
80–84 3 1 6 1 0 1 0 12
85+ 2 0 0 1 0 0 0 3
Age not
stated 0 0 1 0 0 0 0 1
All ages 4,640 2,872 2,915 1,525 977 474 252 13,655
Ages 20–69
years 4,614 2,855 2,890 1,515 961 471 249 13,555
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes
1. Northern Territory data are unavailable for 2001.
2. These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas; however, the likely impact of double counting is probably very small.
Source: State and territory Cervical Cytology Registry data.
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Table 8a: Number of women screened by age, states and territories, 2000
Age group NSW Vic Qld WA SA(a) Tas ACT NT Australia
20–24 54,311 45,637 35,011 19,340 14,251 4,849 3,332 2,581 179,312
25–29 83,176 67,289 45,787 25,623 18,861 5,813 4,489 3,496 254,534
30–34 87,608 71,913 46,487 27,275 20,521 6,217 4,611 3,399 268,031
35–39 89,792 70,492 46,677 28,213 21,478 6,679 4,474 2,935 270,740
40–44 79,978 64,332 42,141 26,282 19,986 6,288 4,180 2,440 245,627
45–49 67,717 55,487 35,455 22,617 17,160 5,216 3,779 2,056 209,487
50–54 56,503 47,826 29,398 17,830 14,521 4,348 3,316 1,445 175,187
55–59 38,304 32,441 19,203 11,521 9,678 2,972 2,001 823 116,943
60–64 27,659 24,586 13,156 8,448 7,654 2,165 1,290 425 85,383
65–69 19,011 17,734 8,744 5,856 5,372 1,546 774 211 59,248
70–74 8,019 6,600 4,195 2,358 3,594 435 268 79 25,548
75–79 2,964 2,391 1,659 905 0 168 80 37 8,204
80–84 842 798 529 300 0 39 19 8 2,535
85+ 306 321 187 119 0 29 5 3 970
Not stated 1,734 0 207 0 11 0 7 16 1,975
All ages 617,924 507,847 328,836 196,687 153,087 46,764 32,625 19,954 1,903,724
Ages 20–69
years 604,059 497,737 322,059 193,005 149,482 46,093 32,246 19,811 1,864,492
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Note: These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas; however, the likely impact of double counting is probably very small.
Source: State and territory Cervical Cytology Registry data.
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Table 8b: Number of women screened by age, states and territories, 2001
Age group NSW Vic Qld WA SA(a) Tas ACT Australia
20–24 55,327 46,511 34,551 19,292 14,136 4,892 3,558 178,267
25–29 81,027 64,645 43,714 24,378 17,509 5,700 4,380 241,353
30–34 89,191 73,696 46,004 27,016 20,161 6,369 4,601 267,038
35–39 88,177 69,967 45,033 26,936 20,314 6,779 4,522 261,728
40–44 81,892 66,241 42,340 25,501 20,004 6,412 4,250 246,640
45–49 69,104 56,362 35,401 21,883 17,098 5,521 3,794 209,163
50–54 58,595 48,786 29,858 18,232 14,698 4,783 3,473 178,425
55–59 40,658 33,830 20,348 11,590 10,340 3,283 2,119 122,168
60–64 29,437 24,988 13,923 8,580 7,669 2,418 1,336 88,351
65–69 20,375 17,710 9,555 5,758 5,585 1,713 860 61,556
70–74 8,283 5,923 4,572 2,321 3,344 452 257 25,152
75–79 2,945 2,071 1,665 809 0 178 106 7,774
80–84 890 626 566 278 0 56 19 2,435
85+ 327 255 196 126 0 21 4 929
Age not
stated 1,895 0 147 0 8 3 5 2,058
All ages 628,123 511,611 327,873 192,700 150,866 48,580 33,284 1,893,037
Ages 20–69
years 613,783 502,736 320,727 189,166 147,514 47,870 32,893 1,854,689
 (a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes 
1. Northern Territory data are unavailable for 2001.
2. These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas; however, the likely impact of double counting is probably very small.
Source: State and territory Cervical Cytology Registry data.
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Table 9a: Age-standardised high-grade abnormality rate on histology per 1,000 women screened
aged 20–69 years, states and territories, 2000
NSW Vic Qld WA SA Tas ACT NT Australia
All ages
AS rate 7.1 5.7 8.8 5.9 6.8 9.6 7.6 12.1 7.1
95% CI 6.9–7.4 5.5–5.9 8.5–9.2 5.6–6.2 6.4–7.2 8.7–10.5 6.6–8.6 10.7–13.5 7.0–7.2
Target age 20–69
AS rate 7.6 6.2 9.4 6.5 7.2 10.6 6.8 12.9 7.5
95% CI 7.4–7.8 6.0–6.4 9.0–9.7 6.1–6.9 6.8–7.6 9.7–11.6 5.9–7.7 11.4–14.4 7.4–7.6
Notes 
1. Rates are standardised to the 1991 Australian total population.
2. These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas; however, the likely impact of double counting is probably very small.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Table 9b: Age-standardised high-grade abnormality rate on histology per 1,000 women screened
aged 20–69 years, states and territories, 2001
NSW Vic Qld WA SA Tas ACT Australia
All ages
AS rate 7.2 5.5 8.5 7.5 6.3 9.4 6.5 7.1
95% CI 7.0–7.4 5.3–5.7 8.2–8.8 7.2–7.9 5.9–6.7 8.6–10.3 5.7–7.3 6.9–7.2
Target age 20–69
AS rate 7.8 5.9 8.9 8.1 6.8 10.3 7.3 7.5
95% CI 7.6–8.1 5.7–6.1 8.6–9.3 7.7–8.5 6.4–7.3 9.4–11.3 6.4–8.2 7.4–7.6
Notes
1. Northern Territory data are unavailable for 2001.
2. Rates are-standardised to the 1991 Australian total population.
3. These numbers may be overestimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas; however, the likely impact of double counting is probably very small.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Indicator 5: Incidence of micro-invasive cervical cancer
Table 10: New cases of micro-invasive cervical cancer by age, Australia, 1989–2000
Age group 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
0–4 0 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0
15–19 0 0 1 0 0 0 0 1 0 0 0 0
20–24 1 4 0 5 1 7 1 6 3 2 2 1
25–29 13 14 14 14 9 17 16 17 10 18 14 12
30–34 28 32 31 32 32 36 42 18 27 18 14 25
35–39 10 25 40 25 26 30 29 35 21 26 20 14
40–44 17 26 30 24 17 24 30 23 21 22 15 7
45–49 6 18 9 13 15 26 23 12 11 15 7 15
50–54 4 6 11 12 17 9 12 11 8 13 7 5
55–59 5 8 7 11 5 5 9 7 8 3 8 4
60–64 7 8 7 8 7 10 11 6 5 5 2 3
65–69 2 6 7 9 10 6 7 10 2 2 3 0
70–74 0 2 4 2 3 6 5 3 4 3 2 0
75–79 1 3 3 2 1 3 5 2 2 2 1 1
80–84 1 0 2 0 0 0 1 1 0 2 0 2
85+ 0 0 0 0 1 2 1 1 0 0 0 0
All ages 95 152 166 157 144 181 192 153 122 131 95 89
Ages 20–69
years 93 147 156 153 139 170 180 145 116 124 92 86
Source:  National Cancer Statistics Clearing House (AIHW).
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Table 11: Age-specific and age-standardised rates of micro-invasive cervical cancer by age,
Australia, 1989–2000
Age group 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0
20–24 0.2 0.6 0.0 0.7 0.1 1.0 0.1 0.9 0.4 0.3 0.3 0.2
25–29 1.8 2.0 2.0 2.0 1.3 2.5 2.3 2.4 1.4 2.4 1.9 1.7
30–34 4.1 4.6 4.4 4.4 4.4 4.9 5.7 2.5 3.8 2.5 2.0 3.5
35–39 1.5 3.8 6.0 3.7 3.8 4.3 4.1 4.8 2.8 3.4 2.6 1.9
40–44 2.9 4.2 4.7 3.7 2.6 3.7 4.5 3.4 3.0 3.1 2.1 1.0
45–49 1.3 3.8 1.8 2.4 2.6 4.4 3.7 1.9 1.7 2.3 1.1 2.2
50–54 1.0 1.5 2.7 2.8 3.9 2.0 2.5 2.2 1.5 2.3 1.2 0.8
55–59 1.4 2.2 2.0 3.0 1.3 1.3 2.3 1.7 1.9 0.7 1.8 0.8
60–64 1.9 2.2 1.9 2.2 1.9 2.8 3.1 1.7 1.4 1.3 0.5 0.8
65–69 0.6 1.7 2.0 2.5 2.8 1.7 2.0 2.8 0.6 0.6 0.9 0.0
70–74 0.0 0.7 1.4 0.7 1.0 1.9 1.5 0.9 1.2 0.9 0.6 0.0
75–79 0.5 1.4 1.3 0.9 0.4 1.3 2.1 0.8 0.8 0.7 0.4 0.3
80–84 0.7 0.0 1.4 0.0 0.0 0.0 0.6 0.6 0.0 1.1 0.0 1.1
85+ 0.0 0.0 0.0 0.0 0.8 1.6 0.7 0.7 0.0 0.0 0.0 0.0
All ages
Crude rate 1.1 1.8 1.9 1.8 1.6 2.0 2.1 1.7 1.3 1.4 1.0 0.9
AS rate (A) 1.1 1.8 1.9 1.8 1.6 2.0 2.1 1.6 1.3 1.3 1.0 0.9
95% CI 0.9–1.4 1.5–2.1 1.6–2.2 1.5–2.1 1.4–1.9 1.7–2.3 1.8–2.4 1.4–1.9 1.1–1.5 1.1–1.6 0.8–1.2 0.7–1.1
AS rate (W) 1.0 1.5 1.6 1.5 1.4 1.7 1.7 1.4 1.1 1.1 0.8 0.8
95% CI 0.8–1.2 1.3–1.8 1.3–1.8 1.3–1.8 1.1–1.6 1.4–1.9 1.5–2.0 1.2–1.6 0.9–1.3 0.9–1.3 0.7–1.0 0.6–0.9
Ages 20–69 years
Crude rate 1.8 2.8 2.9 2.8 2.5 3.0 3.2 2.5 2.0 2.1 1.5 1.4
AS rate (A) 1.8 2.8 2.9 2.8 2.5 3.0 3.1 2.5 2.0 2.0 1.5 1.4
95% CI 1.4–2.1 2.3–3.2 2.5–3.4 2.4–3.2 2.1–2.9 2.5–3.5 2.7–3.6 2.1–2.9 1.6–2.3 1.7–2.4 1.2–1.8 1.1–1.7
AS rate (W) 1.7 2.7 2.7 2.7 2.4 2.9 3.0 2.4 1.9 2.0 1.5 1.4
95% CI 1.4–2.0 2.2–3.1 2.3–3.1 2.3–3.1 2.0–2.8 2.5–3.3 2.6–3.5 2.0–2.8 1.5–2.2 1.7–2.3 1.2–1.8 1.1–1.7
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source:  National Cancer Statistics Clearing House (AIHW).
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Indicator 6: Incidence of invasive squamous, adenocarcinoma,
adeno-squamous and other cervical cancer
Table 12: New cases of cervical cancer by age, Australia, 1989–2000
Age group 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
0–4 1 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 1 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0
15–19 1 1 1 0 1 1 2 1 1 2 0 2
20–24 16 12 12 9 10 16 4 15 10 10 8 7
25–29 67 59 49 53 37 49 52 43 44 48 55 40
30–34 130 113 120 107 105 124 112 68 78 84 74 83
35–39 122 156 140 126 129 131 110 141 99 102 102 68
40–44 128 139 150 132 128 131 118 117 102 101 104 79
45–49 94 120 104 101 101 131 99 102 79 110 76 72
50–54 82 70 90 77 89 87 58 80 74 65 66 58
55–59 83 80 63 78 79 73 69 64 51 52 49 57
60–64 85 78 81 76 76 88 71 61 52 56 63 63
65–69 100 76 89 88 91 94 78 65 57 55 54 51
70–74 67 66 79 72 63 78 71 59 45 61 46 57
75–79 51 51 48 53 46 65 50 51 45 44 42 50
80–84 28 29 35 34 37 40 30 41 32 39 33 37
85+ 18 23 33 22 21 22 33 25 28 29 21 21
All ages 1,072 1,073 1,094 1,028 1,013 1,131 957 933 797 858 793 745
Ages 20–69 years 907 903 898 847 845 924 771 756 646 683 651 578
Note: The above table includes the incidence of micro-invasive and invasive cervical cancers.
Source:  National Cancer Statistics Clearing House (AIHW).
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Table 13: Age-specific and age-standardised incidence rates of cervical cancer by age, Australia,
1989–2000
Age group 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.1 0.1 0.2 0.0 0.2 0.2 0.3 0.2 0.2 0.3 0.0 0.3
20–24 2.4 1.8 1.7 1.3 1.4 2.3 0.6 2.2 1.5 1.5 1.2 1.1
25–29 9.5 8.3 7.0 7.7 5.4 7.2 7.6 6.1 6.0 6.5 7.5 5.5
30–34 19.2 16.3 16.9 14.8 14.4 16.9 15.3 9.4 10.9 11.8 10.4 11.6
35–39 18.9 23.8 21.1 18.6 18.7 18.8 15.4 19.3 13.3 13.5 13.5 9.0
40–44 21.5 22.5 23.5 20.6 19.8 19.9 17.7 17.2 14.7 14.3 14.6 10.8
45–49 20.6 25.1 20.7 18.8 17.6 22.0 16.1 15.9 12.3 16.8 11.4 10.7
50–54 21.1 17.5 21.8 18.2 20.5 19.2 12.2 16.1 13.8 11.3 11.0 9.3
55–59 23.0 22.3 17.6 21.3 21.0 18.9 17.4 15.7 12.1 11.9 10.8 12.0
60–64 22.9 21.0 21.9 20.8 21.1 24.7 19.9 17.1 14.3 15.0 16.4 15.9
65–69 29.2 21.8 25.3 24.9 25.6 26.5 22.0 18.3 16.2 15.7 15.6 14.8
70–74 25.2 24.4 28.0 24.6 20.8 24.6 22.0 18.0 13.7 18.4 13.8 17.1
75–79 23.7 23.1 21.3 23.1 20.0 28.5 21.4 20.9 17.5 16.3 15.0 17.4
80–84 20.9 20.8 24.1 22.5 23.4 23.9 17.4 23.2 17.8 21.4 18.0 19.5
85+ 17.4 21.8 30.0 19.0 17.2 17.3 24.6 17.7 18.8 18.6 12.6 12.0
All ages
Crude rate 12.7 12.5 12.6 11.7 11.4 12.6 10.5 10.1 8.5 9.1 8.3 7.7
AS rate (A) 12.7 12.4 12.3 11.4 11.0 12.1 10.0 9.5 8.0 8.4 7.8 7.1
AS rate (W) 10.5 10.3 10.1 9.3 9.1 9.9 8.2 7.8 6.5 6.9 6.4 5.8
Ages 20–69 years
Crude rate 17.4 17.0 16.6 15.4 15.2 16.4 13.5 13.1 11.0 11.5 10.8 9.5
AS rate (A) 17.4 17.0 16.6 15.4 15.1 16.3 13.4 12.8 10.8 11.2 10.6 9.3
AS rate (W) 17.0 16.7 16.2 15.0 14.7 15.9 13.0 12.6 10.5 11.0 10.4 9.1
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
64
Table 14a: New cases of cervical cancer by age, states and territories, 1996–1999
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 2 1 1 0 0 0 0 0 4
20–24 11 8 16 3 0 5 0 0 43
25–29 61 37 48 13 16 7 5 3 190
30–34 105 57 72 30 26 12 0 2 304
35–39 147 94 103 33 24 24 9 10 444
40–44 130 108 91 52 24 8 5 6 424
45–49 134 91 65 34 25 6 5 7 367
50–54 122 60 54 21 14 5 3 6 285
55–59 65 62 41 19 16 5 4 4 216
60–64 80 60 47 17 18 7 1 2 232
65–69 89 49 51 22 12 4 4 0 231
70–74 83 57 28 22 12 4 3 2 211
75–79 65 45 37 14 14 5 1 1 182
80–84 53 46 19 15 8 2 2 0 145
85+ 35 29 20 13 5 0 1 0 103
All ages 1,182 804 693 308 214 94 43 43 3,381
Ages 20–69 years 944 626 588 244 175 83 36 40 2,736
Source:  National Cancer Statistics Clearing House (AIHW).
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Table 14b: Age-specific rates of cervical cancer, states and territories, 1996–1999
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.2 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.2
20–24 1.2 1.2 3.1 1.1 0.0 8.1 0.0 0.0 1.6
25–29 6.3 5.0 9.0 4.6 7.5 10.7 9.5 8.0 6.6
30–34 10.9 7.9 14.0 10.8 11.9 17.7 0.0 5.9 10.6
35–39 14.6 12.7 19.0 11.3 10.2 31.7 17.5 31.9 14.9
40–44 13.9 15.6 18.0 18.5 10.8 11.2 10.0 21.9 15.2
45–49 15.5 14.1 13.7 13.3 11.8 9.1 10.2 30.4 14.1
50–54 16.4 10.9 13.3 10.2 7.7 8.9 7.8 35.2 12.9
55–59 11.1 14.4 13.3 12.0 11.2 11.0 15.7 38.6 12.6
60–64 15.6 15.8 18.6 12.9 14.2 17.7 5.3 29.9 15.7
65–69 17.9 13.5 21.4 18.2 9.6 10.5 25.3 0.0 16.5
70–74 17.7 16.6 12.8 20.6 9.7 11.3 20.8 63.3 16.0
75–79 17.3 16.6 21.0 16.7 13.9 17.1 9.1 49.3 17.3
80–84 20.8 24.9 15.9 25.6 11.7 9.8 29.2 0.0 20.1
85+ 16.3 17.8 20.0 24.9 8.4 0.0 19.5 0.0 16.8
All ages
Crude rate 9.3 8.6 10.1 8.6 7.1 9.8 6.9 12.1 9.0
AS rate (A) 8.6 7.8 9.8 8.2 6.5 9.7 6.7 14.6 8.4
95% CI 8.1–9.1 7.3–8.4 9.2–10.5 7.3–9.1 5.7–7.5 7.9–11.7 4.7–9.0 9.8–19.8 8.1–8.7
AS rate (W) 7.1 6.4 8.1 6.6 5.4 8.0 5.6 12.3 6.9
95% CI 6.7–7.5 5.9–6.9 7.5–8.7 5.8–7.3 4.7–6.2 6.4–9.8 3.9–7.4 8.4–16.4 6.7–7.2
Ages 20–69 years
Crude rate 11.8 10.5 13.7 10.7 9.3 14.1 8.9 17.9 11.6
AS rate (A) 11.5 10.3 13.7 10.6 9.1 14.1 9.1 18.6 11.4
95% CI 10.8–12.2 9.5–11.1 12.6–14.7 9.2–11.9 7.8–10.5 11.1–17.4 6.2–12.3 12.5–24.9 10.9–11.8
AS rate (W) 11.3 10.1 13.3 10.3 8.9 13.5 9.0 18.8 11.1
95% CI 10.6–12.1 9.4–10.9 12.2–14.3 8.9–11.6 7.7–10.2 10.6–16.5 5.8–11.9 12.6–25.1 10.7–11.6
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
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Table 15a: Number of new cases of cervical cancer by age, states and territories, 1997–2000
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 3 1 1 0 0 0 0 0 5
20–24 12 5 12 2 0 4 0 0 35
25–29 63 32 46 13 16 9 6 2 187
30–34 118 55 76 28 28 10 2 2 319
35–39 122 69 91 31 22 20 8 8 371
40–44 123 95 85 44 21 8 5 5 386
45–49 119 85 56 39 24 5 5 4 337
50–54 113 54 46 20 18 6 2 4 263
55–59 73 56 40 15 14 5 3 3 209
60–64 78 58 54 16 21 4 1 2 234
65–69 86 47 44 19 12 6 3 0 217
70–74 78 55 34 21 14 3 3 1 209
75–79 64 45 32 14 17 4 2 3 181
80–84 51 40 19 18 10 1 2 0 141
85+ 35 25 20 11 6 1 1 0 99
All ages 1,138 722 656 291 223 86 43 34 3,193
Ages 20–69 years 907 556 550 227 176 77 35 30 2,558
Source: National Cancer Statistics Clearing House (AIHW).
67
Table 15b: Age-specific rates of cervical cancer, states and territories, 1997–2000
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.4 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.2
20–24 1.4 0.8 2.4 0.8 0.0 6.7 0.0 0.0 1.3
25–29 6.4 4.3 8.5 4.6 7.6 13.9 11.3 5.3 6.4
30–34 12.3 7.6 14.7 10.0 13.0 15.1 4.0 5.8 11.2
35–39 12.0 9.3 16.5 10.5 9.4 26.7 15.6 25.0 12.3
40–44 12.9 13.5 16.4 15.4 9.3 11.1 10.0 17.8 13.6
45–49 13.6 13.0 11.6 14.9 11.2 7.5 10.2 16.7 12.8
50–54 14.5 9.3 10.7 9.1 9.4 10.1 4.9 21.8 11.3
55–59 12.0 12.6 12.3 9.1 9.5 10.7 11.1 26.5 11.7
60–64 14.9 15.0 20.5 11.7 16.2 9.9 5.1 28.4 15.4
65–69 17.5 13.1 18.5 15.7 9.8 15.9 18.7 0.0 15.6
70–74 16.6 16.0 15.3 19.3 11.4 8.5 20.5 30.7 15.8
75–79 16.4 15.9 17.5 15.9 16.2 13.3 16.9 142.5 16.5
80–84 19.6 21.4 15.5 30.4 14.4 4.8 27.8 0.0 19.2
85+ 15.5 14.6 18.9 19.9 9.5 5.8 17.9 0.0 15.3
All ages
Crude rate 8.9 7.6 9.4 8.0 7.4 9.0 6.9 9.4 8.4
AS rate (A) 8.2 6.9 9.1 7.5 6.7 8.8 6.6 12.6 7.8
95% CI 7.6–8.6 6.4–7.4 8.4–9.8 6.7–8.5 5.8–7.7 7.1–10.8 4.6–8.6 7.6–17.8 7.5–8.1
AS rate (W) 6.7 5.6 7.5 6.0 5.5 7.4 5.4 9.7 6.4
95% CI 6.3–7.1 5.2–6.1 6.9–8.1 5.3–6.7 4.7–6.3 5.8–9.1 3.9–7.0 6.2–13.0 6.1–6.6
Ages 20–69 years
Crude rate 11.3 9.3 12.6 9.8 9.3 13.1 8.6 13.1 10.7
AS rate (A) 11.0 9.0 12.6 9.6 9.1 13.1 8.7 13.6 10.5
95% CI 10.2–11.7 8.3–9.8 11.6–13.7 8.4–11.0 7.8–10.5 10.2–16.2 5.7–11.7 8.8–19.4 10.1–10.9
AS rate (W) 10.7 8.9 12.2 9.3 8.9 12.7 8.5 13.6 10.2
95% CI 10.0–11.4 8.1–9.6 11.1–13.2 8.2–10.6 7.6–10.3 9.8–15.7 5.8–11.5 8.7–19.0 9.8–10.6
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
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Table 16a: New cases of cervical cancer by histological type for women aged 20–69 years, Australia,
1989–2000
Histological type 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Squamous 687 641 650 612 597 630 545 529 449 484 466 398
Adenocarcinoma 116 148 144 141 142 192 147 148 129 140 127 117
Adeno-squamous 48 50 43 51 47 40 34 40 32 30 23 30
Other 56 64 61 43 59 62 45 39 36 29 35 30
Total 907 903 898 847 845 924 771 756 646 683 651 575
Micro-invasive 93 147 156 153 139 170 180 145 116 124 92 86
Source: National Cancer Statistics Clearing House (AIHW).
Table 16b: Age-standardised incidence rates for cervical cancer by histological type for women
aged 20–69 years, Australia, 1989–2000
Histological type 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Squamous 13.2 12.1 11.9 11.1 10.7 11.1 9.5 9.0 7.5 8.0 7.6 6.4
Adenocarcinoma 2.2 2.8 2.6 2.6 2.5 3.4 2.6 2.5 2.1 2.3 2.1 1.9
Adeno-squamous 0.9 0.9 0.8 0.9 0.8 0.7 0.6 0.7 0.5 0.5 0.4 0.5
Other 1.1 1.2 1.1 0.8 1.1 1.1 0.8 0.7 0.6 0.5 0.6 0.5
Micro-invasive 1.8 2.8 2.9 2.8 2.5 3.0 3.1 2.5 2.0 2.0 1.5 1.4
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
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Table 17a: New cases of cervical cancer by histological type for women, all ages, Australia,
1989–2000
Histological type 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Squamous 808 769 792 753 706 780 675 667 546 609 574 520
Adenocarcinoma 136 171 172 157 164 222 173 168 159 166 147 137
Adeno-squamous 53 56 50 56 56 50 39 47 38 35 25 31
Other 75 77 80 62 87 78 70 51 54 48 47 54
Total 1,072 1,073 1,094 1,028 1,013 1,130 957 933 797 858 793 742
Micro-invasive 95 152 166 157 144 181 192 153 122 131 95 89
Source: National Cancer Statistics Clearing House (AIHW).
Table 17b: Age-standardised incidence rates for cervical cancer by histological type for women, all
ages, Australia, 1989–2000
Histological type 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Squamous 8.9 8.6 8.7 8.0 7.5 8.1 7.1 6.8 5.2 5.7 5.3 4.9
Adenocarcinoma 1.5 1.9 1.8 1.7 1.7 2.4 1.8 1.7 1.5 1.6 1.5 1.4
Adeno-squamous 0.6 0.6 0.6 0.6 0.6 0.5 0.4 0.5 0.4 0.3 0.2 0.3
Other 0.8 0.8 0.8 0.6 0.8 0.8 0.7 0.5 0.5 0.4 0.5 0.5
Micro-invasive 1.1 1.8 1.9 1.8 1.6 2.0 2.1 1.6 1.3 1.3 1.0 0.9
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
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Indicator 8: Incidence by location
Table 18: New cases of cervical cancer by age and location, 1993–1996 and 1997–2000
Metropolitan Rural Remote
Age group 1993–1996 1997–2000 1993–1996 1997–2000 1993–1996 1997–2000
0–4 0 0 0 0 0 0
5–9 0 0 0 0 0 0
10–14 1 0 0 0 0 0
15–19 3 4 2 1 0 0
20–24 33 27 10 8 2 0
25–29 130 139 42 42 9 6
30–34 277 229 117 80 15 10
35–39 367 255 128 100 16 16
40–44 349 276 132 91 13 19
45–49 322 254 92 74 18 9
50–54 221 202 83 55 9 6
55–59 196 149 77 57 12 3
60–64 211 163 78 66 8 5
65–69 229 161 84 53 15 3
70–74 200 161 64 43 8 5
75–79 147 131 61 48 4 2
80–84 103 103 41 36 4 2
85+ 75 74 23 24 3 1
All ages 2,863 2,327 1,034 778 137 88
Ages 20–69
years 2,335 1,854 842 626 118 78
Note: The numbers are presented as 4-year rolling blocks of data.
Source: National Cancer Statistics Clearing House (AIHW).
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Table 19: Age-specific and age-standardised incidence rates for cervical cancer by age and location,
1993–1996 and 1997–2000
Metropolitan Rural Remote
Age group 1993–1996 1997–2000 1993–1996 1997–2000 1993–1996 1997–2000
0–4 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.1 0.0 0.0 0.0 0.0 0.0
15–19 0.2 0.2 0.3 0.1 0.0 0.1
20–24 1.5 1.3 1.7 1.6 2.3 0.0
25–29 6.3 6.3 6.9 6.9 9.5 6.5
30–34 13.1 10.9 16.4 12.2 15.5 10.8
35–39 18.2 11.8 17.7 13.1 18.3 18.2
40–44 18.3 13.6 19.7 12.5 18.7 24.4
45–49 18.3 13.3 15.4 11.1 30.2 14.1
50–54 16.6 12.0 17.2 9.2 20.2 11.1
55–59 17.9 11.9 17.6 11.6 35.2 7.6
60–64 21.2 15.5 19.0 15.0 28.1 17.3
65–69 22.9 16.7 21.1 13.1 67.5 13.4
70–74 22.0 17.2 18.3 11.7 44.3 25.5
75–79 22.0 16.8 23.9 16.1 33.8 15.0
80–84 21.2 19.7 22.7 17.8 47.6 21.9
85+ 19.7 15.9 16.8 13.9 41.1 12.6
All ages
AS rate (A) 15.0 11.3 15.1 10.6 22.9 12.8
95% CI 14.5–15.6 10.9–11.8 14.2–16.0 9.8–11.4 19.0–27.0 10.0–15.9
AS rate (W) 14.4 10.8 14.4 10.2 21.8 12.1
95% CI 13.9–15.6 10.4–11.8 13.5–16.0 9.4–11.4 18.3–27.0 9.7–15.9
Ages 20–69 years
AS rate (A) 14.2 10.6 14.4 10.2 20.7 11.9
95% CI 13.7–14.8 10.1–11.1 13.4–15.3 9.3–11.0 17.0–24.8 9.4–14.9
AS rate (W) 13.9 10.3 13.9 9.9 20.3 11.4
95% CI 13.4–14.4 9.9–10.8 13.0–14.9 9.1–10.6 16.6–24.3 9.0–14.5
Notes
1. The numbers are presented as 4-year rolling blocks of data.
2. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source:  National Cancer Statistics Clearing House (AIHW).
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Indicator 7: Mortality
Table 20: Deaths from cervical cancer by age, Australia, 1982–2001
Age group ’82 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ‘01
0–4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 0
20–24 1 1 0 0 2 2 0 1 1 3 0 0 0 0 1 0 3 1 1 2
25–29 7 8 10 6 6 5 3 3 10 5 5 2 6 3 1 2 6 2 4 2
30–34 13 12 13 20 12 15 12 21 14 13 15 11 11 7 13 8 5 6 10 12
35–39 12 18 19 17 16 20 15 18 30 25 19 25 11 16 23 18 19 7 12 15
40–44 22 20 20 18 26 20 24 24 36 19 27 32 28 21 20 16 19 18 14 23
45–49 24 28 26 21 24 19 27 31 36 29 26 23 35 32 30 28 16 25 27 35
50–54 29 26 25 25 25 24 19 27 17 21 13 29 37 26 13 21 24 15 19 27
55–59 41 40 21 31 41 32 41 20 25 25 23 20 26 34 22 24 15 14 19 23
60–64 47 36 41 41 41 28 41 33 34 33 31 25 24 30 21 22 28 15 24 6
65–69 39 49 43 52 50 46 41 54 43 35 25 30 37 37 29 30 19 21 26 18
70–74 35 30 33 43 32 55 34 48 25 37 45 38 33 43 41 36 28 30 37 27
75–79 34 20 29 29 23 29 35 29 32 30 32 28 30 30 38 32 26 26 25 14
80–84 21 22 26 26 23 20 34 24 8 22 35 24 26 27 22 27 26 19 23 19
85+ 18 21 21 29 24 16 17 22 25 32 23 24 24 20 24 30 31 21 26 39
All ages 342 330 327 359 343 329 343 355 337 329 319 311 329 328 296 294 265 220 267 262
Ages 20–69
years 234 238 218 230 242 210 222 231 246 208 184 197 216 207 172 169 154 124 156 163
Note: Deaths were derived from place of usual residence and by year of registration.
Source: AIHW Mortality Database.
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Table 21: Age-specific and age-standardised death rates for cervical cancer by age, Australia,
1982–2001
Age group ’82 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ’01
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.1 0.1 0.0 0.0 0.3 0.3 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.2 0.2 0.3
25–29 1.1 1.2 1.5 0.9 0.9 0.7 0.4 0.4 1.4 0.7 0.7 0.3 0.9 0.4 0.1 0.3 0.8 0.3 0.5 0.3
30–34 2.1 1.9 2.1 3.1 1.9 2.3 1.8 3.0 2.0 1.8 2.0 1.5 1.5 0.9 1.8 1.1 0.7 0.8 1.4 1.6
35–39 2.2 3.2 3.2 2.8 2.5 3.1 2.3 2.7 4.6 3.7 2.7 3.6 1.5 2.2 3.1 2.4 2.5 0.9 1.6 2.0
40–44 5.1 4.5 4.3 3.7 5.4 3.7 4.1 3.9 5.9 2.9 4.3 5.0 4.3 3.1 2.9 2.3 2.7 2.5 1.9 3.1
45–49 6.4 7.6 6.9 5.2 5.7 4.4 6.3 6.9 7.6 5.8 4.9 3.9 5.9 5.2 4.7 4.4 2.5 3.8 4.0 5.1
50–54 7.9 7.2 7.0 7.1 6.8 6.4 4.9 7.1 4.2 5.0 3.0 6.8 8.2 5.6 2.6 3.9 4.2 2.5 3.1 4.2
55–59 11.1 10.7 5.5 8.4 11.1 8.8 11.3 5.4 6.8 7.1 6.2 5.2 6.9 8.7 5.3 5.7 3.5 3.1 4.0 4.6
60–64 14.2 10.6 11.5 11.3 11.2 7.7 11.1 9.0 9.3 9.0 8.6 7.1 6.6 8.5 5.8 6.1 7.6 4.0 6.2 1.5
65–69 13.5 16.8 14.9 17.8 16.4 14.6 12.5 15.7 12.4 10.0 7.2 8.5 10.5 10.5 8.3 8.5 5.4 6.1 7.5 5.2
70–74 15.0 12.5 13.2 16.6 12.3 20.5 12.8 18.1 9.4 13.2 15.4 12.6 10.5 13.4 12.6 11.0 8.5 9.1 11.2 8.1
75–79 21.3 11.6 16.7 16.0 11.8 14.8 17.1 13.7 14.7 13.5 14.1 12.4 13.3 13.0 15.7 12.5 9.7 9.2 8.7 4.8
80–84 19.6 19.9 23.4 22.9 19.0 15.8 26.6 17.6 5.6 14.8 23.3 14.9 15.8 15.9 12.2 15.1 14.4 10.6 12.3 9.4
85+ 22.7 25.6 24.7 33.1 24.9 16.1 16.7 20.9 23.2 29.4 19.5 19.3 18.4 14.6 16.6 20.1 19.9 12.7 15.2 21.3
All ages
AS rate (A) 5.9 5.5 5.4 5.7 5.4 5.0 5.1 5.2 4.9 4.5 4.3 4.1 4.3 4.2 3.7 3.5 3.1 2.5 3.0 2.8
As rate (W) 5.2 5.0 4.7 4.9 4.8 4.4 4.4 4.6 4.4 4.0 3.6 3.6 3.8 3.7 3.1 3.0 2.7 2.2 2.7 2.5
Ages 20–69 years
AS rate (A) 5.1 5.1 4.7 4.8 4.9 4.2 4.3 4.4 4.6 3.8 3.3 3.5 3.8 3.5 2.9 2.8 2.5 2.0 2.5 2.4
As rate (W) 5.1 5.1 4.6 4.7 4.9 4.1 4.3 4.4 4.6 3.8 3.3 3.5 3.8 3.6 2.9 2.8 2.5 2.0 2.5 2.4
Notes
1. Rates for all ages are based on data for women aged 15 years and over.
2. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: AIHW Mortality Database.
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Table 22: Deaths from cervical cancer by age, states and territories, 1994–1997
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 1 0 0 0 0 0 0 0 1
20–24 0 0 1 0 0 0 0 0 1
25–29 1 4 5 0 0 0 2 0 12
30–34 13 11 8 5 1 1 0 0 39
35–39 24 16 10 9 5 2 0 2 68
40–44 37 15 13 9 3 5 3 1 86
45–49 54 23 17 14 6 5 3 6 128
50–54 39 19 23 10 3 3 3 0 100
55–59 37 20 20 15 7 6 2 2 109
60–64 39 19 13 8 7 9 1 2 98
65–69 52 40 19 14 5 4 1 2 137
70–74 60 42 25 10 10 7 2 1 157
75–75 46 32 34 7 11 3 2 1 136
80–84 34 29 14 10 14 1 1 0 103
85+ 36 23 10 15 9 4 1 0 98
All ages 473 293 212 126 81 50 21 17 1,273
Ages 20–69
years 296 167 129 84 37 35 15 15 778
Notes
1. Numbers were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths were derived from place of usual residence and by year of registration.
Source: AIHW Mortality Database.
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Table 23: Age-specific and age-standardised death rates for cervical cancer by age, states and
territories, 1994–1997
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0
25–29 0.1 0.5 0.9 0.0 0.0 0.0 3.8 0.0 0.4
30–34 1.4 1.5 1.6 1.8 0.5 1.5 0.0 0.0 1.4
35–39 2.4 2.2 1.8 3.1 2.1 2.6 0.0 6.4 2.3
40–44 4.0 2.2 2.6 3.2 1.4 7.0 6.0 3.6 3.1
45–49 6.2 3.6 3.6 5.5 2.8 7.6 6.1 26.1 4.9
50–54 5.3 3.5 5.7 4.9 1.6 5.3 7.8 0.0 4.6
55–59 6.3 4.6 6.5 9.5 4.9 13.1 7.8 19.3 6.4
60–64 7.6 5.0 5.1 6.0 5.5 22.7 5.3 29.9 6.7
65–69 10.5 11.0 8.0 11.6 4.0 10.5 6.3 44.1 9.8
70–74 12.8 12.2 11.4 9.4 8.1 19.8 13.8 31.7 11.9
75–75 12.3 11.8 19.3 8.3 10.9 10.3 18.1 49.3 13.0
80–84 13.3 15.7 11.7 17.1 20.5 4.9 14.6 0.0 14.4
85+ 16.8 14.1 10.0 28.7 15.1 24.4 19.5 0.0 16.0
All ages
AS rate (A) 4.8 4.0 4.5 5.0 3.1 6.8 5.5 13.1 4.5
95% CI 4.4–5.3 3.6–4.4 4.1–4.9 4.6–5.5 2.8–3.3 6.2–7.4 5.0–6.0 12.0–14.3 4.1–4.9
AS rate (W) 4.2 3.3 3.6 4.2 2.5 6.3 4.6 11.0 3.8
95% CI 3.8–4.6 3.0–3.7 3.3–4.0 3.8–4.6 2.2–2.7 5.7–6.9 4.2–5.0 10.0–12.0 3.5–4.2
Ages 20–69 years
AS rate (A) 3.7 2.8 3.2 3.9 1.9 5.7 4.0 11.0 3.4
95% CI 3.4–4.0 2.5–3.2 2.8–3.6 3.3–4.6 1.5–2.3 4.2–7.3 2.3–5.7 5.8–16.2 3.2–3.6
AS rate (W) 3.5 2.7 2.9 3.6 1.8 5.6 3.8 9.7 3.2
95% CI 3.2–3.9 2.4–3.0 2.6–3.3 3.0–4.2 1.4–2.2 4.1–7.2 2.2–5.5 5.1–14.4 3.0–3.4
Notes
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: AIHW Mortality Database.
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Table 24: Deaths from cervical cancer by age, states and territories, 1998–2001
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 0
20–24 2 2 2 1 0 0 0 0 5
25–29 0 4 6 5 1 3 0 0 14
30–34 23 11 9 5 8 0 0 0 29
35–39 25 15 5 6 2 1 0 1 56
40–44 33 14 25 8 7 2 2 1 67
45–49 32 27 30 11 6 2 1 0 96
50–54 30 20 19 8 5 5 3 1 79
55–59 26 14 18 10 5 2 1 2 72
60–64 20 10 9 3 3 0 0 3 89
65–69 12 13 12 9 5 2 1 1 96
70–74 31 23 10 11 13 2 0 1 131
75–79 27 10 8 3 4 0 1 0 109
80–84 35 18 11 15 5 2 2 1 95
85+ 51 40 38 20 10 6 4 2 108
All ages 261 158 151 86 50 24 12 10 1,046
Ages 20–69
years 203 130 135 66 42 17 8 9 603
Notes
1. Numbers were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths were derived from place of usual residence and by year of registration.
Source: AIHW Mortality Database.
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Table 25: Age-specific and age-standardised death rates for cervical cancer by age, states and
territories, 1998–2001
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.2 0.3 0.4 0.4 0.0 0.0 0.0 0.0 0.2
25–29 0.0 0.5 1.1 1.8 0.5 4.8 0.0 0.0 0.5
30–34 2.4 1.5 1.7 1.8 3.8 0.0 0.0 0.0 1.0
35–39 2.5 2.0 0.9 2.0 0.9 1.4 0.0 3.1 1.9
40–44 3.4 2.0 4.7 2.8 3.1 2.8 4.0 3.5 2.3
45–49 3.6 4.1 6.1 4.1 2.8 3.0 2.1 0.0 3.6
50–54 3.7 3.3 4.2 3.4 2.5 8.1 6.9 5.1 3.3
55–59 4.1 3.0 5.2 5.8 3.3 4.1 3.5 16.4 3.9
60–64 3.7 2.5 3.3 2.1 2.3 0.0 0.0 39.6 5.7
65–69 2.5 3.6 5.0 7.3 4.1 5.3 6.1 20.4 6.9
70–74 6.6 6.7 4.5 10.0 10.7 5.7 0.0 29.2 9.9
75–75 6.7 3.4 4.2 3.3 3.7 0.0 8.0 0.0 9.7
80–84 13.1 9.4 8.7 24.9 7.0 9.5 26.3 72.6 12.7
85+ 21.5 22.4 34.1 34.3 15.2 33.0 65.9 177.8 16.0
All ages
AS rate (A) 3.1 2.7 3.5 3.9 2.8 3.2 3.2 10.4 3.3
95% CI 2.7–3.5 2.3–3.0 3.1–3.9 3.4–4.3 2.4–3.1 2.8–3.6 2.8–3.6 9.2–11.7 2.9–3.7
AS rate (W) 2.8 2.4 3.3 3.4 2.5 3.1 2.6 8.9 3.0
95% CI 2.5–3.1 2.1–2.7 2.9–3.7 3.0–3.8 2.2–2.8 2.7–3.5 2.3–2.9 7.8–10.0 2.6–3.3
Ages 20–69 years
AS rate (A) 2.4 2.0 2.9 2.7 2.1 2.6 1.8 6.2 2.4
95% CI 2.0–2.7 1.7–2.4 2.4–3.4 2.1–3.4 1.5–2.8 1.4–3.9 0.6–3.1 2.2–10.3 2.2–2.6
AS rate (W) 2.3 2.0 2.9 2.7 2.0 2.7 1.8 6.3 2.4
95% CI 2.0–2.6 1.7–2.4 2.4–3.4 2.1–3.4 1.4–2.6 1.4–4.1 0.6–3.1 2.2–10.3 2.2–2.6
Notes
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: AIHW Mortality Database.
78
Table 26: Deaths from cervical cancer by age and location, 1994–1997 and 1998–2001
Metropolitan Rural Remote
Age group 1994–1997 1998–2001 1994–1997 1998–2001 1994–1997 1998–2001
0–4 0 0 0 0 0 0
5–9 0 0 0 0 0 0
10–14 0 0 0 0 0 0
15–19 1 0 0 0 0 0
20–24 1 4 0 3 0 0
25–29 9 9 3 9 0 1
30–34 25 38 12 17 1 1
35–39 51 36 14 16 2 3
40–44 52 64 30 26 2 2
45–49 88 79 28 27 9 3
50–54 71 61 24 27 4 3
55–59 74 58 29 19 4 1
60–64 63 37 28 10 5 1
65–69 87 37 40 15 7 3
70–74 107 67 44 22 3 2
75–75 94 39 37 10 2 4
80–84 70 65 29 21 2 3
85+ 73 115 24 48 0 8
All ages 864 709 343 270 40 35
Ages 20–69
years 520 423 209 169 33 18
Notes
1. Deaths were derived from place of usual residence and by year of registration.
2. The number of deaths is presented as 4-year rolling blocks of data.
Source: AIHW Mortality Database.
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Table 27:Age-specific and age-standardised death rates for cervical cancer by age and location,
1994–1997 and 1998–2001
Metropolitan Rural Remote
Age group 1994–1997 1998–2001 1994–1997 1998–2001 1994–1997 1998–2001
0–4 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.1 0.0 0.0 0.0 0.0 0.0
20–24 0.0 0.0 0.0 0.2 0.6 0.0
25–29 0.4 0.5 0.0 0.4 1.5 1.1
30–34 1.2 1.7 1.0 1.8 2.6 1.1
35–39 2.5 1.9 2.3 1.7 2.1 3.4
40–44 2.7 4.4 2.7 3.1 3.6 2.6
45–49 4.9 4.6 14.3 4.1 4.1 4.5
50–54 5.0 4.6 8.2 3.5 4.6 5.3
55–59 6.5 6.6 10.8 4.4 3.9 2.4
60–64 6.3 6.9 17.7 3.5 2.3 3.3
65–69 8.8 10.0 30.0 3.8 3.7 12.6
70–74 11.6 12.4 16.8 7.2 6.0 10.5
75–75 13.7 14.2 16.2 4.8 3.4 28.8
80–84 14.0 15.6 22.5 12.2 10.7 30.0
85+ 18.2 17.0 0.0 23.6 27.8 85.5
All ages
AS rate (A) 4.2 3.1 4.5 3.3 7.6 5.7
95% CI 3.9–4.5 2.8-3.3 4.0-5.0 2.9-3.8 5.2-9.9 3.9-7.8
AS rate (W) 3.8 2.8 4.0 3.1 7.3 4.5
95% CI 3.5–4.1 2.5–3.0 3.6–4.5 2.7–3.5 5.0–9.5 3.0–6.2
Ages 20–69 years
AS rate (A) 3.1 2.3 3.4 2.7 6.6 3.0
95% CI 2.8–3.4 2.1–2.5 2.9–3.8 2.3–3.1 4.3–8.8 1.7–4.6
AS rate (W) 3.1 2.3 3.3 2.7 6.7 2.9
95% CI 2.8–3.4 2.1–2.5 2.9–3.8 2.3–3.1 4.3–9.1 1.6–4.4
Notes
1. The age-standardised rates are presented as 4-year rolling blocks of data.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: AIHW Mortality Database.
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Table 28: Deaths from cervical cancer by age and Indigenous status, Queensland, South Australia,
Western Australia and Northern Territory, 1996–1999, 1997–2000 and 1998–2001
Indigenous Non-Indigenous
Age group 1996–1999 1997–2000 1998–2001 1996–1999 1997–2000 1998–2001
0–4 0 0 0 0 0 0
5–9 0 0 0 0 0 0
10–14 0 0 0 0 0 0
15–19 0 0 0 0 0 0
20–24 0 0 0 0 0 3
25–29 1 1 1 5 6 11
30–34 1 2 1 8 13 21
35–39 2 2 3 11 15 11
40–44 5 5 3 19 17 38
45–49 2 5 1 21 30 46
50–54 1 0 1 19 21 32
55–59 1 2 3 17 24 32
60–64 2 2 3 27 34 15
65–69 2 3 4 20 31 23
70–74 3 4 2 34 35 33
75+ 3 3 11 76 91 106
All ages 23 29 33 256 317 371
Ages 20–69
years 17 22 20 147 191 232
Notes
1. Deaths were derived from place of usual residence and by year of registration.
2. The number of deaths is presented as 4-year rolling blocks of data.
3. Only Queensland (from 1998), South Australia, Western Australia and the Northern Territory have Indigenous death registration data
considered to be of a publishable standard.
Source: AIHW Mortality Database.
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Table 29: Age-specific and age-standardised death rates for cervical cancer by age and Indigenous
status, Queensland, South Australia, Western Australia and Northern Territory, 1996–1999,
1997–2000 and 1998–2001
Indigenous Non-Indigenous
Age group 1996–1999 1997–2000 1998–2001 1996–1999 1997–2000 1998–2001
0–4 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.0 0.0 0.0 0.0 0.0 0.0
25–29 2.8 2.5 2.2 0.7 0.7 1.1
30–34 3.3 5.6 2.4 1.1 1.5 2.1
35–39 7.8 6.7 8.5 1.4 1.6 1.0
40–44 24.5 20.7 10.6 2.5 1.9 3.6
45–49 13.0 27.1 4.5 2.9 3.5 4.7
50–54 8.5 0.0 4.9 3.1 2.8 3.6
55–59 12.5 21.4 27.0 3.7 4.3 4.8
60–64 31.0 27.0 34.1 6.9 7.3 2.7
65–69 42.1 55.3 58.2 5.5 7.3 4.8
70–74 101.8 115.6 48.4 9.9 8.8 7.2
75+ 79.7 70.6 214.3 12.1 12.1 12.0
All ages
AS rate (A) 16.7 19.7 25.8 2.3 2.5 3.3
95% CI 8.5–26.3 11.0–30.0 16.9-36.1 2.0–2.7 2.1–2.8 3.0-3.6
AS rate (W) 16.0 18.2 19.0 2.8 3.0 3.0
95% CI 9.1–23.5 11.7–25.6 12.6-25.8 2.5–3.2 2.7–3.3 2.7-3.3
Ages 20–69 years
AS rate (A) 9.8 11.3 11.4 1.9 2.1 2.5
95% CI 4.6–16.1 6.2–17.1 6.3–17.6 1.6–2.3 1.7–2.4 2.2–2.8
AS rate (W) 10.6 12.9 11.0 2.3 2.5 2.5
95% CI 5.3–16.8 7.6–18.8 6.4–16.4 1.9–2.6 2.1–2.8 2.2–2.8
Notes
1. The age-standardised rates are presented as 4-year rolling blocks of data.
2. Deaths derived from place of usual residence and by year of registration.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
5. Only Queensland (from 1998), South Australia, Western Australia and the Northern Territory have Indigenous death registration data
considered to be of a publishable standard.
6. The increases in indigenous age-standardised rates for all ages are related to the inclusion of Queensland data for 1998–2001. Queensland
accounts for almost half of the Indigenous population when the four jurisdictions are combined. When Queensland data is excluded, the
1998–2001 mortality rate falls to 17.2 for all ages and 9.7 for ages 20–69.
Source: AIHW Mortality Database.
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Summary
 The total number of women who participated in cervical screening in 1999–2000 was
3,314,787 of whom 3,244,329 (98%) were in the screening program target age group of
20–69 years.
 Between the periods 1998–1999 and 1999–2000 the proportion of women in the target
population (women aged 20 to 69 years) participating in cervical screening declined from
64.8% to 62.6%.
 Participation in screening declined in all 5-year age groups within the target population
between 1998–1999 and 1999–2000. The largest decline was in younger age groups—
decreasing from 66.0% to 62.4% for women aged 25–29 years and from 52.0% to 49.5% for
women aged 20–24 years.
 The recommended screening interval is 2 years following a negative smear. Of a cohort of
women screened in February 1999 who had a negative Pap smear result, 32% screened
again within 21 months. It is not known what proportion of this early re-screening is
justified on clinical grounds.
 A low-grade abnormality includes atypia, warty atypia, possible CIN, equivocal CIN,
and CIN 1, while a high-grade abnormality is defined to include CIN 12, CIN 2 and
CIN 3 or adenocarcinoma in situ. The ratio of histologically confirmed low-grade
abnormalities to high-grade abnormalities was 1.4 for Australia in 2000, the same as for
1999. The 1999 ratio does not include data for Queensland.
 In 2000, the National Cervical Screening Program detected 13,851 women in the target
age group 20–69 years with high-grade abnormalities. The number of high-grade
abnormalities was highest in the younger age groups. In the age groups 35–39 years or
less the rate of high-grade abnormalities was over 10 per 1,000 women screened whereas
it was less than 2 per 1,000 in women in the age groups 50–54 years and over.
 The number of new cases of cervical cancer declined in Australia in recent years. There
were 787 new cases in Australia in 1999 compared with 1,066 new cases detected in 1988.
 Cervical cancer is the 15th most common cause of cancer mortality in women, accounting
for 267 deaths in 2000. The age-standardised mortality rate from cervical cancer in the
target age group, although fluctuating, declined over time from 5.0 per 100,000 women to
2.5 per 100,000 women between the years 1981 and 2000. During the same period the age-
standardised cervical cancer mortality rate for all ages also declined from 6.2 per 100,000
women to 3.5 per 100,000 women.
 Women in the target age group from remote locations experienced a relatively high
mortality rate from cervical cancer—3.7 deaths per 100,000 women compared with
2.4 deaths per 100,000 women in metropolitan and rural locations. However, between the
periods 1993–1996 and 1997–2000, the age-standardised cervical cancer mortality rate
declined in all regions (metropolitan, rural and remote).
 Prior to 1998, only Western Australia, South Australia and the Northern Territory had
Indigenous mortality registration data of sufficient quality to be publishable. In 1998,
Queensland’s coverage of Indigenous deaths reached an acceptable level to be included
in the analysis of Indigenous mortality data. For these jurisdictions, in the period
1997–2000 there were 22 deaths (an age-standardised mortality rate of 11.3 per 100,000
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women) from cervical cancer among Indigenous women in the target age group. This is
over five times the corresponding rate in non-Indigenous women (2.1 per 100,000
women). Compared with the 1995–1998 mortality rate for Indigenous women in the
target age group, which was 17.5 per 100,000 women, there was a decline in mortality in
the 1997–2000 period. However, these rates are based on relatively small numbers of
cases and may be subject to large variability. Despite the relatively large size of the
apparent decline in the rate, it is still within the range of variation that would be expected
due to chance.
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National cervical screening
monitoring indicators
This report monitors the performance of the National Cervical Screening Program using 10
indicators. Indicators are used as summary measures of program activity, performance and
outcome. They help measure changes in disease patterns and examine the contribution health
interventions may have in preventing or reducing deaths. They can also be used to assist in the
evaluation of screening or other health interventions.
Screening indicators for the National Cervical Screening Program cover the areas of
participation, early re-screening, low- and high-grade abnormality detection, incidence and
mortality. The National Advisory Committee and state and territory cervical screening
programs have endorsed these indicators. Indicators are reviewed annually and, in this report,
definitions of Indicators 2 and 5 have been changed compared with the definitions used in
previous reports.
A listing of the 10 indicators and their definitions follows. The target age group for the National
Cervical Screening Program is 20 to 69 years.
Indicator 1: Participation rate for cervical screening
Percentage of women screened, in a 24-month period by 5-year age groups (20–24, 25–29,
30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69), for all ages (20+) and the target age
group (20–69 years).
Indicator 2: Early re-screening
Proportion of women re-screened by number of re-screens during a 21-month period following
a negative smear.
Indicator 3: Low-grade abnormality detection
Number of women with a histologically verified low-grade intraepithelial abnormality detected
in a 12-month period as a ratio of the number of women with a histologically verified high-
grade intraepithelial abnormality detected in the same period.
Indicator 4: High-grade abnormality detection
Detection rate for histologically verified high-grade intraepithelial abnormalities per 1,000
women screened in a 12-month period, by 5-year age groups (20–24, 25–29, 30–34, 35–39,
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group
(20–69 years, age-standardised).
Indicator 5: Incidence of micro-invasive squamous cell carcinoma
Incidence rate of micro-invasive squamous cell carcinoma per 100,000 estimated resident
female population in a 12-month period, by 5-year age groups (20–24, 25–29, 30–34, 35–39,
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group
(20–69 years, age-standardised).
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Indicator 6: Incidence of squamous, adenocarcinoma, adeno-squamous and
other cervical cancer
Incidence rate of squamous, adenocarcinoma, adeno-squamous and other cervical cancer per
100,000 estimated resident female population in a 12-month period, by 5-year age groups
(20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+)
and for the target age group (20–69 years, age-standardised).
Indicator 7: Mortality
Death rate from cervical cancer per 100,000 estimated resident female population in a
12-month period, by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years—
age-standardised).
Periodic indicators
Periodic indicators have been developed to report on issues that are of importance in
monitoring the outcomes of the cervical screening program over a longer period of time than 1
year. This longer period allows for a greater aggregation of information on issues that are
subject to wide annual fluctuations and allows for a more confident and meaningful estimate of
the outcomes. The periodic indicators presented in this report are based on a reporting period
of 4 years.
Periodic incidence and mortality indicators by location
Indicator 8: Incidence by location
Incidence rate of cervical cancer per 100,000 estimated resident female population in a 4-year
period, by geographic location1 and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44,
45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group
(20–69 years, age-standardised).
Indicator 9: Mortality by location
Death rate from cervical cancer per 100,000 estimated resident female population in a 4-year
period, by geographic location1 and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44,
45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group
(20–69 years, age-standardised).
Postcode and statistical local area information for incidence and mortality is routinely collected
at the point of diagnosis or death. These data have been classified using the Rural, Remote and
Metropolitan Areas classification (RRMA). This classification was developed in 1994 by the
then Department of Primary Industries and Energy and the then Department of Human
Services and Health as a framework by which various data sources could be analysed for
metropolitan, rural and remote zones. The RRMA groups are classified according to Statistical
                                                     
1 See Table A for location classified by RRMA.
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Local Area based on the Australian Standard Geographical Classification (ASGC) version 2.1
(DPIE & DHSH 1994). Concordance algorithms have been developed to convert statistical local
area information coded according to earlier and later ASGC versions into rural, remote and
metropolitan area groupings.
Table A: Structure of the Rural, Remote and Metropolitan Areas classification
Zone Category
Metropolitan zone Capital cities
Other metropolitan centres (urban centre population >100,000)
Rural zone Large rural centres (urban centre population 25,000–99,999)
Small rural centres (urban centre population 10,000–24,999)
Other rural areas (urban centre population <10,000)
Remote zone Remote centres (urban centre population >5,000)
Other remote area (urban centre population <5,000)
Source: DPIE & DHSH 1994.
Indicator 10: Indigenous mortality
Death rate from cervical cancer per 100,000 estimated resident female population in a 4-year
period by Indigenous status and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49,
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years,
age-standardised).
This indicator examines the patterns of mortality among Indigenous women.
Identification of Indigenous status is still very fragmented and generally of poor quality in
health data collections, and cervical screening data are no exception. Of the seven cervical
screening indicators, only one indicator can be stratified by Indigenous status: mortality. Even
for this, coverage is not complete. Only Western Australia, South Australia, the Northern
Territory and Queensland are currently considered to have adequate coverage of Indigenous
deaths in the registration of deaths. Therefore, mortality data from these jurisdictions only are
analysed in this report.
Confidence intervals
Where indicators include a comparison between states and territories, between time periods,
between geographic locations or between Indigenous and non-Indigenous women, a 95%
confidence interval (CI) is presented along with the rates. This is because the observed value of
a rate may vary due to chance even where there is no variation in the underlying value of the
rate. The 95% confidence interval provides a probability that the difference is not due to chance.
Where the confidence intervals do not overlap, there is at least 95% confidence that the change
in a rate is greater than that which could be explained by chance. Where the intervals do
overlap, then there is not a 95% confidence that changes in the rate are due to chance.
For example, the participation rate for New South Wales in 1998–1999 was 60.8% with a
confidence interval of 60.7% to 60.9%. The corresponding rate for 1999–2000 was 60.2% with a
confidence interval of 60.1% to 60.3%. These two intervals do not overlap, so there is at least
95% confidence that the difference between the 1998–1999 and 1999–2000 rates is larger than we
would expect due to chance alone.
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Another example is the comparison between cervical cancer mortality rates for women living in
rural and remote areas. In the period 1997 to 2000 there were 2.4 cervical cancer deaths per
100,000 women living in rural areas. This rate had a confidence interval of 2.2 to 2.6. The
corresponding rate for women in remote areas was 3.7 per 100,000 women, with a confidence
interval of 2.2 to 5.4. These confidence intervals overlap, so despite the relatively large
difference between the two observed rates there is less than 95% probability that these
differences are not caused by chance. This arises from the fact that remote areas of Australia
have small populations, which leads to small numbers of deaths from any specific cause, and
these small numbers may fluctuate from year to year over time. This in turn leads to relatively
wide confidence intervals for an observed death rate.
It is important to note that this result does not imply that the difference between the two rates
is definitely due to chance. Instead, an overlapping confidence interval represents a difference
in rates which is too small to differentiate between a real difference and one which is due to
chance variation.
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Participation
The major objective of the National Cervical Screening Program is to reduce morbidity and
deaths from cervical cancer by detecting treatable pre-cancerous lesions before their
progression to cancer. Through increased participation, more women with pre-cancerous
abnormalities can be detected and treated before progression to cervical cancer, thus reducing
morbidity to women. In addition, increased participation will lead to the detection of more
women with early stages of cancer where treatment can reduce mortality.
The program, through a variety of recruitment initiatives, actively targets women in the age
group 20–69 years. The recommended screening interval for women in the target age group
20–69 years who have ever been sexually active at any stage in their lives is 2 years. Pap smears
may cease at the age of 70 years for women who have had two normal Pap smears within the
last 5 years. Women over 70 years who have never had a Pap smear, or who request a Pap
smear, are screened.
Some women in the target population are unlikely to require screening. They include:
 those who have had a total hysterectomy with their cervix removed;
 those who have never been sexually active; and
 women with a previously diagnosed gynaecological cancer (this last group is monitored
under a clinical arrangement) (Snider & Beauvais 1998).
Participation rate calculations should in principle exclude all three groups from the data. In
practice, the data are adjusted to remove women who have had a hysterectomy but the latter
two groups cannot be excluded due to methodological difficulties.
State and territory Programs have strategic plans in place to increase participation of women in
cervical screening. Such strategies include targeting priority population-groups including
Indigenous women, rural and remote women, and women from culturally and linguistically
diverse backgrounds.
The objective, measurement and usefulness of participation as an indicator is outlined below:
 The participation indicator measures the proportion of the target population covered by the
cervical screening program and the current screening policy of a 2-yearly interval.
 This indicator is important in assessing the contribution of the cervical screening program
to changes in incidence and mortality.
 The indicator can be used as a means of evaluating recruitment practices, particularly if
participation rates are analysed by demographic characteristics.
 When this indicator is used in conjunction with others, it can be used to support analysis
relating to target groups and screening intervals.
 The data presented for this indicator refer to the 2-year period 1999–2000. Data for the
period 1998–1999 are also included for comparison.
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State- and territory-specific issues
 Except for Western Australia and the Australian Capital Territory, the participation rates
are based on all women who were screened in that state or territory. This may lead to an
over-estimation of numbers of women screened because of double counting of some
women between states. This may be the result of difficulty in identifying state of residence
for women in border areas and inclusion of women resident overseas.
 The reference period for this indicator is from 1 January 1999 to 31 December 2000.
Queensland data, however, refer to the 2-year period from March 1999 to February 2001.
This is because the Queensland Pap Smear Register began in February 1999 and therefore
no data are available for the earlier period.
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Indicator 1: Participation rate for cervical screening
Percentage of women screened in a 24-month period, by 5-year age groups (20–24, 25–29,
30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the
target age group (20–69 years).
The graphs and tables below refer to the data for the target age group only. For detailed data
refer to Tables 1b and 2b (pages 132 and 134).
Notes
1. Participation rates have been adjusted for the estimated proportion of women who have had a hysterectomy.
2. These data exclude women who have opted not to be on the register.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 1: Participation rates in the National Cervical Screening Program, by age group, Australia,
1998–1999 and 1999–2000
Age group
2-year
period 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69
(Per cent)
1998–1999 52.0 66.0 69.7 71.4 70.9 69.9 72.8 63.9 57.4 45.2 64.8
1999–2000 49.5 62.4 67.0 68.7 68.8 67.8 71.3 62.5 56.5 44.2 62.6
Notes
1. The Queensland register began in February 1999; therefore no data were available for the 1998–1999 period.
2. Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
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 In 1999–2000, 62.6% of women in the target age group 20–69 years participated in cervical
screening. The proportion of women participating in screening has declined significantly
between the two periods 1998–1999 and 1999–2000. Excluding Queensland data which were
not included in 1998–1999 the proportion of women who participated in screening was
63.3% in 1999–2000, a statistically significant decline from 64.8% in 1998–1999.
 The total number of women screened in Australia in 1999–2000 was 3,314,787, of whom
3,244,329 (98%) were in the target age range of 20–69 years (Table 2a, page 133).
 Participation in screening is highest at the age groups 35–39 to 50–54 but declines sharply
from the age group 55–59.
 Between the two reporting periods, the age-specific participation rates declined in all age
groups. This decline was greatest at younger ages. Screening rates for women aged
25–29 years decreased from 66.0% to 62.4% and for women aged 20–24 years from 52.0%
to 49.5%.
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Notes
1. Rates are expressed as the percentage of the eligible female population and age-standardised to the Australian 1991 population.
2. No data were available for Queensland for the period 1998–1999 as the Queensland register began in February 1999.
3. Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 2: Participation (age-standardised) in the National Cervical Screening Program by women aged
20–69 years, states and territories, 1998–1999 and 1999–2000
2-year period/
rate NSW Vic Qld(a) WA(b) SA Tas ACT(b) NT Australia
1998–1999
AS rate 60.8 68.9 n.a. 65.4 67.6 66.3 67.6 64.5 64.8
95% CI 60.7–60.9 68.8–69.0 n.a. 65.1–65.6 67.3–67.8 65.8–66.7 67.0–68.1 63.7–65.3 64.8–64.9
1999–2000
AS rate 60.2 66.2 59.5 62.8 66.2 65.5 65.1 65.6 62.6
95% CI 60.1–60.3 66.1–66.3 59.3–59.6 62.6–63.1 66.0–66.5 65.0–65.9 64.6–65.7 64.9–66.4 62.5–62.6
(a) Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
(b) The WA and ACT Registries only register women with a valid WA  or ACT address respectively.
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 In 1999–2000, the proportion of women screened in the target age group of 20–69 years in
states and territories varied from a high of 66.2% in Victoria and South Australia to a low of
59.5% in Queensland.
 Compared to 1998–1999, all jurisdictions except the Northern Territory experienced a
decreased rate of participation in 1999–2000. The rate of decline was statistically significant
in New South Wales, Victoria, Western Australia, South Australia and the Australian
Capital Territory. Queensland had no data for the period 1998–1999.
 The Northern Territory registered an increased participation rate in the target age group,
but the increase is not statistically significant.
 All registers except those in Western Australia and the Australian Capital Territory keep
records of Pap smears for women screened in their jurisdiction but who live outside that
jurisdiction. The largest proportion of interstate women recorded for 1999–2000 was in New
South Wales (0.9% of all women screened in the state).
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Early re-screening
The National Cervical Screening Program seeks to maximise reductions in incidence of and
mortality from cervical cancer. The design of the screening program defines two key
parameters to achieve these objectives—target populations and screening intervals. Compliance
with these parameters is crucial in maintaining the effectiveness of the program and in
maintaining cost efficiency in order that resources may be used to increase population
coverage. For most women who have a negative smear, the recommended interval before their
next screen is 2 years.
This indicator is defined as the repeating of a Pap smear within 21 months of a negative smear
report.
This indicator:
 tracks over a period of 21 months a cohort of women from all states and territories, who
had a negative smear result in February 1999, to determine the extent of early re-screening
within the National Cervical Screening Program. The exception to this is Queensland where
the index month is March. February was selected as the index month nationally because it
has been shown to be a relatively stable month in terms of the number of women who are
screened. This pattern has been consistent over a number of years, partly because fewer
women take holidays at this time;
 measures the compliance with the recommended screening interval following a negative
smear; and
 is important in assessing screening coverage around the recommended interval, as
significant differences may reduce program effectiveness.
This indicator should be interpreted with caution as some early re-screening after a negative
Pap smear report is appropriate and in accordance with the National Health and Medical
Research Council (NHMRC) guidelines. Specifically, if a woman has a history of histologically
proven high-grade abnormality, then annual screening is recommended. If a woman is being
monitored after treatment or during the resolution phase of a low-grade abnormality, it is
appropriate for her to be screened earlier than the 24 months interval.
Data issues
The data published in previous reports for Indicator 2, early re-screening, are not directly
comparable with the data in this report as this indicator has been modified to change the
follow-up period from 24 months to 21 months. This change has been made because women
often have their Pap smear taken at a time convenient to them and are likely to have their
biennial screening immediately before the 24-month anniversary. Also for some women,
prescriptions for oral contraceptives lapse at 22 months and the women are then likely to
combine their Pap smears at their visit to the GP for renewing their scripts for contraceptives.
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Indicator 2: Early re-screening
Proportion of women re-screened, by number of re-screens during a 21-month period
following a negative smear.
Refer to Table 4 (p. 135).
Note:  The reference period for this indicator was the 21 months following the index month February 1999. For Queensland the index month
was March 1999.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 3: Proportion of women re-screened, by number of screens during the 21-month period
following a negative smear in February 1999, Australia
21-month period 0 screens 1 screen 2 screens 3+ screens
(Per cent)
Feb 1999–Nov 2000 68.0 27.3 3.8 0.9
Note: Previously published data for this indicator refer to a cohort of women followed up for a period of 24 months. Therefore, the data published in
previous reports are not directly comparable to the data published here.
This indicator, early re-screening, tracked over a period of 21 months a cohort of 175,723
Australian women who had a negative smear result in the index month to ascertain how many
of them had early repeat screens.
 Of these women 68% were not re-screened in the follow-up period, 27% had one additional
screening, 3.9% two additional screenings and less than 1% had 3 or more additional
screenings.
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Refer to Table 4 (p. 135).
Note: The reference period for this indicator was the 21 months following the index month February 1999. For Queensland the index
month was March 1999.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 4: Proportion of women re-screened, by number of screens during the 21-month period
following a negative smear in February 1999, states and territories
No. of
screens NSW Vic Qld WA SA Tas ACT NT Australia
(Per cent)
0 screens 67.5 66.1 70.8 66.8 70.2 68.9 71.3 70.8 68.0
1 screen 28.3 28.3 24.7 29.1 25.4 26.6 24.0 25.0 27.3
2 or more 4.2 5.6 4.5 4.2 4.5 4.4 4.7 4.2 4.7
 Over 70% of the women in Queensland, South Australia, the Australian Capital Territory
and the Northern Territory who had a negative Pap smear result in the index month had no
additional screenings during the follow-up period of 21 months.
 The lowest proportion of women who had additional smears was in the Australian Capital
Territory (28.7%) and the highest was in Victoria (33.9%).
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Low-grade abnormalities
The Pap smear test is able to identify a range of abnormalities in cervical cells. Some of these
abnormalities (the so-called high-grade abnormalities) have a greater chance of becoming
malignant, and are therefore treated aggressively. The chance of low-grade abnormalities
progressing to malignant change is very much less.
In this report a low-grade intraepithelial abnormality includes:
 atypia;
 warty atypia (human papilloma virus (HPV) effect);
 possible cervical intraepithelial neoplasia (CIN) (see Glossary);
 equivocal CIN;
 CIN 1; and
 endocervical dysplasia not otherwise specified (NOS).
The indicator is measured as the ratio of histologically verified low-grade intraepithelial
abnormalities detected to histologically verified high-grade intraepithelial abnormalities.
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Indicator 3: Low-grade abnormality detection
Number of women with a histologically verified low-grade intraepithelial abnormality
detected in a 12-month period as a ratio of the number of women with a histologically
verified high-grade intraepithelial abnormality detected in the same period.
Refer to Tables 5a and 5b (p. 136).
Note: Data for Queensland were incomplete for 1999 as the Queensland register began in February 1999.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 5: Ratio of low- to high-grade abnormalities, by women aged 20–69 years, states and territories,
1999 and 2000
Year NSW Vic Qld WA SA Tas ACT NT Australia
(Ratio)
1999 1.4 1.2 n.a. 1.7 1.4 1.4 1.2 0.9 1.4
2000 1.4 1.2 1.6 1.7 1.5 1.4 1.2 1.1 1.4
 The ratio of histologically confirmed low-grade intraepithelial abnormalities to high-grade
intraepithelial abnormalities in Australia in 2000 was 1.4, which was the same as for 1999
(1.4). Excluding Queensland from the 2000 data for a valid comparison, the ratio still
remains at 1.4.
 The ratio of low-grade to high-grade abnormalities in 2000 varied from 1.1 in the Northern
Territory to 1.7 in Western Australia. The younger age structure of the female population in
the Northern Territory is partly responsible for this result as the rate of high-grade
abnormalities found is much higher in women less than 35 years of age (see Indicator 4).
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 Between the two periods 1999 and 2000, the ratios of low-grade to high-grade abnormalities
increased in South Australia, and in the Northern Territory. In the Northern Territory, in
1999, there were more cases of high-grade than low-grade abnormalities detected but the
reverse was true in 2000.
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High-grade abnormalities
High-grade lesions have a greater probability of progressing to invasive cancer than low-grade
lesions. Therefore, one of the aims of the National Cervical Screening Program is to set a
screening interval which detects most of these lesions before they progress and become
invasive. This indicator measures the frequency of this type of abnormality in the screened
community. A high-grade intraepithelial abnormality is defined in this report as CIN 1/2, CIN
2, CIN 3 or adenocarcinoma in situ.
The National Health and Medical Research Council has produced guidelines to assist in the
management of women who have low- and high-grade intraepithelial abnormalities (DHSH
1994b).
State- and territory- specific issues
 The reference period for Indicator 4 was 12 months from January to December 2000 for all
states and territories, except for Queensland where data refer to a 12-month period from
March 2000 to February 2001.
 The Queensland register commenced in February 1999; therefore data for Queensland were
not available for 1998–1999.
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Indicator 4: High-grade abnormality detection
Detection rate for histologically verified high-grade intraepithelial abnormalities per 1,000
women screened in a 12-month period, by 5-year age groups (20–24, 25–29, 30–34, 35–39,
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group
(20–69 years, age-standardised).
The graph and table below refer to the data for the target age group only. For detailed data
refer to Tables 6a and 6b (pages 137 and 138).
Notes
1. Queensland data were not available in 1999.
2. The reference period for this indicator is from January to December 2000; for Queensland it is from March 2000 to February 2001.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 6: High-grade abnormalities per 1,000 women, by age group, Australia, 1999 and 2000
Age group
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69
(Number per 1,000 women)
1999 16.8 15.0 10.0 6.7 4.4 3.2 2.0 1.7 1.6 2.0 7.6
2000 16.3 15.5 10.3 6.5 4.5 3.0 1.9 1.5 1.5 1.7 7.5
Note: Queensland was included in 2000 data but not in 1999 data.
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 Of the 1,864,492 women screened in the target age group 20–69 years in 2000, high-grade
intra-epithelial abnormalities were detected in 7.4 per 1,000 women (13,851).
 The age-standardised rate of histologically verified high-grade abnormalities declined from
7.6 per 1,000 women screened in the target age group 20–69 years in 1999 to 7.5 per 1,000
women screened in 2000. Queensland data were not included in 1999, and, when
Queensland was excluded from 2000 data for comparison, the age-standardised rate of
histologically verified high-grade abnormalities for Australia in 2000 was 7.1 per 1,000
women screened, a statistically significant fall from 7.6 per 1,000 in 1999.
 High-grade abnormalities per 1,000 women are highest in the younger ages. For example,
women in the age groups under 35–39 had a rate of high-grade abnormalities of 10 per
1,000 or over. In contrast, the rate of high-grade abnormalities among women in age groups
above 50–54 was less than 2 per 1,000.
 Between the two periods 1999 and 2000 the age-specific rates of high-grade abnormalities
detected decreased in most age groups, in particular, in the older age groups. When
Queensland was excluded, the age-specific rates of high-grade abnormalities detected in
2000 declined further in every age group except in the age groups 60–64 and 65–69 where
the rates remained the same as before.
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Refer to Tables 9a and 9b (p. 143).
Notes
1. The Queensland Health Pap Smear Register began operations in February 1999; therefore, no data were available for 1999.
2. The reference period for this indicator is from January to December 2000; for Queensland, it is from March 2000 to February 2001.
3. Rates are standardised to the 1991 Australian total population.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 7: Age-standardised rate of high-grade abnormalities per 1,000 women screened aged
20–69 years, states and territories, 1999 and 2000
AS rate NSW Vic Qld WA SA Tas ACT NT Australia
1999 7.7 6.9 n.a 7.7 8.5 9.9 6.8 8.7 7.6
95% CI 7.4–7.9 6.7–7.2 n.a 7.4–8.2 8.0–9.0 9.0–10.9 5.8–7.7 7.4–10.2 7.4–7.7
2000 7.6 6.2 9.4 6.5 7.2 10.6 6.8 12.9 7.5
95% CI 7.4–7.8 5.9–6.4 9.0–9.7 6.1–6.9 6.8–7.7 9.7–11.5 5.8–7.6 11.2–14.7 7.4–7.6
 In 2000, the age-standardised rate of high-grade abnormalities varied considerably among
states and territories. The lowest rate was observed in Victoria (6.2 per 1,000 women) and
the highest rate was in the Northern Territory (12.9 per 1,000 women).
 Except in Tasmania, the Australian Capital Territory and the Northern Territory, in all
jurisdictions the age-standardised rate of high-grade abnormalities declined between 1999
and 2000. In Victoria, Western Australia, and South Australia the decreases in the rates of
high-grade abnormalities were statistically significant.
 In the Northern Territory and Tasmania, the rates increased between 1999 and 2000; of
these, only the increase in the Northern Territory is statistically significant.
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Incidence
A major objective of the National Cervical Screening Program is to minimise the incidence of
cervical cancer by detecting treatable pre-cancerous lesions before their progression to cancer.
However, where these pre-cancerous lesions cannot be detected, diagnosis of cancer at its
earliest stage, the micro-invasive stage, is the most desirable alternative. The next two
indicators measure the incidence rates of micro-invasive and all cervical cancers in the
community.
In 1994 the International Federation of Gynaecology and Obstetrics endorsed the following
definition of micro-invasive carcinoma of the cervix:
Stage 1a1. Measured invasion of stroma no greater than 3 mm in depth and no wider than
7 mm.
Stage 1a2. Measured invasion of stroma greater than 3 mm and no greater than 5 mm in depth
and no wider than 7 mm. The depth of invasion should not be more than
5 mm taken from the base of the epithelium, either surface or glandular, from which
it originates. Vascular space involvement, either venous or lymphatic, should not
alter the staging (Ostor & Mulvany 1996).
Micro-invasive squamous cell carcinoma makes up the largest share of the micro-invasive
cancer which is reported in Indicator 5. There are also other forms of micro-invasive cancers
such as adenocarcinoma and adeno-squamous cell carcinoma for which data are not available
to include in this indicator.
In interpreting cervical cancer incidence statistics, it should be noted that cervical screening has
been available on an ad hoc basis since the 1960s, but it is only since the late 1980s and early
1990s that there has been an organised national approach to screening at a population level.
The introduction of cervical screening programs may result in the paradox whereby in the
short term the number of new cases of micro-invasive cancer increases because cancers are
found earlier than they would have been without screening, with the rate of more advanced
cancers decreasing in the longer term.
For this report the most recent national data available on incidence data are for 1999, in contrast
to screening data which are available for 2000. This time lag in availability of incidence data is
expected to reduce over the next 2 years.
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Indicator 5: Incidence of micro-invasive cervical
cancer
Incidence rates of micro-invasive squamous cell carcinoma per 100,000 estimated resident
female population in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39,
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group
(20–69 years, age-standardised).
The graphs and tables below refer to the data for the target age group only. For detailed data
refer to Table 11 (page 145).
1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
New cases per 100,000
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 8: Age-standardised incidence rates for micro-invasive squamous cell cancer, women aged
20–69 years, Australia, 1988–1999
1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
(Rate per 100,000 women)
AS rate 1.7 1.8 2.7 2.9 2.8 2.5 3.0 3.1 2.5 2.0 2.0 1.5
 The age-standardised incidence rate of micro-invasive cervical cancer was 1.4 per 100,000
women for all women in 1999, and 1.5 per 100,000 for the target age group 20–69 years
(Table 11, page 145).
 In 1999 there were 95 new cases of micro-invasive cervical cancer among women of all ages,
and for the target age group 20–69 years there were 92 new cases (Table 10, page 144).
 The age-standardised incidence rates for micro-invasive squamous cell carcinoma of the
cervix have fluctuated during the period 1988–1999. Note that the number of cases of micro-
invasive cancer is very low and the rates are therefore unstable (Tables 10 and 11, pages 144
and 145).
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Note: Rates are expressed per 100,000 women.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 9: Age-specific incidence rates of micro-invasive squamous cell cancer, women aged
20–69 years, Australia, 1998 and 1999
Age group
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69
1998 0.3 2.3 2.5 3.4 3.1 2.3 2.3 0.7 1.3 0.6
1999 0.3 1.9 2.0 2.6 2.1 1.0 1.2 1.8 0.5 0.9
 In both 1998 and 1999, women in the age group 35–39 years had the highest incidence rate
of micro-invasive squamous cell cancer. In 1999, there were 20 cases of micro-invasive
squamous cell cervical cancer in women aged 35–39 years. It should be noted that the rates
for age groups 45–49 and over in 1999 are based on small numbers of cases (less than
10 cases in each 5-year age group) (Tables 10 and 11, pages 144 and 145).
116
Indicator 6: Incidence of invasive squamous,
adenocarcinoma, adeno-squamous and other cervical
cancer
Incidence rates of squamous, adenocarcinoma, adeno-squamous and other cervical cancer
per 100,000 estimated resident female population in a 12-month period, by 5-year age groups
(20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79,
80–84, 85+) and for the target age group (20–69 years, age-standardised).
For detailed data refer to Table 13 (page 147).
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Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 10: Age-standardised incidence rates of cervical cancer, Australia, 1988–1999
Age 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
(Rate per 100,000 women)
All ages 12.9 12.6 12.4 12.3 11.3 11.0 12.1 10.0 9.5 8.0 8.4 7.7
20–69 years 17.7 17.4 17.0 16.6 15.3 15.1 16.3 13.4 12.8 10.8 11.2 10.5
 In 1999, the incidence rate of all cervical cancers declined to 7.7 per 100,000 women for all
women in Australia, and 10.5 per 100,000 women in the target group (Table 13, page 147).
 In 1999, cervical cancer was the 10th most frequently diagnosed new cancer in women.
There were 787 new cases of cervical cancer diagnosed in Australia in 1999, and of these 646
were women in the target age group 20–69 years (Table 12, page 146).
 Between 1988 and 1999 the age-standardised incidence rate for cervical cancer for women of
all ages declined by 40.3%, and in the target age group by 40.7% (Table 13, page 147).
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Refer to Table 13 (page 147).
Note: Rates are expressed per 100,000 women.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 11: Age-specific incidence rates of cervical cancer, Australia, 1998 and 1999
Age group
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69
(Rate per 100,000 women)
1998 1.5 6.5 11.9 13.5 14.3 16.6 11.3 12.2 14.7 16.0 9.1
1999 1.1 7.5 10.3 13.1 14.5 11.4 10.8 10.5 16.3 15.6 8.2
 The age-specific rate of cervical cancer incidence rises rapidly in women from age 20–24
through to age 40–44 years; in 1999 the age-specific rate for women aged 40–44 years was
14.5 per 100,000 women. From that age, the rate declines to 10.5 at age group 55–59, and
then rises again.
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Refer to Tables 14b and 15b (pp. 149 and 151).
Notes
1. Rates are expressed per 100,000 women and age standardised to the Australian 1991 population.
2. Bars on graphs represent 95% confidence intervals.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 12: Age-standardised cervical cancer incidence rates, women aged 20–69 years, states and
territories, 1995–1998 and 1996–1999
NSW Vic Qld WA SA Tas ACT NT Australia
1995–1998 12.2 11.5 13.3 12.4 8.4 15.5 9.8 21.9 12.0
95% CI 11.4–13.0 10.6–12.4 12.2–14.4 10.8–13.9 7.1–9.6 12.2–18.9 6.6–13.0 15.2–28.6 11.6–12.5
1996–1999 11.4 10.3 13.5 10.6 9.1 14.1 9.0 18.7 11.3
95% CI 10.7–12.2 9.5–11.1 12.4–14.5 9.2–11.9 7.7–10.4 11.0–17.1 6.1–12.0 13.0–24.4 10.9–11.7
 There were considerable differences in the incidence of cervical cancer among states and
territories for women aged 20–69 years. In the period 1996–1999, the Australian Capital
Territory had the lowest incidence at 9.0 per 100,000 women while the Northern Territory
had the highest rate of cervical cancer incidence of 18.7 per 100,000 women. Both
Queensland (13.5) and the Northern Territory (18.7) were significantly above the national
average (11.3) while South Australia (9.1) was significantly below.
 Between the two periods 1995–1998 and 1996–1999 the incidence rate declined in all states
and territories except in Queensland and South Australia. However, the decline is not
statistically significant (Tables 14b and 15b, pages 149 and 151).
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Refer to Table 16b (page 152).
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 13: Age-standardised incidence rates of cervical cancer by histological type, women
aged 20–69 years, Australia, 1988–1999
Histological type 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Squamous 12.9 13.2 12.1 12.0 11.1 10.7 11.2 9.6 9.1 7.7 8.1 7.7
Adenocarcinoma 3.1 2.2 2.8 2.7 2.6 2.5 3.4 2.6 2.6 2.2 2.4 2.1
Adeno-squamous 0.8 0.9 0.9 0.8 0.9 0.9 0.7 0.6 0.7 0.5 0.5 0.4
Other 0.9 1.0 1.2 1.1 0.7 1.1 1.1 0.7 0.7 0.6 0.5 0.5
 In 1999, squamous cell carcinomas of the cervix accounted for approximately 71.8% of all
new cases of cervical cancer in women aged 20–69 years, adenocarcinomas 19.5%, adeno-
squamous 3.6% and a range of other mixed and unknown histologies comprised the
remaining 5.1% (Table 16a, page 152).
120
Indicator 8: Incidence by location
Incidence rates of cervical cancer per 100,000 estimated resident female population in a
4-year period, by location and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49,
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age (20–69
years—age-standardised).
The graph and table below refer to the data for the target age group only. For detailed data
refer to Table 19 (page 155).
Notes
1. The age-standardised rates are presented as 4-year rolling blocks of data. These years were selected to be comparable
with the mortality by location indicator presented later in this report.
2. Rates are expressed per 100,000 women and age standardised to the Australian 1991 population.
3. Bars on graphs represent 95% confidence intervals.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 14: Age-standardised incidence rates of cervical cancer, by location, women aged 20–69 years,
Australia, 1995–1998 and 1996–1999
Metropolitan Rural Remote
1995–1998 1996–1999 1995–1998 1996–1999 1995–1998 1996–1999
AS rate 12.1 11.3 11.7 11.3 15.2 14.5
95% CI 11.6–12.6 10.8–11.8 10.8–12.6 10.5–12.1 12.1–18.3 11.5–17.5
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 In the 4-year period 1996–1999 there were 2,432 new cases (72% of all new cases) of cervical
cancer in metropolitan locations, 840 new cases (25% of all new cases) in rural locations and
102 new cases (3% of all new cases) in remote locations (Table 18, page 154).
 In the period 1996–1999, the age-standardised cervical cancer incidence rate for women in
the target age group 20–69 years was higher in remote locations (14.5 per 100,000 women)
than in metropolitan and rural locations. This difference was not statistically significant.
During the same period, the corresponding rates of cervical cancer incidence in both
metropolitan and rural locations were 11.3 per 100,000 women (Table 19, page 155).
 The age-standardised incidence rate of cervical cancer in all locations for women aged
20–69 years declined between the periods 1995–1998 and 1996–1999. However, the decline
is not statistically significant.
Age-specific features
 Very few cervical cancers occur in women under the age of 20. The incidence rate of
cervical cancer increases with age.
 Between the periods 1995–1998 and 1996–1999 age-specific rates for the incidence of cervical
cancer declined in almost all ages in metropolitan and rural areas. However, the age pattern
of cervical cancer incidence in remote areas shows fluctuations between the same periods.
This may be due to the small numbers of cervical cancer occurring in these areas.
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Mortality
Cancer of the cervix is one of the few cancers for which there is an efficacious screening test for
detection of precursors of the disease at a pre-cancerous stage, and most deaths due to cervical
cancer are potentially avoidable (Marcus & Crane 1998). However, some deaths do occur and
the objective of the National Cervical Screening Program is to reduce this mortality rate.
These indicators measure the level of mortality from cervical cancer in the total female
population by age and other demographic characteristics. This indicator is important because
from it an assessment can be made of changes in mortality in different age groups and
particular target groups over time. However, it should be noted that changes in the mortality
rates may not be evident for a number of years following an improvement in the participation
rate. Therefore the effectiveness of this measure needs to be viewed in the longer rather than
the shorter term.
Data issues
 Two major changes that have occurred in the classification and processing of Australian
mortality data require some caution when interpreting mortality data over time. They are:
1. the introduction of the tenth revision of the International Classification of Diseases
(ICD-10) for classifying deaths registered from 1 January 1999; and
2. the introduction of the Automated Coding System (ACS) for processing deaths
registered from 1 January 1997.
 As a result of this there is now a break in the mortality data series. In order to make
mortality data coded using ICD-9 and ICD-10 comparable, the Australian Bureau of
Statistics (ABS) has derived comparability factors to adjust data based on ICD-9. These
comparability factors are derived from the movements in the underlying causes of death
coded in ICD-9 compared to ICD-10 (ABS 2000).
 For cervical cancer deaths, the comparability factor is 0.98, and the pre-1997 mortality data
presented in this report have been adjusted accordingly. The effect of this is that the pre-
1997 number of deaths appearing in this report are different from figures in previous
Cervical Screening in Australia reports.
 Prior to 1998, only South Australia, Western Australia and the Northern Territory had a
relatively high coverage of Indigenous status identification in the deaths data. In 1998
Queensland’s coverage of Indigenous deaths reached an acceptable level following the
introduction of a new Death Information Form in 1996–97 which included a question on
Indigenous status (ABS 1999). Therefore, in this report, cervical cancer deaths for
Indigenous Australians include data from Queensland (for 1998 to 2000), South Australia,
Western Australia and the Northern Territory.
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Indicator 7: Mortality
Death rates from cervical cancer per 100,000 estimated resident female population in a
12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years—
age-standardised).
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National Cervical Screening Program
8
Refer to Table 21 (p. 157).
Notes
1. Rates are expressed per 100,000 women.
2. Deaths were derived from place of usual residence and by year of registration
3. Rates for all ages are based on data for women aged 15 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
Source: AIHW Mortality Database.
Figure 15: Age-standardised death rates from cervical cancer, Australia, 1981–2000
’81 ’82 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00
All ages 6.2 5.9 5.5 5.4 5.7 5.4 5.0 5.1 5.2 4.9 4.6 4.3 4.1 4.3 4.2 3.7 3.5 3.1 2.5 3.0
20–69 years 5.0 5.1 5.1 4.7 4.8 4.9 4.2 4.3 4.4 4.6 3.8 3.3 3.5 3.8 3.6 2.9 2.8 2.5 2.0 2.5
 Cervical cancer was the 15th most common cause of cancer deaths in Australian women in
2000, accounting for 267 deaths.
 The age-standardised death rate for women of all ages was 3.0 per 100,000 in 2000.
Mortality from cervical cancer, although fluctuating, has declined over time.
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Notes
1. Rates are expressed per 100,000 women.
2. Deaths were derived from place of usual residence and by year of registration.
Source: AIHW Mortality Database.
Figure 16: Age-specific cervical cancer death rates, by age group, Australia, 1987–1990 and 1997–2000
Age group
Period 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
1987–1990 0.1 0.7 2.3 3.2 4.4 6.3 5.6 8.1 9.3 13.8 15.2 15.0 16.2 19.3
1997–2000 0.2 0.5 1.0 1.9 2.4 3.7 3.4 4.1 5.9 6.9 9.9 10.0 13.1 16.8
 The age-specific rates of cervical cancer mortality increased with rising age—very few
deaths occurred at younger ages while most deaths concentrated at older ages. In the
period 1997–2000, within the target age group, the age-specific mortality ranged from
0.2 deaths per 100,000 women in the age group 20–24 to 6.9 deaths per 100,000 women in
the age group 65–69.
 The age-specific mortality between the two reference periods declined in all age groups
except for the age group 20–24 years.
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Refer to Tables 23 and 25 (pp. 159 and 161).
Notes
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths derived from place of usual residence and by year of registration.
3. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW Mortality Database.
Figure 17: Age-standardised cervical cancer death rates, women aged 20–69 years, states and
territories, 1993–1996 and 1997–2000
NSW Vic Qld WA SA Tas ACT NT Australia
Rate 1993–1996 3.5 3.0 3.5 4.4 2.3 5.7 3.2 11.8 3.4
95% CI 3.1–4.0 2.5–3.4 2.9–4.0 3.4–5.2 1.6–2.9 3.7–7.5 1.5–5.2 5.8–18.8 3.2–3.7
Rate 1997–2000 2.5 1.9 2.9 2.9 1.8 3.5 3.7 4.4 2.4
95% CI 2.1–2.9 1.5–2.2 2.3–3.3 2.2–3.6 1.3–2.4 2.1–5.1 1.8–6.0 1.6–7.6 2.2–2.6
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 There were 1,046 deaths from cervical cancer in all states and territories in 1997–2000.
 The age-standardised mortality rates varied from 4.4 per 100,000 women in the Northern
Territory to 1.8 per 100,000 women in South Australia. Although the Northern Territory
mortality rate declined considerably between the two periods, the rates are based on a very
small number of deaths and are therefore subject to great variability.
 In all jurisdictions except the Australian Capital Territory the death rate declined between
the two periods. Only the declines in New South Wales and Victorian rates, however, are
statistically significant.
 The mortality rate in the Australian Capital Territory increased between the two periods;
this increase is not statistically significant.
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Indicator 9: Mortality by location
Death rates from cervical cancer per 100,000 estimated resident female population in a
4-year period, by location and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49,
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years,
age-standardised).
The graph and table below refer to the data for the target age group only. For additional data
refer to Tables 26 and 27, pages 162 and 163)
Notes:
1. The age-standardised rates are presented as 4-year rolling blocks of data.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW Mortality Database.
Figure 18: Age-standardised cervical cancer death rates, by location, women aged 20–69 years,
1993–1996 and 1997–2000
Metropolitan Rural Remote
1993–1996 1997–2000 1993–1996 1997–2000 1993–1996 1997–2000
Rate 3.2 2.4 3.6 2.4 7.4 3.7
95% CI 3.0–3.5 2.2–2.6 3.2–4.1 2.1–2.8 5.0–9.9 2.2–5.4
128
 During the 4-year period 1997–2000 there were 735 deaths (70% of all cervical deaths in that
period) in metropolitan areas, 276 deaths (26% of all cervical deaths) in rural areas and
35 deaths (4% of all cervical deaths) in remote areas (Table 26, page 162).
 The age-standardised death rate for women in the target age group 20–69 years was highest
in remote locations. The difference was statistically significant from other locations in the
period 1993–1996, but during the period 1997–2000, the difference was not statistically
significant. The high rate of mortality in remote locations may reflect the relatively high
proportion of Indigenous people in remote areas, and the high death rates among
Indigenous women. Both metropolitan and rural locations had similar rates of mortality
from cervical cancer.
 In all three regions the age-standardised mortality rates declined between the periods
1993–1996 and 1997–2000; however, only the declines in metropolitan and rural areas were
statistically significant. The largest overall mortality reduction was in remote areas (a
mortality reduction of 50% between 1993–1996 and 1997–2000), but these rates are based on
small numbers and therefore the decline is not statistically significant. Between the same
two periods, in metropolitan areas, there was a 25% decline in cervical cancer mortality and
in rural areas, it was 33%.
Age-specific features
 In the target age group of 20–69 years, age-specific mortality from cervical cancer increases
with age. However, it is higher still among women in their 70s and 80s.
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Indicator 10: Indigenous mortality
Death rates from cervical cancer per 100,000 estimated resident female population in a
4-year period, by Indigenous status and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44,
45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group
(20–69 years, age-standardised).
The graph and table below refer to the data for the target age group only. For detailed data
refer to Tables 28 and 29 (pages 164 and 165).
Notes
1. The age-standardised rates are presented as 4-year rolling blocks of data.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
4. Only Queensland (from 1998), South Australia, Western Australia and the Northern Territory have Indigenous death registration data
considered to be of a publishable standard.
5. Bars on graphs represent 95% confidence intervals.
Source: AIHW Mortality Database.
Figure 19: Age-standardised cervical cancer mortality rates, by Indigenous status, women aged
20–69 years, 1995–1998, 1996–1999 and 1997–2000
Indigenous Non-Indigenous
1995–1998 1996–1999 1997–2000 1995–1998 1996–1999 1997–2000
AS rate 17.5 10.6 11.3 2.3 1.9 2.1
95% CI 8.8–26.5 5.2–17.1 6.2–17.1 1.9–2.7 1.6–2.3 1.7–2.4
Note: Indigenous and non-Indigenous deaths from Queensland for 1998, 1999 and 2000 are included in the above table.
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 Due to the difficulties of Indigenous identification in health data collections, only
Indigenous mortality data from Queensland (from 1998), Western Australia, South
Australia and the Northern Territory are considered to be of publishable standard.
Therefore, all cervical cancer mortality data for both Indigenous women and non-
Indigenous women used in this analysis are confined to these jurisdictions.
 There were 22 deaths, an age-standardised rate of 11.3 per 100,000 women, attributable to
cervical cancer among Indigenous women in the target age group in 1997–2000 period. This
is over 5 times the mortality rate for non-Indigenous women in the same age range (2.1 per
100,000 women) (Tables 28 and 29, pages 164 and 165).
 The Indigenous cervical cancer mortality rate among women in the target age group
declined over time from 17.5 in 1995–1998 to 11.3 deaths per 100,000 women in
1997–2000. The Queensland data only cover part of this period, so their inclusion may effect
the comparison. When Queensland data were excluded from the analysis, the Indigenous
mortality rate from cervical cancer still declined from 22 in 1995–1998 to 15.1 per 100,000
women in 1997–2001. However, the death rates for Indigenous women are based on
relatively small numbers of cases and may be subject to large variability. This is reflected in
the wide confidence intervals associated with the mortality rates. Despite the relatively
large size of the apparent decline in the rate, it is still within the range of variation that
would be expected due to chance, that is, it is not statistically significant (Table 29, page
165).
 Mortality from cervical cancer among non-Indigenous women fluctuated over time.
Age-specific features
 The numbers of deaths among Indigenous women in Queensland, Western Australia, South
Australia and the Northern Territory are either very small or none in many age groups and
care is needed in interpreting the rates.
 Mortality rates generally increased with increasing age in both Indigenous and non-
Indigenous women.
 Compared with non-Indigenous women, Indigenous women experienced high rates of
mortality in every age group.
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Tables
Indicator 1: Participation rate for cervical screening
Table 1a: Number of women participating in the National Cervical Screening Program, by age,
states and territories, 1998–1999
Age group NSW Vic WA(a) SA(b) Tas ACT(a) NT Total
20–24 105,105 89,660 36,858 27,282 9,466 6,803 4,700 279,874
25–29 152,831 128,002 47,821 36,257 11,298 8,589 6,208 391,006
30–34 154,747 129,131 48,370 37,393 11,482 8,293 5,586 395,002
35–39 158,287 129,303 49,374 39,258 12,479 8,350 4,963 402,014
40–44 135,791 112,158 43,327 35,207 10,685 7,563 4,050 348,781
45–49 114,246 96,199 35,585 30,489 9,030 7,019 3,321 295,889
50–54 91,705 77,518 26,608 24,842 7,222 5,785 2,217 235,897
55–59 61,286 52,870 17,411 16,762 4,845 3,404 1,273 157,851
60–64 45,955 41,426 13,272 13,327 3,689 2,177 641 120,487
65–69 32,950 32,337 9,512 10,243 2,753 1,413 355 89,563
70–74 14,341 12,107 3,656 7,043 842 583 147 38,719
75–79 5,440 4,559 1,311 n.a. 334 198 72 11,914
80+ 2,051 2,055 431 n.a. 134 67 23 4,761
Not stated 5,485 n.a. n.a. 31 7 15 28 5,566
All ages 1,080,220 907,325 333,536 278,134 84,266 60,259 33,584 2,777,324
Ages 20–69
years 1,052,903 888,604 328,138 271,060 82,949 59,396 33,314 2,716,364
(a) The WA and ACT registers only register women with a valid WA or ACT address respectively.
(b) South Australia has grouped women aged 70 years or more, and for the purpose of this table, they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate Registers and inclusion of women
resident overseas.
2. The Queensland Health Pap Smear Register began operations in February 1999. Hence no data are available for 1998–1999.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Table 1b: Proportion of women participating in the National Cervical Screening Program, by age,
states and territories, 1998–1999
Age group NSW Vic WA(a) SA(b) Tas ACT(a) NT Total
(Per cent)
20–24 48.1 53.6 54.7 55.9 63.7 51.9 59.7 52.0
25–29 62.3 69.2 67.6 68.9 70.1 65.4 65.8 66.0
30–34 66.6 72.9 71.2 71.5 71.6 69.3 66.9 69.7
35–39 67.9 75.5 72.3 72.9 72.4 71.5 67.7 71.4
40–44 67.2 74.9 71.2 74.0 70.0 71.8 68.0 70.9
45–49 66.1 74.7 68.8 72.2 68.8 73.1 71.1 69.9
50–54 68.5 78.0 70.7 75.4 71.1 82.4 70.6 72.8
55–59 59.2 69.6 61.9 66.9 60.7 74.3 67.0 63.9
60–64 52.0 63.6 57.5 61.2 54.1 66.1 53.8 57.4
65–69 39.1 52.2 45.7 48.5 42.3 51.7 44.9 45.2
All ages
Crude rate 56.9 64.1 61.9 62.2 60.9 64.2 64.9 60.6
AS rate 56.2 63.8 60.4 62.8 60.9 62.6 60.4 60.0
95% CI 56.1–56.3 63.6–63.9 60.2–60.6 62.5–63.0 60.5–61.4 62.1–63.1 59.7–61.2 59.9–60.0
Ages 20–69 years
Crude rate 61.4 69.3 66.1 68.1 66.8 67.8 65.8 65.4
AS rate 60.8 68.9 65.4 67.6 66.3 67.6 64.5 64.8
95% CI 60.7–60.9 68.8–69.0 65.1–65.6 67.3–67.8 65.8–66.7 67.0–68.1 63.7–65.3 64.8–64.9
(a) The WA and ACT registers only register women with a valid WA and ACT address respectively.
(b) South Australia has grouped all women aged 70 years or more, and for the purposes of this table they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
2. The Queensland Health Pap Smear Register began operations in February 1999. Hence no data are available for 1998–1999.
3. Rates are standardised to the 1991 Australian total population.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Table 2a: Number of women participating in the National Cervical Screening Program, by age, states
and territories, 1999–2000
Age group NSW Vic Qld WA(a) SA(b) Tas ACT(a) NT Australia
20–24 99,812 83,943 64,583 34,401 25,727 8,939 6,354 4,587 328,346
25–29 147,289 120,835 82,879 44,631 33,896 10,398 8,083 6,067 454,078
30–34 151,934 125,001 81,147 46,230 36,101 11,047 8,072 5,782 465,314
35–39 156,192 124,293 83,093 47,573 38,032 11,999 7,964 4,941 474,087
40–44 137,205 110,095 73,124 42,825 35,019 10,864 7,369 4,170 420,671
45–49 115,982 94,509 61,746 35,698 30,326 9,101 6,706 3,490 357,558
50–54 95,632 78,785 50,876 27,795 25,564 7,582 5,848 2,491 294,573
55–59 64,864 53,943 33,397 17,857 17,313 5,123 3,485 1,444 197,426
60–64 48,312 41,339 23,470 13,451 13,827 3,822 2,243 719 147,183
65–69 34,003 30,654 16,317 9,346 10,135 2,849 1,388 401 105,093
70–74 14,487 11,283 7,955 3,583 6,517 788 491 147 45,251
75–79 5,487 4,233 3,228 1,230 n.a. 321 168 79 14,746
80+ 2,113 1,946 1,423 542 n.a. 140 58 20 6,242
Not stated 3,720 27 408 0 24 4 15 21 4,219
All ages 1,077,032 880,886 583,646 325,162 272,481 82,977 58,244 34,359 3,314,787
Ages 20–69
years 1,051,225 863,397 570,632 319,807 265,940 81,724 57,512 34,092 3,244,329
(a) The WA and ACT registers only register women with a valid WA or ACT address respectively.
(b) South Australia has grouped women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
2. Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
134
Table 2b: Proportion of women participating in the National Cervical Screening Program, by age,
states and territories, 1999–2000
Age group NSW Vic Qld WA(a) SA(b) Tas ACT(c) NT Australia
(Per cent)
20–24 45.6 50.0 51.7 50.6 53.5 61.3 48.8 58.8 49.5
25–29 59.6 65.5 61.2 62.9 65.8 66.3 62.1 64.9 62.4
30–34 65.3 69.9 64.0 67.9 69.9 70.1 67.7 67.6 67.0
35–39 67.2 72.3 64.8 69.5 71.5 71.2 69.2 66.6 68.7
40–44 67.0 72.5 64.8 69.5 72.6 70.7 69.7 69.7 68.8
45–49 66.1 72.1 63.2 67.3 71.3 68.4 70.2 72.4 67.8
50–54 69.3 76.4 65.9 70.3 75.1 72.2 79.9 75.2 71.3
55–59 60.2 68.3 57.1 60.7 66.3 62.0 71.7 70.0 62.5
60–64 53.7 62.2 51.0 56.4 62.3 54.6 65.3 58.6 56.5
65–69 40.8 49.7 39.9 44.5 48.6 43.9 49.9 48.3 44.2
All ages
Crude rate 55.2 60.4 55.4 58.5 59.5 58.9 61.4 65.3 57.5
AS rate 55.0 60.4 54.5 57.4 60.4 59.4 59.5 60.7 57.2
95% CI 54.9–55.1 60.3–60.6 54.4–54.7 57.2–57.6 60.2–60.6 59.0–59.8 58.9–60.0 60.0–61.4 57.1–57.2
Ages 20–69 years
Crude rate 60.7 66.6 60.2 63.5 66.7 66.0 65.3 66.4 63.1
AS rate 60.2 66.2 59.5 62.8 66.2 65.5 65.1 65.6 62.6
95% CI 60.1–60.3 66.1–66.3 59.3–59.6 62.6–63.1 66.0–66.5 65.0–65.9 64.6–65.7 64.9–66.4 62.5–62.6
(a) The WA and ACT registers only register women with a valid WA and ACT address respectively.
(b) South Australia has grouped all women aged 70 years or more, and for the purposes of this table they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
2. Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
3. Rates are standardised to the 1991 Australian total population.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Indicator 2: Early re-screening
Table 3: Number of women with repeat screenings in the 21 months following a negative Pap smear
in February 1999, states and territories, and Australia, 1999–2000
No. of tests NSW Vic Qld WA(a) SA Tas ACT(a) NT Australia
0 36,482 33,041 23,870 10,568 9,438 2,624 2,147 1,386 119,556
1 15,212 14,126 8,341 4,601 3,411 1,012 723 490 47,916
2 1,902 2,126 1,202 547 478 138 125 73 6,591
3 317 504 244 96 97 28 16 8 1,310
4 45 117 62 16 23 4 2 0 269
5 or more 6 55 10 3 5 1 0 1 81
(a) The WA and ACT registries only register women with a valid WA and ACT address respectively.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate Registers and inclusion of women resident
overseas.
2. The follow-up period for Queensland data is from March 1999 to December 2000.
Source: State and territory Cervical Cytology Registry data.
Table 4: Percentage of women with repeat screenings in the 21 months following a negative smear
in February 1999, states and territories, and Australia, 1999–2000
No. of tests NSW Vic Qld WA(a) SA Tas ACT(a) NT Australia
0 67.5 66.1 70.8 66.8 70.2 68.9 71.3 70.8 68.0
1 28.3 28.3 24.7 29.1 25.4 26.6 24.0 25.0 27.3
2 3.5 4.3 3.6 3.5 3.6 3.6 4.1 3.7 3.8
3 0.6 1.0 0.7 0.6 0.7 0.7 0.5 0.4 0.7
4 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.0 0.2
5 or more 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0
(a) The WA and ACT registries only register women with a valid WA and ACT address respectively.
Note: These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas.
Source: State and territory Cervical Cytology Registry data.
136
Indicator 3: Low-grade abnormality detection
Table 5a: Number of low- and high-grade abnormalities on histology for women aged 20–69 years,
states and territories, 1999
Abnormalities NSW Vic WA SA Tas ACT NT Total
Low-grade 6,207 4197 2563 1767 640 221 158 15,753
High-grade 4,523 3546 1509 1237 470 178 179 11,642
Ratio 1.37 1.18 1.70 1.43 1.36 1.24 0.88 1.35
As a percentage of all screens in 1999
Low-grade 1.0 0.8 1.3 1.2 1.4 1.8 0.9 1.0
High-grade 0.8 0.7 0.8 0.8 1.0 1.4 1.0 0.8
Notes
1. The Queensland Health Pap Smear Register began operations in February 1999; therefore no data are available for 1999.
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
Source: State and territory Cervical Cytology Registry data.
Table 5b: Number of low- and high-grade abnormalities on histology for women aged 20–69 years,
states and territories, 2000
Abnormalities NSW Vic Qld WA SA Tas ACT NT Australia
Low-grade 6,381 3,701 5,016 2,075 1,541 678 273 320 19,985
High-grade 4,493 2,986 3,105 1,240 1,045 478 220 284 13,851
Ratio 1.42 1.24 1.62 1.67 1.47 1.42 1.24 1.13 1.44
As a percentage of all screens in 2000
Low-grade 1.1 0.7 1.6 1.1 1.0 1.5 0.5 1.6 1.1
High-grade 0.7 0.6 1.0 0.6 0.7 1.0 0.4 1.4 0.7
Note: These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas.
Source: State and territory Cervical Cytology Registry data.
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Indicator 4: High-grade abnormality detection
Table 6a: Rate of histologically confirmed high-grade abnormalities per 1,000 women screened, by
age, states and territories, 1999
Age group NSW Vic WA SA(a) Tas ACT NT Total
20–24 18.3 15.9 15.5 16.8 23.1 8.5 13.4 16.8
25–29 14.8 14.1 17.4 15.4 21.0 10.1 15.8 15.0
30–34 9.9 9.2 10.6 11.8 12.1 10.1 11.1 10.0
35–39 6.7 6.2 6.7 7.0 8.4 8.3 9.6 6.7
40–44 4.3 3.8 4.4 6.5 5.8 5.5 4.0 4.4
45–49 3.0 2.7 3.1 5.0 4.6 4.4 4.8 3.2
50–54 2.2 1.4 1.5 2.9 3.0 1.5 3.9 2.0
55–59 1.4 1.5 1.6 2.6 1.4 3.1 7.9 1.7
60–64 1.3 1.7 1.6 1.8 1.9 3.4 0.0 1.6
65–69 2.2 1.3 2.3 2.4 1.3 6.8 9.3 2.0
70–74 1.7 2.4 0.9 6.8 4.4 10.9 12.8 2.9
75–79 4.5 1.5 5.7 n.a. 0.0 48.1 0.0 4.1
80–84 2.4 2.5 3.8 n.a. 20.4 0.0 0.0 3.0
85+ 0.0 2.9 44.4 n.a. 0.0 0.0 0.0 4.4
All ages 7.4 6.8 7.8 8.3 9.9 7.0 9.7 7.5
Ages 20–69
years 7.6 6.9 7.9 8.4 10.0 6.8 9.7 7.5
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
2. No data were available for Queensland for this period.
Source: State and territory Cervical Cytology Registry data.
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Table 6b: Rate of histologically confirmed high-grade abnormalities per 1,000 women screened, by
age, states and territories, 2000
Age group NSW Vic Qld WA SA(a) Tas ACT NT Australia
20–24 17.0 13.8 19.0 13.8 13.8 27.0 13.8 24.0 16.3
25–29 15.4 13.1 19.7 14.8 13.8 18.1 9.4 23.7 15.5
30–34 10.3 8.6 12.8 9.1 10.9 12.1 12.1 15.6 10.3
35–39 6.2 5.3 8.6 5.6 6.1 10.9 5.4 12.3 6.5
40–44 5.0 3.4 5.5 3.2 4.9 7.0 3.1 11.5 4.5
45–49 2.8 2.3 4.1 2.2 3.4 4.4 4.8 6.3 3.0
50–54 1.9 1.2 2.6 1.3 2.3 3.4 3.6 1.4 1.9
55–59 1.3 1.0 3.0 1.0 1.8 1.7 2.5 3.6 1.5
60–64 1.4 1.1 1.5 1.7 2.4 1.4 1.6 4.7 1.5
65–69 2.2 1.1 1.6 1.0 2.0 2.6 2.6 9.5 1.7
70–74 3.0 2.0 2.4 1.3 8.6 2.3 0.0 12.7 3.2
75–79 3.7 2.1 6.0 1.1 n.a. 0.0 50.0 0.0 3.8
80–84 4.8 2.5 9.5 0.0 n.a. 0.0 0.0 0.0 4.3
85+ 6.5 0.0 0.0 8.4 n.a. 0.0 0.0 0.0 3.1
All ages 7.3 5.9 9.5 6.3 7.0 10.2 6.9 14.3 7.3
Ages 20–69
years 7.4 6.0 9.6 6.4 7.0 10.4 6.8 14.3 7.4
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Note: These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
Source: State and territory Cervical Cytology Registry data.
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Table 7a: Number of histologically confirmed high-grade abnormalities, by age, states and territories,
1999
Age group NSW Vic WA SA(a) Tas ACT NT Total
20–24 1,031 787 316 247 118 31 35 2,565
25–29 1,252 1,031 466 300 131 49 54 3,283
30–34 859 690 290 240 79 46 34 2,238
35–39 599 461 188 150 59 38 25 1,520
40–44 332 249 114 125 36 23 9 888
45–49 201 152 67 84 24 17 9 554
50–54 122 64 25 41 13 5 5 275
55–59 51 48 17 24 4 6 6 156
60–64 35 40 13 13 4 4 0 109
65–69 41 22 13 13 2 5 2 98
70–74 14 16 2 23 2 3 1 61
75–79 14 4 5 0 0 5 0 28
80–84 2 2 1 0 1 0 0 6
85+ 0 1 2 0 0 0 0 3
Age not
stated 5 0 0 0 0 0 0 5
All ages 4,558 3,569 1,519 1,260 473 232 180 11,789
Ages 20–69
years 4,523 3,546 1,509 1,237 470 224 179 11,686
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
2. No data were available for Queensland for this period.
Source: State and territory Cervical Cytology Registry data.
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Table 7b: Number of histologically confirmed high-grade abnormalities, by age, states and territories,
2000
Age group NSW Vic Qld WA SA(a) Tas ACT NT Australia
20–24 924 632 665 266 196 131 46 62 2,922
25–29 1,284 880 904 379 260 105 42 83 3,937
30–34 898 619 593 249 224 75 56 53 2,767
35–39 559 373 400 158 131 73 24 36 1,754
40–44 399 217 231 84 97 44 13 28 1,113
45–49 192 128 146 50 58 23 18 13 628
50–54 107 58 75 23 33 15 12 2 325
55–59 49 31 57 11 17 5 5 3 178
60–64 40 28 20 14 18 3 2 2 127
65–69 41 20 14 6 11 4 2 2 100
70–74 24 13 10 3 31 1 0 1 83
75–79 11 5 10 1 0 0 4 0 31
80–84 4 2 5 0 0 0 0 0 11
85+ 2 0 0 1 0 0 0 0 3
Age not
stated 2 0 1 0 0 0 0 0 3
All ages 4,536 3,006 3,131 1,245 1,076 479 224 285 13,982
Ages 20–69
years 4,493 2,986 3,105 1,240 1,045 478 220 284 13,851
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group
Note: These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
Source: State and territory Cervical Cytology Registry data.
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Table 8a: Number of women screened, by age, states and territories, 1999
Age group NSW Vic WA SA(a) Tas ACT NT Total
20–24 56,207 49,642 20,430 14,682 5,112 3,647 2,617 152,337
25–29 84,768 72,923 26,751 19,534 6,247 4,856 3,420 218,499
30–34 87,185 74,662 27,357 20,319 6,536 4,573 3,068 223,700
35–39 89,864 74,680 28,256 21,299 7,065 4,557 2,616 228,337
40–44 77,916 65,350 25,624 19,272 6,199 4,184 2,225 200,770
45–49 66,105 56,250 21,453 16,760 5,225 3,875 1,860 171,528
50–54 54,472 46,336 16,802 13,938 4,302 3,299 1,289 140,438
55–59 36,266 31,374 10,801 9,400 2,854 1,922 757 93,374
60–64 27,057 23,708 8,133 7,351 2,113 1,164 361 69,887
65–69 18,896 17,423 5,611 5,476 1,582 738 215 49,941
70–74 8,061 6,696 2,276 3,361 451 276 78 21,199
75–79 3,103 2,600 872 n.a. 173 104 46 6,898
80–84 832 811 260 n.a. 49 19 7 1,978
85+ 263 344 45 n.a. 21 10 2 685
Age not
stated
2,406 0 0 11 5 8 11 2,441
All ages 613,401 522,799 194,671 151,403 47,934 33,232 18,572 1,582,012
Ages 20–69
years 598,736 512,348 191,218 148,031 47,235 32,815 18,428 1,548,811
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
2. No data were available for Queensland for this period.
Source: State and territory Cervical Cytology Registry data.
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Table 8b: Number of women screened, by age, states and territories, 2000
Age
group NSW Vic Qld WA SA(a) Tas ACT NT Australia
20–24 54,311 45,637 35,011 19,340 14,251 4,849 3,332 2,581 179,312
25–29 83,176 67,289 45,787 25,623 18,861 5,813 4,489 3,496 254,534
30–34 87,608 71,913 46,487 27,275 20,521 6,217 4,611 3,399 268,031
35–39 89,792 70,492 46,677 28,213 21,478 6,679 4,474 2,935 270,740
40–44 79,978 64,332 42,141 26,282 19,986 6,288 4,180 2,440 245,627
45–49 67,717 55,487 35,455 22,617 17,160 5,216 3,779 2,056 209,487
50–54 56,503 47,826 29,398 17,830 14,521 4,348 3,316 1,445 175,187
55–59 38,304 32,441 19,203 11,521 9,678 2,972 2,001 823 116,943
60–64 27,659 24,586 13,156 8,448 7,654 2,165 1,290 425 85,383
65–69 19,011 17,734 8,744 5,856 5,372 1,546 774 211 59,248
70–74 8,019 6,600 4,195 2,358 3,594 435 268 79 25,548
75–79 2,964 2,391 1,659 905 0 168 80 37 8,204
80–84 842 798 529 300 0 39 19 8 2,535
85+ 306 321 187 119 0 29 5 3 970
Age not
stated 1,734 0 207 0 11 0 7 16 1,975
All
ages 617,924 507,847 328,836 196,687 153,087 46,764 32,625 19,954 1,903,724
Ages
20–69
years 604,059 497,737 322,059 193,005 149,482 46,093 32,246 19,811 1,864,492
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Note: These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
Source: State and territory Cervical Cytology Registry data.
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Table 9a: Age-standardised high-grade abnormality rate on histology per 1,000 women screened aged
20–69 years, states and territories, 1999
NSW Vic WA SA Tas ACT NT Total
All ages
AS rate 7.1 6.4 7.8 7.9 9.5 6.5 8.4 7.1
95% CI 6.9–7.3 6.2–6.7 7.0–8.8 7.4–8.3 8.4–10.7 5.5–7.5 6.8–10.2 7.0–7.3
Target age 20–69
AS rate 7.7 6.9 7.7 8.5 9.9 6.8 8.7 7.6
95% CI 7.4–7.9 6.7–7.2 7.4–8.2 8.0–9.0 9.0–10.9 5.8–7.7 7.4–10.2 7.4–7.7
Notes
1. No data were available for Queensland for this period.
2. Standardised to the 1991 Australian total population.
3. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Table 9b: Age-standardised high-grade abnormality rate on histology per 1,000 women screened aged
20–69 years, states and territories, 2000
NSW Vic Qld WA SA Tas ACT NT Australia
All ages
AS rate 7.1 5.7 8.8 5.8 6.8 9.6 7.6 12.1 7.1
95% CI 6.9–7.4 5.5–6.0 8.5–9.2 5.5–6.1 6.4–7.2 8.7–10.5 6.0–9.7 10.4–14.0 7.0–7.2
Target age
20–69
AS rate 7.6 6.2 9.4 6.5 7.2 10.6 6.8 12.9 7.5
95% CI 7.4–7.8 5.9–6.4 9.0–9.7 6.1–6.9 6.8–7.7 9.7–11.5 5.8–7.6 11.2–14.7 7.4–7.6
Notes
1. Rates are standardised to the 1991 Australian total population.
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Indicator 5: Incidence of micro-invasive cervical cancer
Table 10: New cases of micro-invasive cervical cancer, by age, Australia, 1988–1999
Age group 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
0–4 0 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 1 0 0 0 0 1 0 0 0
20–24 4 1 4 0 5 1 7 1 6 3 2 2
25–29 13 13 14 14 14 9 17 16 17 10 17 14
30–34 20 28 32 31 32 32 36 42 18 27 18 14
35–39 13 10 24 40 25 26 29 29 35 21 26 20
40–44 12 17 25 30 24 17 24 30 23 21 22 15
45–49 9 6 18 9 13 14 26 23 12 11 15 7
50–54 6 4 5 11 12 17 9 12 11 8 13 7
55–59 5 5 8 7 11 4 5 9 7 8 3 8
60–64 2 7 8 7 8 7 10 11 6 5 5 2
65–69 2 2 6 7 9 10 6 7 10 2 2 3
70–74 0 0 2 4 2 3 6 5 3 4 3 2
75–79 1 1 3 3 2 1 3 5 2 2 2 1
80–84 0 1 0 2 0 0 0 1 1 0 2 0
85+ 0 0 0 0 0 1 2 1 1 0 0 0
All ages 87 95 149 166 157 142 180 192 153 122 130 95
Ages 20–69
years 86 93 144 156 153 137 169 180 145 116 123 92
Source:  National Cancer Statistics Clearing House (AIHW).
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Table 11: Age-specific and age-standardised rates of micro-invasive cervical cancer, by age, Australia,
1988–1999
Age group 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0
20–24 0.6 0.2 0.6 0.0 0.7 0.1 1.0 0.1 0.9 0.4 0.3 0.3
25–29 1.9 1.8 2.0 2.0 2.0 1.3 2.5 2.3 2.4 1.4 2.3 1.9
30–34 3.0 4.1 4.6 4.4 4.4 4.4 4.9 5.7 2.5 3.8 2.5 2.0
35–39 2.0 1.5 3.7 6.0 3.7 3.8 4.2 4.1 4.8 2.8 3.4 2.6
40–44 2.1 2.9 4.0 4.7 3.7 2.6 3.7 4.5 3.4 3.0 3.1 2.1
45–49 2.1 1.3 3.8 1.8 2.4 2.4 4.4 3.7 1.9 1.7 2.3 1.0
50–54 1.6 1.0 1.2 2.7 2.8 3.9 2.0 2.5 2.2 1.5 2.3 1.2
55–59 1.4 1.4 2.2 2.0 3.0 1.1 1.3 2.3 1.7 1.9 0.7 1.8
60–64 0.5 1.9 2.2 1.9 2.2 1.9 2.8 3.1 1.7 1.4 1.3 0.5
65–69 0.6 0.6 1.7 2.0 2.5 2.8 1.7 2.0 2.8 0.6 0.6 0.9
70–74 0.0 0.0 0.7 1.4 0.7 1.0 1.9 1.5 0.9 1.2 0.9 0.6
75–79 0.5 0.5 1.4 1.3 0.9 0.4 1.3 2.1 0.8 0.8 0.7 0.4
80–84 0.0 0.7 0.0 1.4 0.0 0.0 0.0 0.6 0.6 0.0 1.1 0.0
85+ 0.0 0.0 0.0 0.0 0.0 0.8 1.6 0.7 0.7 0.0 0.0 0.0
All ages
Crude rate 1.5 1.6 2.5 2.7 2.5 2.2 2.8 2.9 2.3 1.8 1.9 1.4
AS rate (A) 1.5 1.6 2.5 2.7 2.5 2.3 2.8 3.0 2.3 1.8 1.9 1.4
95% CI 1.2–1.9 1.2–1.9 2.1–2.9 2.3–3.1 2.1–2.9 1.9–2.6 2.4–3.2 2.5–3.3 1.9–2.7 1.5–2.1 1.5–2.1 1.1–1.7
AS rate (W) 1.6 1.6 2.5 2.6 2.5 2.2 2.8 2.9 2.3 1.8 1.9 1.4
95% CI 1.2–1.9 1.2–1.8 2–2.9 2.2–3 2.1–2.9 1.8–2.5 2.4–3.2 2.4–3.2 1.9–2.6 1.4–2.1 1.5–2.1 1.1–1.7
Age 20–69 years
Crude rate 1.7 1.8 2.7 2.9 2.8 2.5 3.0 3.2 2.5 2.0 2.1 1.5
AS rate (A) 1.7 1.8 2.7 2.9 2.8 2.5 3.0 3.1 2.5 2.0 2.0 1.5
95% CI 1.3–2.1 1.4–2.2 2.3–3.2 2.4–3.3 2.3–3.2 2.0–2.9 2.5–3.4 2.7–3.6 2.1–2.9 1.6–2.3 1.7–2.4 1.2–1.8
AS rate (W) 1.7 1.7 2.6 2.7 2.7 2.3 2.9 3.0 2.4 1.9 2.0 1.5
95% CI 1.3–2.0 1.4–2.0 2.2–3.0 2.3–3.1 2.3–3.1 1.9–2.7 2.5–3.3 2.6–3.4 2.0–2.8 1.5–2.2 1.6–2.3 1.2–1.8
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source:  National Cancer Statistics Clearing House (AIHW).
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Indicator 6: Incidence of invasive squamous, adenocarcinoma,
adeno-squamous and other cervical cancer
Table 12: New cases of cervical cancer, by age, Australia, 1988–1999
Age group 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
0–4 1 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 1 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0
15–19 4 1 1 1 0 1 1 2 1 1 2 0
20–24 19 16 12 12 9 9 16 3 15 10 10 7
25–29 77 67 59 47 53 37 50 51 43 43 48 55
30–34 128 131 112 119 106 105 123 112 68 78 85 74
35–39 137 122 155 140 126 129 130 110 141 99 102 100
40–44 124 127 139 150 130 128 131 118 116 102 101 104
45–49 92 93 121 105 100 101 131 99 102 79 109 76
50–54 63 82 68 90 77 89 88 58 80 75 65 65
55–59 67 83 80 63 78 78 73 69 63 51 53 48
60–64 90 86 78 81 76 76 88 71 61 51 55 63
65–69 102 99 75 89 87 91 94 77 65 56 56 54
70–74 54 66 66 78 72 64 77 73 59 45 61 44
75–79 50 51 51 48 53 46 65 50 51 46 45 41
80–84 35 28 29 36 35 37 40 30 41 32 39 35
85+ 23 19 23 33 22 21 24 34 25 28 29 21
All ages 1,066 1,071 1,069 1,092 1,024 1,012 1,132 957 931 796 860 787
Ages 20–69 years 899 906 899 896 842 843 924 768 754 644 684 646
Note: The above table includes the incidence of micro-invasive and invasive cervical cancers.
Source:  National Cancer Statistics Clearing House (AIHW).
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Table 13: Age-specific and age-standardised incidence rates of cervical cancer, by age, Australia,
1988–1999
Age group 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
0–4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.6 0.1 0.1 0.2 0.0 0.2 0.2 0.3 0.2 0.2 0.3 0.0
20–24 2.9 2.4 1.8 1.7 1.3 1.3 2.3 0.4 2.2 1.5 1.5 1.1
25–29 11.1 9.5 8.3 6.7 7.7 5.4 7.4 7.4 6.1 5.9 6.5 7.5
30–34 19.4 19.3 16.1 16.7 14.6 14.4 16.7 15.3 9.4 10.9 11.9 10.3
35–39 21.6 18.9 23.6 21.1 18.6 18.7 18.6 15.4 19.3 13.3 13.5 13.1
40–44 21.8 21.3 22.5 23.5 20.3 19.8 19.9 17.7 17.1 14.7 14.3 14.5
45–49 21.1 20.4 25.3 20.9 18.6 17.6 22.0 16.1 15.9 12.3 16.6 11.4
50–54 16.7 21.1 17.0 21.8 18.2 20.5 19.4 12.2 16.1 13.9 11.3 10.8
55–59 18.4 23.0 22.3 17.6 21.3 20.8 18.9 17.4 15.5 12.1 12.2 10.5
60–64 24.3 23.2 21.0 21.9 20.8 21.1 24.7 19.9 17.1 14.0 14.7 16.3
65–69 31.0 28.9 21.5 25.3 24.6 25.6 26.5 21.7 18.3 15.9 16.0 15.6
70–74 20.2 24.8 24.4 27.6 24.6 21.1 24.3 22.6 18.0 13.7 18.4 13.2
75–79 24.3 23.7 23.1 21.3 23.1 20.0 28.5 21.4 20.9 17.9 16.7 14.6
80–84 27.1 20.9 20.8 24.8 23.1 23.4 23.9 17.4 23.2 17.8 21.4 19.0
85+ 23.0 18.4 21.8 30.0 19.0 17.2 18.8 25.3 17.7 18.8 18.6 12.7
All ages
Crude rate 12.9 12.7 12.5 12.6 11.7 11.4 12.6 10.5 10.1 8.5 9.1 8.2
AS Rate (A) 12.9 12.6 12.4 12.3 11.3 11.0 12.1 10.0 9.5 8.0 8.4 7.7
AS Rate (W) 10.6 10.5 10.2 10.1 9.3 9.1 9.9 8.2 7.8 6.5 6.9 6.3
Ages 20–69 years
Crude rate 17.7 17.4 16.9 16.6 15.3 15.2 16.4 13.5 13.0 11.0 11.5 10.7
AS Rate (A) 17.7 17.4 17.0 16.6 15.3 15.1 16.3 13.4 12.8 10.8 11.2 10.5
AS Rate (W) 17.2 17.0 16.6 16.1 14.9 14.7 15.9 13.0 12.5 10.5 11.0 10.2
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
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Table 14a: Number of new cases of cervical cancer by age, states and territories, 1995–1998
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 3 1 2 0 0 0 0 0 6
20–24 11 6 14 3 0 4 0 0 38
25–29 56 41 42 15 16 8 4 3 185
30–34 120 78 75 30 23 15 1 1 343
35–39 155 99 100 38 20 20 9 11 452
40–44 137 117 77 58 24 8 10 6 437
45–49 145 95 65 41 22 9 4 8 389
50–54 117 61 54 20 11 5 5 5 278
55–59 81 61 45 24 13 6 4 2 236
60–64 82 65 38 24 15 10 2 2 238
65–69 85 63 53 26 16 7 1 3 254
70–74 91 54 38 23 21 5 4 2 238
75–79 66 54 39 12 13 6 0 2 192
80–84 47 49 17 14 11 1 3 0 142
85+ 34 36 24 15 6 0 1 0 116
All ages 1,230 880 683 343 211 104 48 45 3,544
Ages 20–69 years 989 686 563 279 160 92 40 41 2,850
Source: National Cancer Statistics Clearing House (AIHW).
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Table 14b: Age-specific rates of cervical cancer, by age, states and territories, 1995–1998
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.4 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.2
20–24 1.2 0.9 2.7 1.1 0.0 6.3 0.0 0.0 1.4
25–29 5.8 5.6 8.0 5.4 7.5 12.1 7.6 8.1 6.5
30–34 12.3 10.7 14.4 10.7 10.3 21.3 2.0 3.0 11.9
35–39 15.6 13.5 18.8 13.1 8.5 26.3 17.3 35.5 15.4
40–44 14.9 17.1 15.5 21.0 10.9 11.3 19.8 22.2 15.9
45–49 17.0 14.9 13.9 16.4 10.5 13.8 8.2 35.4 15.2
50–54 16.5 11.7 14.1 10.3 6.4 9.3 13.9 31.3 13.3
55–59 14.1 14.5 15.3 15.6 9.3 13.5 16.4 20.3 14.2
60–64 16.1 17.3 15.4 18.5 11.9 25.4 11.0 31.3 16.4
65–69 16.9 17.3 22.3 21.7 12.6 18.5 6.4 67.8 18.0
70–74 19.4 15.8 17.5 21.8 17.0 14.1 27.8 65.9 18.2
75–79 18.3 20.9 23.2 15.0 13.5 21.3 0.0 101.0 19.1
80–84 18.5 26.4 14.5 23.8 16.1 4.9 45.4 0.0 20.0
85+ 16.7 23.1 25.5 30.3 10.6 0.0 20.9 0.0 20.0
All ages
Crude rate 9.8 9.5 10.2 9.7 7.1 10.8 7.7 12.9 9.6
AS rate (A) 9.1 8.7 9.8 9.3 6.4 10.7 7.8 17.9 9.0
95% CI 8.6–9.6 8.1–9.3 9.1–10.6 8.3–10.3 5.5–7.2 8.6–12.8 5.6–10.0 12.7–23.2 8.7–9.3
AS rate (W) 7.5 7.1 8.0 7.6 5.2 8.9 6.3 14.4 7.3
95% CI 7.1–7.9 6.6–7.5 7.4–8.6 6.8–8.4 4.5–5.9 7.2–10.6 4.5–8.1 10.2–18.6 7.1–7.6
Ages 20–69 years
Crude rate 12.5 11.7 13.4 12.5 8.5 15.6 9.9 18.6 12.2
AS rate (A) 12.2 11.5 13.3 12.4 8.4 15.5 9.8 21.9 12.0
95% CI 11.4–13.0 10.6–12.4 12.2–14.4 10.8–13.9 7.1–9.6 12.2–18.9 6.6–13.0 15.2–28.6 11.6–12.5
AS rate (W) 12.0 11.2 12.9 12.0 8.1 15.0 9.7 21.6 11.7
95% CI 11.2–12.7 10.3–12.1 11.9–14.0 10.5–13.5 6.9–9.3 11.8–18.2 6.5–12.8 15.0–28.2 11.3–12.2
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
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Table 15a: Number of new cases of cervical cancer, by age, states and territories, 1996–1999
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 2 1 1 0 0 0 0 0 4
20–24 11 8 15 3 0 5 0 0 42
25–29 61 37 47 13 16 7 5 3 189
30–34 105 58 72 30 26 12 0 2 305
35–39 147 93 102 33 24 24 9 10 442
40–44 130 107 91 52 24 8 5 6 423
45–49 134 90 64 34 25 6 5 8 366
50–54 122 60 54 21 14 5 3 6 285
55–59 64 62 41 19 16 5 4 4 215
60–64 80 60 45 17 18 7 1 2 230
65–69 89 50 50 22 12 4 4 0 231
70–74 83 55 27 22 13 4 3 2 209
75–79 65 45 37 14 14 5 1 2 183
80–84 53 46 21 15 8 2 2 0 147
85+ 35 29 20 13 5 0 1 0 103
All ages 1,181 801 687 308 215 94 43 45 3,374
Ages 20–69 years 943 625 581 244 175 83 36 41 2,728
Source: National Cancer Statistics Clearing House (AIHW).
151
Table 15b: Age-specific rates of cervical cancer, by age, states and territories, 1996–1999
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.2 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.2
20–24 1.3 1.2 3.0 1.1 0.0 8.2 0.0 0.0 1.6
25–29 6.2 5.0 8.8 4.6 7.5 10.6 9.3 7.9 6.5
30–34 10.8 8.0 13.9 10.7 11.8 17.6 0.0 5.9 10.6
35–39 14.5 12.5 18.7 11.2 10.2 31.5 17.2 31.5 14.8
40–44 13.9 15.4 17.9 18.5 10.8 11.2 9.9 21.6 15.1
45–49 15.4 13.9 13.4 13.2 11.7 9.1 10.1 34.0 14.0
50–54 16.3 10.9 13.3 10.2 7.6 8.8 7.7 34.8 12.9
55–59 10.8 14.3 13.2 11.9 11.2 10.9 15.5 37.4 12.5
60–64 15.4 15.7 17.7 12.7 14.2 17.6 5.3 29.6 15.5
65–69 17.9 13.8 21.0 18.2 9.6 10.6 25.3 0.0 16.5
70–74 17.6 16.0 12.3 20.5 10.5 11.3 20.5 62.7 15.8
75–79 17.3 16.6 21.0 16.6 13.9 17.1 9.1 95.1 17.4
80–84 20.5 24.6 17.5 25.3 11.6 9.7 28.7 0.0 20.3
85+ 16.3 17.8 20.1 24.9 8.4 0.0 19.4 0.0 16.8
All ages
Crude rate 9.3 8.5 10.0 8.5 7.2 9.8 6.9 12.6 9.0
AS rate (A) 8.5 7.8 9.7 8.2 6.5 9.7 7.0 15.7 8.4
95% CI 8.0–9.0 7.2–8.3 9.0–10.4 7.3–9.1 5.7–7.4 7.7–11.6 4.9–9.1 11.1–20.3 8.1–8.7
AS rate (W) 7.0 6.4 8.0 6.5 5.4 8.0 5.7 12.8 6.9
95% CI 6.6–7.4 5.9–6.8 7.4–8.6 5.8–7.3 4.7–6.1 6.4–9.6 4.0–7.4 9.1–16.6 6.6–7.1
Ages 20–69 years
Crude rate 11.8 8.5 10.9 8.7 7.5 11.3 7.1 14.7 977.9
AS rate (A) 11.4 10.3 13.5 10.6 9.1 14.1 9.0 18.7 11.3
95% CI 10.7–12.2 9.5–11.1 12.4–14.5 9.2–11.9 7.7–10.4 11.0–17.1 6.1–12.0 13.0–24.4 10.9–11.7
AS rate (W) 11.2 10.1 13.0 10.2 8.9 13.5 8.8 19.0 11.0
95% CI 10.5–11.9 9.3–10.9 12.0–14.1 8.9–11.5 7.5–10.2 10.6–16.4 6.0–11.7 13.2–24.8 10.6–11.5
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
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Table 16a: Number of new cases of cervical cancer, by histological type for women aged
20–69 years, Australia, 1988–1999
Histological type 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Squamous 657 688 639 650 610 596 630 546 527 450 484 464
Adenocarcinoma 157 116 149 146 141 141 192 147 148 129 140 126
Adeno-squamous 40 48 50 41 51 47 40 34 40 32 30 23
Other 45 54 61 59 40 59 62 41 39 33 30 33
Total 899 906 899 896 842 843 924 768 754 644 684 646
Micro-invasive 86 87 140 154 151 134 169 176 145 115 116 92
Source: National Cancer Statistics Clearing House (AIHW).
Table 16b: Age-standardised incidence rates for cervical cancer, by histological type for women aged
20–69 years, Australia, 1988–1999
Histological type 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Squamous 12.9 13.2 12.1 12.0 11.1 10.7 11.1 9.5 9.0 7.5 8.0 7.5
Adenocarcinoma 3.1 0.0 2.8 2.7 2.6 2.5 3.4 2.6 2.5 2.1 2.3 2.0
Adeno-squamous 0.8 0.9 0.9 0.8 0.9 0.8 0.7 0.6 0.7 0.5 0.5 0.4
Other 0.9 1.0 1.1 1.1 0.7 1.1 1.1 0.7 0.7 0.6 0.5 0.5
Micro-invasive 1.1 1.1 1.7 1.8 1.8 1.5 1.9 2.0 1.6 1.2 1.3 1.0
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A).
Source: National Cancer Statistics Clearing House (AIHW).
153
Table 17a: Number of new cases of cervical cancer, by histological type for women, all ages, Australia,
1988–1999
Histological type 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Squamous 777 808 767 793 751 705 780 677 665 548 610 571
Adenocarcinoma 179 136 172 174 157 163 222 173 168 159 165 147
Adeno-squamous 45 53 56 48 56 56 50 39 47 38 35 25
Other 65 74 74 77 60 88 80 68 51 51 50 44
Total 1,066 1,071 1,069 1,092 1,024 1,012 1,132 957 931 796 860 787
Micro-invasive 87 89 145 164 155 139 180 188 153 121 123 95
Source: National Cancer Statistics Clearing House (AIHW).
Table 17b: Age-standardised incidence rates for cervical cancer, by histological type for women, all
ages, Australia, 1988–1999
Histological type 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Squamous 9.4 9.6 8.9 8.9 8.3 7.7 8.3 7.1 6.8 5.5 6.0 5.6
Adenocarcinoma 2.2 0.0 2.0 2.0 1.8 1.8 2.4 1.8 1.7 1.6 1.7 1.4
Adeno-squamous 0.6 0.6 0.7 0.5 0.6 0.6 0.5 0.4 0.5 0.4 0.3 0.2
Other 0.8 0.9 0.8 0.8 0.6 0.9 0.9 0.7 0.5 0.5 0.5 0.4
Micro-invasive 1.1 1.2 1.8 1.9 1.8 1.6 2.0 2.1 1.6 1.3 1.3 1.0
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A).
Source: National Cancer Statistics Clearing House (AIHW).
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Indicator 8: Incidence by location
Table 18: Number of new cases of cervical cancer, by age and location, 1995–1998 and 1996–1999
Metropolitan Rural Remote
Age group 1995–1998 1996–1999 1995–1998 1996–1999 1995–1998 1996–1999
0–4 0 0 0 0 0 0
5–9 0 0 0 0 0 0
10–14 0 0 0 0 0 0
15–19 4 2 2 2 0 0
20–24 24 29 14 13 0 0
25–29 136 142 43 40 6 7
30–34 234 209 98 89 11 8
35–39 321 303 110 116 21 23
40–44 329 305 96 101 12 17
45–49 300 277 80 78 8 11
50–54 205 213 67 64 7 8
55–59 167 151 62 59 7 5
60–64 165 158 68 67 5 5
65–69 183 173 59 51 12 7
70–74 182 156 51 48 5 5
75–79 138 133 51 48 3 2
80–84 101 105 38 39 3 3
85+ 89 78 24 23 3 2
All ages 2,577 2,432 863 840 104 102
Ages 20–69
years 2,063 1,959 697 679 90 90
Note: The numbers are presented as 4-year rolling blocks of data.
Source: National Cancer Statistics Clearing House (AIHW).
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Table 19: Age-specific and age-standardised incidence rates for cervical cancer, by age and
location, 1995–1998 and 1996–1999
Metropolitan Rural Remote
Age group 1995–1998 1996–1999 1995–1998 1996–1999 1995–1998 1996–1999
0–4 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.2 0.1 0.3 0.3 0.1 0.1
20–24 1.1 1.4 2.6 2.5 0.0 0.0
25–29 6.3 6.5 7.1 6.6 6.5 7.2
30–34 11.1 10.0 14.4 13.3 11.6 8.5
35–39 15.3 14.3 14.6 15.3 24.2 25.5
40–44 16.7 15.2 13.7 14.2 16.6 23.2
45–49 16.2 14.7 12.7 12.1 13.3 16.8
50–54 13.7 13.4 12.5 11.5 13.2 15.2
55–59 14.4 12.6 13.6 12.4 19.5 13.0
60–64 16.4 15.5 16.5 16.0 16.9 16.6
65–69 18.6 17.7 14.6 12.8 51.8 29.9
70–74 19.6 16.7 14.1 13.3 30.5 27.2
75–79 19.2 17.6 18.8 17.0 24.0 15.6
80–84 19.9 20.5 19.9 20.2 33.2 31.7
85+ 21.3 17.7 15.5 14.1 35.9 23.1
All ages
AS rate (A) 9.1 8.4 8.6 8.3 11.8 10.9
95% CI 8.7–9.5 8.1–8.7 8.0–9.2 7.7–8.9 9.5–14.1 8.8–13.0
AS rate (W) 7.4 6.9 7 6.8 9.3 8.8
95% CI 7.1–7.7 6.6–7.2 6.5–7.5 6.3–7.3 7.5–11.1 7.1–10.5
Ages 20–69 years
AS rate (A) 12.1 11.3 11.7 11.3 15.2 14.5
95% CI 11.6–12.6 10.8–11.8 10.8–12.6 10.5–12.1 12.1–18.3 11.5–17.5
AS rate (W) 11.8 11.1 11.4 10.9 14.5 14.0
95% CI 11.3–12.3 10.6–11.6 10.6–12.2 10.1–11.7 11.5–17.5 11.1–16.9
Notes
1. The numbers are presented as 4-year rolling blocks of data.
2. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source:  National Cancer Statistics Clearing House (AIHW).
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Indicator 7: Mortality
Table 20: Number of deaths from cervical cancer, by age, Australia, 1981–2000
Age group ’81 ’82 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00
0–4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0
20–24 0 1 1 0 0 2 2 0 1 1 3 0 0 0 0 1 0 3 1 1
25–29 4 7 8 10 6 6 5 3 3 10 5 5 2 6 3 1 2 6 2 4
30–34 12 13 12 13 20 12 15 12 21 14 13 15 11 11 7 13 8 5 6 10
35–39 14 12 18 19 17 16 20 15 18 30 25 19 25 11 16 23 18 19 7 12
40–44 17 22 20 20 18 26 20 24 24 36 19 27 32 28 21 20 16 19 18 14
45–49 18 24 28 26 21 24 19 27 31 36 29 26 23 35 32 30 28 16 25 27
50–54 30 29 26 25 25 25 24 19 27 17 21 13 29 37 26 13 21 24 15 19
55–59 36 41 40 21 31 41 32 41 20 25 25 23 20 26 34 22 24 15 14 19
60–64 46 47 36 41 41 41 28 41 33 34 33 31 25 24 30 21 22 28 15 24
65–69 52 39 49 43 52 50 46 41 54 43 35 25 30 37 37 29 30 19 21 26
70–74 42 35 30 33 43 32 55 34 48 25 37 45 38 33 43 41 36 28 30 37
75–79 40 34 20 29 29 23 29 35 29 32 30 32 28 30 30 38 32 26 26 25
80–84 25 21 22 26 26 23 20 34 24 8 22 35 24 26 27 22 27 26 19 23
85+ 19 18 21 21 29 24 16 17 22 25 32 23 24 24 20 24 30 31 21 26
All ages 354 342 330 327 359 343 329 343 355 337 329 319 311 329 328 296 294 265 220 267
Ages 20–69
years 228 234 238 218 230 242 210 222 231 246 208 184 197 216 207 172 169 154 124 156
Note: Deaths were derived from place of usual residence and by year of registration.
Source: AIHW Mortality Database.
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Table 21: Age-specific and age-standardised death rates for cervical cancer, by age, Australia,
1981–2000
Age group ’81 ’82 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0
20–24 0.0 0.1 0.1 0.0 0.0 0.3 0.3 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.2 0.2
25–29 0.6 1.1 1.2 1.5 0.9 0.9 0.7 0.4 0.4 1.4 0.7 0.7 0.3 0.9 0.4 0.1 0.3 0.8 0.3 0.5
30–34 1.9 2.1 1.9 2.1 3.1 1.9 2.3 1.8 3.0 2.0 1.8 2.0 1.5 1.5 0.9 1.8 1.1 0.7 0.8 1.4
35–39 2.8 2.2 3.2 3.2 2.8 2.5 3.1 2.3 2.7 4.6 3.7 2.7 3.6 1.5 2.2 3.1 2.4 2.5 0.9 1.6
40–44 4.1 5.1 4.5 4.3 3.7 5.4 3.7 4.1 3.9 5.9 2.9 4.3 5.0 4.3 3.1 2.9 2.3 2.7 2.5 1.9
45–49 4.9 6.4 7.6 6.9 5.2 5.7 4.4 6.3 6.9 7.6 5.8 4.9 3.9 5.9 5.2 4.7 4.4 2.5 3.8 4.0
50–54 8.0 7.9 7.2 7.0 7.1 6.8 6.4 4.9 7.1 4.2 5.0 3.0 6.8 8.2 5.6 2.6 3.9 4.2 2.5 3.1
55–59 9.8 11.1 10.7 5.5 8.4 11.1 8.8 11.3 5.4 6.8 7.1 6.2 5.2 6.9 8.7 5.3 5.7 3.5 3.1 4.0
60–64 14.3 14.2 10.6 11.5 11.3 11.2 7.7 11.1 9.0 9.3 9.0 8.6 7.1 6.6 8.5 5.8 6.1 7.6 4.0 6.2
65–69 18.2 13.5 16.8 14.9 17.8 16.4 14.6 12.5 15.7 12.4 10.0 7.2 8.5 10.5 10.5 8.3 8.5 5.4 6.1 7.5
70–74 18.7 15.0 12.5 13.2 16.6 12.3 20.5 12.8 18.1 9.4 13.2 15.4 12.6 10.5 13.4 12.6 11.0 8.5 9.1 11.2
75–79 26.0 21.3 11.6 16.7 16.0 11.8 14.8 17.1 13.7 14.7 13.5 14.1 12.4 13.3 13.0 15.7 12.5 9.7 9.2 8.7
80–84 24.0 19.6 19.9 23.4 22.9 19.0 15.8 26.6 17.6 5.6 14.8 23.3 14.9 15.8 15.9 12.2 15.1 14.4 10.6 12.3
85+ 24.9 22.7 25.6 24.7 33.1 24.9 16.1 16.7 20.9 23.2 29.4 19.5 19.3 18.4 14.6 16.6 20.1 19.9 12.7 15.2
All ages
AS rate (A) 6.2 5.9 5.5 5.4 5.7 5.4 5.0 5.1 5.2 4.9 4.6 4.3 4.1 4.3 4.2 3.7 3.5 3.1 2.5 3.0
As rate (W) 5.3 5.2 5.0 4.7 4.9 4.8 4.4 4.4 4.6 4.4 4.0 3.6 3.6 3.8 3.7 3.1 3.0 2.7 2.2 2.7
Ages 20–69 years
AS rate (A) 5.0 5.1 5.1 4.7 4.8 4.9 4.2 4.3 4.4 4.6 3.8 3.3 3.5 3.8 3.6 2.9 2.8 2.5 2.0 2.5
As rate (W) 5.0 5.1 5.1 4.6 4.7 4.9 4.1 4.3 4.4 4.5 3.8 3.3 3.5 3.8 3.6 2.8 2.8 2.5 2.0 2.5
Notes
1. Rates for all ages are based on data for women aged 15 years and over.
2. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 Population (A) and the World Standard
Population (W).
Source: AIHW Mortality Database.
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Table 22: Number of deaths from cervical cancer, by age, states and territories, 1993–1996
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 1 0 0 0 0 0 0 0 1
20–24 0 0 1 0 0 0 0 0 1
25–29 2 3 5 0 0 0 2 0 12
30–34 13 11 9 6 2 1 0 0 41
35–39 25 16 16 8 6 1 0 2 74
40–44 38 25 16 12 4 4 2 1 101
45–49 50 21 17 16 5 7 2 4 121
50–54 41 18 23 11 4 4 3 3 106
55–59 32 23 17 13 8 7 1 2 102
60–64 37 19 14 12 9 6 2 2 100
65–69 44 40 22 15 7 5 0 2 134
70–74 57 41 25 14 12 7 1 0 156
75–75 42 28 33 7 10 4 2 1 127
80–84 31 27 16 9 12 2 1 1 99
85+ 30 26 9 10 9 4 2 0 90
All ages 445 297 220 130 86 51 18 18 1,264
Ages 20–69
years 283 173 137 91 44 34 12 16 791
Notes
1. Numbers were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths were derived from place of usual residence and by year of registration.
Source: AIHW Mortality Database.
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Table 23: Age-specific and age-standardised death rates for cervical cancer, by age, states and
territories, 1993–1996
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0
25–29 0.2 0.4 1.0 0.0 0.0 0.0 3.9 0.0 0.4
30–34 1.3 1.5 1.7 2.1 0.8 1.3 0.0 0.0 1.4
35–39 2.7 2.2 3.1 2.8 2.6 1.3 0.0 6.7 2.6
40–44 4.3 3.7 3.3 4.5 1.8 5.7 3.9 3.8 3.8
45–49 6.1 3.4 3.8 6.8 2.4 10.9 4.2 19.0 5.0
50–54 6.5 3.8 6.8 6.3 2.5 8.0 9.5 21.6 5.7
55–59 5.9 5.6 6.2 8.9 5.9 16.2 4.4 23.1 6.5
60–64 7.4 5.0 5.7 9.4 7.0 15.0 11.5 33.7 7.0
65–69 8.7 10.9 9.2 12.5 5.2 12.8 0.0 48.0 9.5
70–74 12.4 12.4 11.7 13.5 9.7 19.3 7.2 0.0 12.3
75–75 12.5 11.8 21.4 9.2 10.9 14.5 22.0 55.1 13.6
80–84 13.0 15.5 14.4 15.7 18.0 10.2 16.6 108.6 14.7
85+ 16.5 18.6 10.5 22.1 17.3 28.1 47.2 0.0 17.2
All ages
AS rate (A) 4.6 4.1 4.7 5.4 3.4 6.9 4.9 14.4 4.5
95% CI 4.1–5.0 3.6–4.5 4.0–5.2 4.3–6.2 2.7–4.1 4.9–8.7 2.6–7.2 7.2–22.5 4.3–4.8
As rate (W) 4.2 3.6 4.2 5.0 3.0 6.6 4.4 13.0 4.1
95% CI 3.8–4.6 3.2–4.0 3.6–4.7 4.0–5.8 2.3–3.6 4.7–8.5 2.3–6.6 7.0–19.7 3.9–4.3
Ages 20–69 years
AS rate (A) 3.5 3.0 3.5 4.4 2.3 5.7 3.2 11.8 3.4
95% CI 3.1–4.0 2.5–3.4 2.9–4.0 3.4–5.2 1.6–2.9 3.7–7.5 1.5–5.2 5.8–18.8 3.2–3.7
As rate (W) 3.5 2.9 3.5 4.4 2.3 5.8 3.5 12.0 3.4
95% CI 3.1–4.0 2.4–3.3 2.8–3.9 3.3–5.2 1.6–3.0 3.8–7.7 1.6–5.6 6.0–19.0 3.2–3.7
Notes
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 Population (A) and the World Standard
Population (W).
Source: AIHW Mortality Database.
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Table 24: Number of deaths from cervical cancer, by age, states and territories, 1997–2000
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 0
20–24 2 2 1 0 0 0 0 0 5
25–29 1 4 5 2 1 0 1 0 14
30–34 7 5 5 8 3 1 0 0 29
35–39 21 12 10 6 2 3 0 2 56
40–44 26 14 14 7 0 1 3 2 67
45–49 33 22 17 9 10 0 3 2 96
50–54 34 12 18 5 4 3 2 1 79
55–59 26 12 18 9 3 2 1 1 72
60–64 25 19 23 8 5 8 0 1 89
65–69 37 14 16 12 9 4 4 0 96
70–74 45 36 21 14 8 4 1 2 131
75–79 39 28 18 7 9 4 2 2 109
80–84 34 27 12 12 7 2 0 1 95
85+ 42 24 16 17 5 3 1 0 108
All ages 372 231 194 116 66 35 18 14 1,046
Ages 20–69
years 212 116 127 66 37 22 14 9 603
Notes
1. Numbers were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths were derived from place of usual residence and by year of registration.
Source: AIHW Mortality Database.
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Table 25: Age-specific and age-standardised death rates for cervical cancer, by age, states and
territories, 1997–2000
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.2 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.2
25–29 0.1 0.5 0.9 0.7 0.5 0.0 1.9 0.0 0.5
30–34 0.7 0.7 1.0 2.9 1.4 1.5 0.0 0.0 1.0
35–39 2.1 1.6 1.8 2.0 0.9 4.0 0.0 6.3 1.9
40–44 2.7 2.0 2.7 2.5 0.0 1.4 6.0 7.2 2.4
45–49 3.8 3.4 3.5 3.4 4.7 0.0 6.2 8.5 3.7
50–54 4.4 2.1 4.2 2.3 2.1 5.1 4.9 5.5 3.4
55–59 4.3 2.7 5.6 5.5 2.0 4.3 3.7 9.0 4.1
60–64 4.8 4.9 8.8 5.9 3.9 19.8 0.0 14.3 5.9
65–69 7.5 3.9 6.7 9.9 7.3 10.6 25.0 0.0 6.9
70–74 9.6 10.5 9.5 12.9 6.5 11.4 6.9 61.2 9.9
75–75 10.0 9.9 9.8 8.0 8.6 13.3 16.9 96.3 10.0
80–84 13.1 14.5 9.8 20.4 10.1 9.7 0.0 78.3 13.1
85+ 18.7 14.1 15.2 30.9 8.0 17.3 18.0 0.0 16.8
All ages
AS rate (A) 3.4 2.9 3.6 4.2 2.5 4.5 4.4 11.1 3.4
95% CI 3.1–3.8 2.5–3.3 3.1–4.1 3.4–4.9 1.9–3.1 3.0–6.1 2.5–6.5 4.6–18.1 3.2–3.6
As rate (W) 3.1 2.5 3.4 3.6 2.2 4.1 4.0 8.5 3.0
95% CI 2.7–3.4 2.2–2.9 2.9–3.9 2.9–4.3 1.7–2.8 2.7–5.7 2.3–6.1 4.1–13.5 2.8–3.2
Ages 20–69 years
AS rate (A) 2.5 1.9 2.9 2.9 1.8 3.5 3.7 4.4 2.4
95% CI 2.1–2.9 1.5–2.2 2.3–3.3 2.2–3.6 1.3–2.4 2.1–5.1 1.8–6.0 1.6–7.6 2.2–2.6
As rate (W) 2.5 1.9 2.9 2.8 1.8 3.5 3.6 4.5 2.4
95% CI 2.1–2.8 1.5–2.2 2.4–3.4 2.1–3.5 1.3–2.4 2.0–5.0 1.9–5.8 1.7–7.8 2.2–2.6
Notes
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 Population (A) and the World Standard
Population (W).
Source: AIHW Mortality Database.
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Table 26: Number of deaths from cervical cancer, by age and location, 1993–1996 and 1997–2000
Metropolitan Rural Remote
Age group 1993–1996 1997–2000 1993–1996 1997–2000 1993–1996 1997–2000
0–4 0 0 0 0 0 0
5–9 0 0 0 0 0 0
10–14 0 0 0 0 0 0
15–19 1 0 0 0 0 0
20–24 1 4 0 1 0 0
25–29 9 8 2 5 1 1
30–34 25 20 15 7 1 2
35–39 53 39 17 16 4 1
40–44 67 48 31 15 3 4
45–49 83 75 29 18 8 3
50–54 73 59 29 19 4 1
55–59 71 49 27 19 4 4
60–64 66 58 28 30 6 1
65–69 84 65 43 27 7 4
70–74 115 87 38 39 3 5
75–75 90 78 36 29 1 2
80–84 70 71 28 19 1 5
85+ 67 74 24 32 0 2
All ages 873 735 349 276 42 35
Ages 20–69
years 531 425 222 157 37 21
Notes
1. Deaths were derived from place of usual residence and by year of registration.
2. The number of deaths is presented as 4-year rolling blocks of data.
Source: AIHW Mortality Database.
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Table 27: Age-specific and age-standardised death rates for cervical cancer, by age and location, 1993–
1996 and 1997–2000
Metropolitan Rural Remote
Age group 1993–1996 1997–2000 1993–1996 1997–2000 1993–1996 1997–2000
0–4 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.1 0.0 0.0 0.0 0.0 0.0
20–24 0.0 0.0 0.0 0.2 0.2 0.0
25–29 0.4 0.3 1.0 0.4 0.8 1.0
30–34 1.2 2.1 1.0 1.0 1.1 2.2
35–39 2.6 2.3 4.6 1.8 2.1 1.1
40–44 3.5 4.7 4.1 2.4 2.1 5.3
45–49 4.7 4.9 12.9 3.9 2.7 4.7
50–54 5.4 6.1 8.5 3.5 3.3 1.8
55–59 6.4 6.3 11.1 3.9 3.9 10.0
60–64 6.6 7.0 21.3 5.6 6.9 3.4
65–69 8.5 10.8 30.4 6.7 6.7 17.0
70–74 12.7 11.0 17.1 9.3 10.6 27.1
75–75 13.5 14.2 8.2 10.0 9.8 14.9
80–84 14.4 15.6 11.8 13.7 9.7 50.5
85+ 17.6 17.0 0.0 16.0 18.6 21.1
All ages
AS rate (A) 4.4 3.3 4.7 3.4 7.9 6.2
95% CI 4.1–4.7 3.1–3.6 4.2–5.2 3.0–3.8 5.4–10.3 4.0–8.3
As rate (W) 3.9 3.0 4.2 3.0 7.8 5.1
95% CI 3.7–4.2 2.7–3.2 3.8–4.7 2.6–3.4 5.4–10.1 3.4–6.9
Ages 20–69 years
AS rate (A) 3.2 2.4 3.6 2.4 7.4 3.7
95% CI 3.0–3.5 2.2–2.6 3.2–4.1 2.1–2.8 5.0–9.9 2.2–5.4
As rate (W) 3.2 2.4 3.6 2.4 7.4 3.6
95% CI 3.0–3.5 2.2–2.6 3.1–4.1 2.1–2.8 5.0–9.9 2.1–5.2
Notes
1. The age-standardised rates are presented as 4-year rolling blocks of data.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: AIHW Mortality Database.
164
Table 28: Number of deaths from cervical cancer, by age and Indigenous status, 1995–1998,
1996–1999 and 1997–2000
Indigenous Non-Indigenous
Age group 1995–1998 1996–1999 1997–2000 1995–1998 1996–1999 1997–2000
0–4 0 0 0 0 0 0
5–9 0 0 0 0 0 0
10–14 0 0 0 0 0 0
15–19 0 0 0 0 0 0
20–24 0 0 0 0 0 0
25–29 0 1 1 5 5 6
30–34 1 1 2 8 8 13
35–39 3 2 2 19 11 15
40–44 4 5 5 9 19 17
45–49 5 2 5 19 21 30
50–54 0 1 0 14 19 21
55–59 1 1 2 26 17 24
60–64 4 2 2 22 27 34
65–69 4 2 3 18 20 31
70–74 2 3 4 23 34 35
75+ 1 3 3 75 76 91
All ages 25 23 29 235 256 317
Ages 20–69
years 22 17 22 138 147 191
Notes
1. Deaths were derived from place of usual residence and by year of registration.
2. The number of deaths is presented as 4-year rolling blocks of data.
3. Only Queensland (from 1998), South Australia, Western Australia and the Northern Territory have Indigenous death registration data
considered to be of a publishable standard.
Source: AIHW Mortality Database.
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Table 29: Age-specific and age-standardised death rates for cervical cancer, by age and Indigenous
status, 1995–1998, 1996–1999 and 1997–2000
Indigenous Non-Indigenous
Age group 1995–1998 1996–1999 1997–2000 1995–1998 1996–1999 1997–2000
0–4 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.0 0.0 0.0 0.0 0.0 0.0
25–29 0.0 2.8 2.5 0.8 0.7 0.7
30–34 3.8 3.3 5.6 1.2 1.1 1.5
35–39 14.0 7.8 6.7 2.8 1.4 1.6
40–44 23.5 24.5 20.7 1.4 2.5 1.9
45–49 39.2 13.0 27.1 3.2 2.9 3.5
50–54 0.0 8.5 0.0 2.9 3.1 2.8
55–59 14.5 12.5 21.4 6.9 3.7 4.3
60–64 72.1 31.0 27.0 6.8 6.9 7.3
65–69 98.9 42.1 55.3 5.8 5.5 7.3
70–74 81.9 101.8 115.6 7.9 9.9 8.8
75+ 30.6 79.7 70.6 14.7 12.1 12.1
All ages
AS Rate (A) 26.5 17.4 19.7 2.6 2.3 2.5
95% CI 15.8–38.0 9.2–26.4 11.5–28.8 2.2–3.0 2.0–2.7 2.2–2.8
As Rate (W) 22.9 16.7 18.2 3.2 2.8 3.0
95% CI 13.8–32.8 9.3–24.5 11.7–25.6 2.7–3.6 2.5–3.2 2.7–3.3
Ages 20–69 years
AS Rate (A) 17.5 10.6 11.3 2.3 1.9 2.1
95% CI 8.8–26.5 5.2–17.1 6.2–17.1 1.9–2.7 1.6–2.3 1.7–2.4
As Rate (W) 20.5 11.4 12.9 2.6 2.3 2.5
95% CI 11.5–29.4 6.0–17.8 7.6–18.8 2.1–3.0 1.9–2.6 2.1–2.8
Notes
1. The age-standardised rates are presented as 4-year rolling blocks of data.
2. Deaths derived from place of usual residence and by year of registration.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
5. Only Queensland (from 1998), South Australia, Western Australia and the Northern Territory have Indigenous death registration data
considered to be of a publishable standard.
Source: AIHW Mortality Database.
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Appendix A: Cervical cancer—symptoms, detection
and treatment
Cervical cancer affects the cells of the cervix, which is the lower part of the womb or uterus
as it joins the inner end of the vagina. Like other cancers, cervical cancer is a disease where
normal cells change, begin to multiply out of control, and form a growth or tumour. The
cancer may arise from the squamous cells at the transformation zone where the squamous
cells on the outside of the cervix join the columnar cells in the lining of the cervical canal
(squamous cell carcinoma) or from the cells in the cervical canal (adenocarcinoma). Over
two-thirds of cervical cancers are squamous cell carcinomas, which are most easily detected
on the Pap smear, and about 20% are adenocarcinomas. If not detected early, the tumour can
invade local tissue and spread (metastasise) to other parts of the body. The main symptoms
of cervical cancer are unusual bleeding from the vagina, and very rarely an unusual vaginal
discharge. However, these symptoms are quite common and may not be due to cancer.
A cervical cancer may take 10 or more years to develop, but before this the cells may show
pre-cancerous changes. These early changes can be detected by a Pap smear (which is
described in more detail below), and with early treatment of these abnormalities, cervical
cancer can be prevented. The most recent classification of these pre-cancerous lesions has
two levels of severity, low-grade epithelial abnormalities (LGEA) and high-grade epithelial
abnormalities (HGEA). An earlier classification described various grades of cervical intra-
epithelial neoplasia (CIN). Low-grade abnormalities include minor changes in squamous
cells and CIN 1, and high-grade abnormalities include CIN 2, CIN 3, squamous carcinoma-
in-situ, adenocarcinoma-in-situ and invasive carcinoma (squamous or adenocarcinoma).
The Pap smear is the most common way to detect pre-cancerous changes, which rarely cause
any symptoms. The test involves a doctor inserting a speculum into the vagina and gently
scraping the surface of the cervix. This process collects cells that are transferred onto a slide
or into a special liquid, which is then sent to a pathology laboratory for assessment. Pap
smears are offered by general practitioners, gynaecologists, family planning clinics, women’s
health centres, hospital outpatient clinics and, in some circumstances, specially trained
nurses.
If the Pap smear shows an abnormality, the woman may be advised to have a repeat smear if
the abnormality is low-grade or she may be advised to have a colposcopy.  With colposcopy,
a doctor is able to look directly at the cervix under magnification using an instrument called
a colposcope. Using a special stain the doctor can highlight any suspicious area, which may
be pre-cancerous or cancerous. The doctor will then take a tissue sample (a biopsy) of the
suspicious area for further examination by the pathologist.
Pre-cancerous changes can be easily and effectively be treated to prevent the progression to
cervical cancer. The type of treatment depends on whether the change observed is low or
high grade, the woman’s age and general health, whether she wants to have children, and
her preferences.
There is a range of treatments for pre-cancerous changes, including laser treatment, loop
excision (LLETZ), cryosurgery (cold coagulation), electrodiathermy, or cone biopsy, (either
by laser or by scalpel). In a small number of instances, a hysterectomy may be necessary.
For invasive cancer, a cone biopsy or hysterectomy is generally performed. If the cancer cells
are detected on the surface of the cervix only, it may be treated by a cone biopsy. If it has
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invaded deeper into the cervix, a hysterectomy is generally performed. In advanced cases, a
radical hysterectomy is needed to remove the cervix and uterus along with a margin of tissue
around the cervix and lymph nodes from the pelvis. Radiotherapy is sometimes used as well
as surgery, and for more advanced cases it may be used on its own.
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Appendix B: Data sources and limitations
All data used in this report are based on calendar years. Data are derived from multiple
sources and are summarised below.
Table B1: Cervical cancer screening indicators data sources
Indicator Description Data source
1 Participation rate for cervical cancer screening National Cervical Screening Program
2 Early rescreening National Cervical Screening Program
3 Low-grade abnormality detection National Cervical Screening Program
4 High-grade abnormality detection National Cervical Screening Program
5 Incidence of micro-invasive cervical cancer
National Cancer Statistics Clearing House (ICD9 180)
National Cancer Statistics Clearing House
6,8 Incidence of squamous, adenocarcinoma, adeno-
squamous and other cervical cancer (ICD9 180)
National Cancer Statistics Clearing House
7,9,10 Mortality from cervical cancer (ICD9 180)
For 1999 data (ICD10 C539)
AIHW Mortality Database
Population data
The Australian Bureau of Statistics estimated resident female population has been used to
calculate incidence and mortality rates. Participation rates were calculated using the average
of the 1998 and 1999 estimated resident female population (see Appendix D for tables). There
may be some variation in published participation rates because national rates use estimated
resident population data in the denominator whereas local data analysis may use census
counts. The denominator population used to calculate cervical screening participation rates
has been adjusted by the estimated proportion of women who have had a hysterectomy by
age. These data were derived from the 1995 National Health Survey, and are tabled in
Appendix D.
The age-standardised rates in this publication are calculated using the total estimated 1991
mid-year Australian resident population. Where appropriate, rates are also standardised to
the World Standard Population for international comparison. Both the Australian and World
Standard Populations are in Appendix D.
Indigenous mortality data
Due to the difficulties of Indigenous identification, mortality data used in Indicator 10 are
based on deaths in Queensland (for 1998, 1999, 2000 and 2001), Western Australia, South
Australia and the Northern Territory only.
Other data limitations
 Hysterectomy fractions are calculated using national data derived from the National
Health Survey using aggregate data that does not necessarily reflect variation at the state
or territory level. In this report, data from the 1995 National Health Survey have been
used to maintain consistency with earlier reporting. In future reports, data from the 2001
National Health Survey on self-reported hysterectomies will be used.
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 Participation rates will be underestimates to the extent that a small percentage of women
choose to opt-off local registers and have been excluded from the statistics in this report.
 The participation numbers for states and territories other than Western Australia and
Australian Capital Territory, and the Australian totals, may be overestimated because of
double counting of some women in registers. This may be the result of difficulty in
identifying state or territory of residence for women in border areas and the inclusion in
registers of women resident overseas.
 Participation rates published by state and territory programs may differ from those in
this publication because of variation in denominators used.
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Appendix C: Methods
This section describes the methods employed to calculate the estimates presented in the
tables in the body of this publication.
Crude rates
A crude rate is defined as the number of events over a specified period of time (e.g. a year)
divided by the total population. For example, a crude cancer incidence rate is similarly
defined as the number of new cases of cancer in a specified period of time divided by the
population at risk. Crude death rates and cancer incidence rates are expressed in this report
as rates per 100,000 population. Crude participation rate is expressed as a percentage.
Age-specific rates
Age-specific rates are calculated by dividing the number of cases occurring in each specified
age group by the corresponding population in the same age group expressed as a percentage
or a rate per 1,000 or 100,000 population. This rate may be calculated for particular age and
sex groupings, e.g.
                                      
years 5450 aged population female  2000
2000)(year  years 54–50 aged cases New  

  100,000 
        
 623,134
58   100,000
        100,000per  9.3 
Age-standardised rates (AS rate)
Rates are adjusted for age to facilitate comparisons between populations that have different
age structures, e.g. between youthful and ageing communities. There are two different
methods commonly used to adjust for age. In this publication we use direct standardisation
in which age-specific rates are multiplied against a constant population (the Australian 1991
Population Standard unless otherwise specified). This effectively removes the influence of
age structure on the summary rate that is described as the age-standardised rate. The method
may be used for the calculation of participation, incidence and mortality rates. The method
used for this calculation comprises three steps.
Step 1: Calculate the age-specific rate (as shown above) for each age group.
Step 2: Calculate the expected number of cases in each 5-year age group by multiplying the
age-specific rates by the corresponding standard population and dividing by 100,000, giving
the expected number of cases.
Step 3: Sum the expected number of cases in each age group to give the age-standardised
rate. Divide this sum by the total of the standard population and multiply by 100,000.
Age-specific
cervical cancer
incidence rate in
females aged 50–54
in the year 2000
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Confidence intervals
Population numbers for incidence, mortality and screening have a natural level of variability
for a single year above and below what might be expected in the mean over many years. The
percentage variability is small for large population numbers but high for small numbers such
as mortality in a young age group. One measure of the likely difference is the standard error,
which indicates the extent to which a population number might have varied by chance in
only one year of data.
In the 95% confidence interval there are about nineteen chances in twenty that the difference
will be less than two standard errors.
The 95% confidence intervals in this report were calculated using the software package
Palisade @risk (http://www.palisade.com). These calculations were based on 1,000
simulations using a binomial or Poisson distribution with the observed data to calculate the
distribution parameters.
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Appendix D: Population data
Table D1: Australian Standard Population(a) and World Standard Population(b)
Age group World Standard Population (W) Australian 1991 Population Standard (A)
0–4 12,000 1,271,703
5–9 10,000 1,272,208
10–14 9,000 1,241,619
15–19 9,000 1,364,074
20–24 8,000 1,396,764
25–29 8,000 1,399,663
30–34 6,000 1,425,735
35–39 6,000 1,328,387
40–44 6,000 1,294,271
45–49 6,000 1,029,145
50–54 5,000 846,934
55–59 4,000 725,950
60–64 4,000 736,868
65–69 3,000 671,390
70–74 2,000 510,755
75–79 1,000 384,495
80–84 500 229,828
85+ 500 154,247
Total 100,000 17,284,036
Sources
(a) ABS (1993).
(b) Doll & Smith (1982).
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Table D2: Hysterectomy fractions for women aged 15–80+ years,
Australia, 1995
Age group % of women who have not had a hysterectomy
18–19 98.4
20–24 99.8
25–29 99.3
30–34 98.0
35–39 91.9
40–44 85.2
45–49 79.1
50–54 68.5
55–59 68.5
60–64 67.8
65–69 68.8
70–74 66.8
75–79 66.8
80+ 61.5
Total 84.3
Source: ABS 1995 National Health Survey.
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Table D3: Estimated resident female populations, by age, states and territories, June 1999
Age
group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 210,825 149,345 117,830 61,742 46,022 15,373 10,369 8,481 620,101
5–9 217,147 157,607 124,506 64,778 48,311 16,591 10,727 8,378 648,219
10–14 213,517 155,122 122,073 66,783 48,963 17,091 10,794 7,465 641,992
15–19 214,180 157,811 125,527 65,940 49,288 16,951 11,568 7,015 648,380
20–24 218,587 167,569 125,120 67,885 48,428 14,750 13,024 7,837 663,257
25–29 248,403 186,122 136,228 71,363 52,440 16,005 13,157 9,524 733,363
30–34 236,656 181,447 128,549 69,303 53,023 16,123 12,164 8,579 706,004
35–39 254,383 187,302 139,312 74,660 58,441 18,625 12,635 8,055 753,568
40–44 238,135 176,533 130,717 71,804 56,080 17,940 12,380 6,971 710,706
45–49 220,757 164,621 122,514 66,279 53,683 16,750 12,104 6,019 662,831
50–54 198,358 147,675 110,532 56,265 48,969 15,085 10,507 4,711 592,163
55–59 154,145 113,036 82,604 41,983 37,196 11,878 6,866 2,900 450,656
60–64 131,505 96,830 66,557 34,641 32,448 10,136 4,947 1,767 378,852
65–69 121,817 90,079 59,234 30,379 30,570 9,450 4,002 1,178 346,720
70–74 117,014 85,765 55,803 27,180 30,571 8,771 3,655 818 329,585
75–79 100,326 73,381 46,982 22,832 26,932 7,774 3,118 538 281,885
80–84 121,721 89,214 57,646 28,481 33,150 9,534 3,227 592 343,574
Total 3,217,476 2,379,459 1,751,734 922,298 754,515 238,827 155,244 90,828 9,511,856
Source: AIHW Population Database based on estimated resident population data compiled by ABS.
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Table D4: Estimated resident female populations, states and territories, June 2000
Age
group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 212,248 150,048 119,160 61,978 45,470 15,236 10,327 8,521 623,100
5–9 220,812 159,285 126,800 65,717 48,675 16,633 10,858 8,396 657,321
10–14 217,827 157,685 124,667 67,662 49,127 16,792 11,001 7,584 652,475
15–19 214,103 157,159 126,223 66,450 49,724 16,702 11,844 7,147 649,402
20–24 211,077 158,650 121,765 63,301 46,456 14,071 12,778 7,714 635,881
25–29 247,422 184,117 135,753 69,930 51,486 15,541 13,323 9,359 727,009
30–34 240,000 185,289 131,615 70,453 53,291 16,169 12,582 8,816 718,323
35–39 255,711 188,110 140,417 74,799 57,901 18,242 12,852 8,251 756,421
40–44 244,599 180,407 134,766 73,321 57,577 18,175 12,722 7,226 728,900
45–49 224,723 166,671 124,670 68,226 54,103 16,897 12,337 6,405 674,128
50–54 207,920 154,790 116,441 60,200 51,550 15,772 11,315 5,088 623,134
55–59 161,449 117,249 88,394 44,223 39,070 12,350 7,449 3,255 473,483
60–64 137,200 100,964 70,601 36,564 33,626 10,633 5,336 1,900 396,853
65–69 121,266 89,014 59,494 30,663 30,036 9,263 4,102 1,235 345,081
70–74 118,405 86,798 56,363 28,027 30,669 8,777 3,742 853 333,643
75–79 102,665 74,696 48,012 23,354 27,472 7,758 3,225 560 287,744
80–84 68,156 48,613 32,106 15,366 18,064 5,345 1,975 369 190,000
85+ 61,529 46,288 28,770 15,009 16,988 4,673 1,607 286 175,151
Total 3,267,112 2,405,833 1,786,017 935,243 761,285 239,029 159,375 92,965 9,648,049
Source: AIHW Population Database based on estimated resident population data compiled by ABS.
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Table D4: Estimated resident female populations, states and territories, June 2001
Age
group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 213,086 150,321 120,456 61,905 44,962 15,150 10,272 8,594 624,858
5–9 220,990 159,060 127,970 65,655 48,495 16,360 10,824 8,379 657,874
10–14 220,821 159,577 127,233 68,044 48,716 16,771 11,073 7,723 660,094
15–19 218,197 160,653 128,582 68,177 50,536 16,636 12,060 7,173 662,077
20–24 212,719 160,769 123,091 63,913 46,344 13,999 13,122 7,616 641,636
25–29 241,462 178,268 132,503 67,908 49,170 14,721 13,030 9,029 706,171
30–34 248,361 191,148 136,310 72,069 53,575 16,257 12,838 9,047 739,696
35–39 253,112 187,977 139,855 74,293 56,832 17,524 12,849 8,204 750,770
40–44 250,299 184,241 138,896 74,398 58,196 18,437 12,815 7,428 744,821
45–49 227,525 168,515 127,283 69,797 54,391 17,073 12,302 6,543 683,539
50–54 215,107 160,647 121,798 63,711 53,246 16,338 11,817 5,513 648,237
55–59 168,272 122,587 93,692 46,062 41,110 12,818 7,906 3,418 495,911
60–64 140,535 102,654 74,133 37,870 34,124 10,988 5,594 2,111 408,042
65–69 121,568 89,321 60,179 31,244 29,788 9,248 4,265 1,290 346,923
70–74 118,705 86,795 57,118 28,484 30,325 8,740 3,731 918 334,826
75–79 103,805 75,974 48,959 23,787 27,745 7,819 3,320 588 292,000
80–84 72,230 51,628 34,293 16,288 19,239 5,547 2,159 412 201,800
85+ 64,220 48,296 30,155 15,998 17,672 4,899 1,765 307 183,313
Total 3,311,014 2,438,431 1,822,506 949,603 764,466 239,325 161,742 94,293 9,782,588
Source: AIHW Population Database based on estimated resident population data compiled by ABS.
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Appendix E: National Cervical Screening Programs
contact list
New South Wales Western Australia
Ms Jayne Ross Ms Nerida Steel
NSW Cervical Screening Program Acting Program Manager
PO Box 533 Cervical Cancer Prevention Program
WENTWORTHVILLE  NSW  2145 1st Floor, Eastpoint Plaza
Phone: +61 2 9845 8046 233 Adelaide Terrace
Email: jayne_ross@wsahs.nsw.gov.au PERTH  WA  6000
Home page: www.csp.nsw.gov.au Phone: +61 8 9237 6920
Fax:  +61 8 9237 6991
Ms Liz Martin Email: nerida.steel@health.wa.gov.au
Phone: +61 2 9391 9532
Email: limar@doh.health.nsw.gov.au
Mr Hassan Mamoon
Data Manager
Phone: +61 2 9845 8046
Victoria South Australia
Dr Heather Mitchell Ms Sue Gilchrist
Medical Director Program Manager
Victorian Cervical Cytology Registry SA Cervical Screening Program
Email: hmitchel@vcs.org.au 2nd Floor, Norwich Centre
55 King William Road
Mr Rory Wilby NORTH ADELAIDE  SA 5006
Program Manager Phone: +61 8 8226 8182
Prevention & Child Health Fax: +61 8 8226 8190
Dept of Human Services Email: sue.gilchrist@dhs.sa.gov.au
Level 17, 120 Spender Street
MELBOURNE  Vic  3000 Ms Penny Iosifids
Phone: +61 3 9250 0300 Data Manager
Home page: www.dhs.vic.org.au Phone: +61 8 8226 8191
Email: penny.iosifidis@dhs.sa.gov.au
Queensland Tasmania
Ms Jennifer Muller Ms Gail Raw
Program Manager Program Manager
Women’s Cancer Screening Services Dept of Health & Human Services
Queensland Health GPO Box 125B
PO Box 48 HOBART  Tas  7001
BRISBANE Qld  4001
Mr Paul Chandler
Margaret Porter-Doherty Data Manager
Registry Manager Phone: +61 3 6230 7753
Phone: +61 7 3234 1596 Email: paul.chandler@dchs.tas.gov.au
Home page: www.health.qld.gov.au Home page: www.dchs.tas.gov.au
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Australian Capital Territory Northern Territory
Ms Helen Sutherland Ms Gae Allcock
Program Manager Program Manager
ACT Health Coordinator
GPO Box 825 Women’s Cancer Prevention Program
CANBERRA  ACT  2601 Territory Health Services
Phone: +61 2 6205 1540 PO Box 40596
Fax: +61 2 6205 1394 CASUARINA  NT  0810
Email: helen.sutherland@act.gov.au Phone: +61 8 8922 6445
Fax: +61 8 8922 5511
Mr Peter Couvee Email: gae.allcock@nt.gov.au
Registry Coordinator
Phone: +61 2 6205 1955
Fax: +61 2 6205 5035
Email: peter.couvee@act.gov.au
Australian Government Department of Health and Ageing
Population Screening Section
Department of Health and Ageing
GPO Box 9848
CANBERRA  ACT  2601
Fax: 61 2 6289 4021
Home page:  www.cervicalscreen.health.gov.au
Appendix F: NHMRC guidelines for the management of women with screen-
detected abnormalities
This reference sheet is a summary of the NHMRC guidelines for the management of women with screen-detected abnormalities. It is intended to
assist medical practitioners to take appropriate action on receipt of Pap smear reports.
Low-grade epithelial abnormalities
Pap smear report Investigation Management
Non-specific minor squamous cell
changes/atypia
Repeat smear at 12-monthly intervals until it reverts to normal.
Minor changes in endocervical cells/ low-grade
glandular change
Repeat smear in 6 months using cytobrush and spatula. If low-
grade abnormality persists, refer for colposcopy and biopsy if
indicated.
If endocervical cell abnormality confirmed, refer to gynaecologist for
appropriate treatment.
HPV effect/HPV-associated cell changes Repeat smear at 6-monthly intervals. If HPV-associated cell
changes persist after 12 months, refer for colposcopy.
If HPV confirmed, continue with 6 monthly smears until 2 negative
reports are received. Repeat smear annually for 2 years then revert
to 2-yearly screening.
Possible CIN 1  HPV/possible mild dysplasia Repeat smear at 6-monthly intervals until 2 successive negative
reports are received. If lesion persists for 12 months, refer for
colposcopy.
If CIN 1 confirmed, follow either observational or active
management program as explained on reverse of sheet.
CIN 1  HPV/mild dysplasia Refer for colposcopy and biopsy if indicated. If CIN 1 confirmed, follow either observational or active
management program as explained on reverse of sheet. If higher
grade abnormality diagnosed, see below.
High-grade epithelial abnormalities
Pap smear report Investigation Management
CIN 2  HPV/moderate dysplasia Refer for colposcopy and directed biopsy. If CIN 2 confirmed, treatment by gynaecologist with appropriate
expertise is required.
CIN 3  HPV/severe dysplasia Refer for colposcopy and directed biopsy. If CIN 3 confirmed, treatment by gynaecologist with appropriate
expertise is required.
CIN 3  HPV with possible invasion;
Endocervical glandular dysplasia; or
Adenocarcinoma in situ
Refer to gynaecologist with expertise in colposcopic evaluation of
malignancies.
Treatment by gynaecologist with appropriate expertise is required.
Invasive squamous cell carcinoma (SCC) or
Adenocarcinoma
Refer to gynaecologist skilled in the management of malignancies,
or a specialist unit, for urgent evaluation and management.
Treatment by gynaecologist with appropriate expertise is required.
Inconclusive – abnormal cells highly suggestive
but not diagnostic of a high-grade abnormality
Refer for colposcopy and possible biopsy, unless there is an
obvious diagnostic difficulty e.g. epithelial atrophy or infection. In
this case, treat the problem and repeat the smear.
If high-grade lesion confirmed, treatment by gynaecologist with
appropriate expertise is required.
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Management of women with low-grade epithelial abnormalities
A cytological assessment of CIN 1 requires referral for colposcopy and, if indicated, biopsy. There is controversy over the management—observational and active. Both treatment
options should be fully discussed with the woman.
Observational management
If the diagnosis of CIN 1 is confirmed and the woman elects not to be treated, cervical smears should be taken at 6-monthly intervals until the abnormality either regresses or
progresses. After 2 negative smears at 6-monthly intervals, smears should be taken at yearly intervals. If two consecutive annual smears are normal the woman can revert to 2-yearly
screening.
Active management
Treatment by an accepted method, either ablative or excisional.
Pap smear report Management
Negative/within normal limits Repeat smear in 2 years.
Negative/within normal limits and no endocervical cells
present
Repeat smear in 2 years.
Negative with inflammation Repeat smear in 2 years.
Note: Investigate any symptoms that are not readily explained, such as post-coital or intermenstrual bleeding. A negative Pap smear must not be taken as reassurance in these
circumstances. Further investigation may involve referral to a gynaecologist.
Unsatisfactory Repeat smear in 6–12 weeks, with treatment and where possible correction of any problems beforehand if appropriate.
Post-treatment assessment
After initial post-treatment colposcopic assessment by gynaecologist, repeat smear at 6-monthly intervals for 1 year.
Following treatment of a high-grade epithelial abnormality, smears should be repeated yearly thereafter. Following
treatment for a low-grade epithelial abnormality, revert to normal 2-yearly screening after 2 consecutive normal smears at
yearly intervals.
Special circumstances
Total hysterectomy for CIN Annual smears from vaginal vault for 5 years, then revert to 2-yearly smears.
Total hysterectomy for benign causes No further smears required if previous smears were negative. Baseline smear if reason for hysterectomy and/or previous
Pap smear history unknown.
Subtotal hysterectomy for benign causes—cervix
present
Continue normal 2-yearly screening.
Abnormality during pregnancy Refer for colposcopy during 1st trimester to exclude invasive disease. If confirmed high-grade abnormality, repeat
colposcopy during mid-trimester to exclude progression. Lesion should be reassessed 8 weeks post-partum.
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Glossary
Ablative therapy: the destruction of cells on the surface of the cervix using laser therapy,
chemicals or diathermy.
ABS: Australian Bureau of Statistics.
ACT: Australian Capital Territory—a land-locked territory of Australia situated within the
state of New South Wales on the eastern seaboard with a population of 319,317 (2001). Its
capital city is Canberra, which is also Australia’s capital city.
Adeno-squamous: a mix of adenocarcinoma and squamous cells in the same sample.
Adenocarcinoma: a cancer formed from the cells of a gland.
Adjuvant: enhancing or administered to enhance the effectiveness of a treatment or
substance.
AHMAC: Australian Health Ministers’ Advisory Council.
AIHW: Australian Institute of Health and Welfare.
ASGC: Australian Standard Geographical Classification: the classification designed by the
ABS to define the geography of Australia.
AS rate: age-standardised rate
Atypia: the condition of being irregular.
Basement membrane: the delicate, non-cellular layer on which an epithelium is seated. The
epithelium forms the surface portion of the skin and lines hollow organs and all passages of
the respiratory, digestive and genito-urinary systems.
Benign: not malignant.
Cancer (malignant neoplasm): a term used to describe one of several diseases which result
when the process of cell division, by which tissues normally grow and renew themselves,
becomes uncontrolled and leads to the development of malignant cells. These cancer cells
multiply in an uncoordinated way, independently of normal growth control mechanisms, to
form a tumour. This tumour may expand locally by invasion or systemically by metastasis
via the lymphatic or vascular systems. If left untreated, most malignant tumours will
eventually result in death.
Cancer death: a death where the underlying cause is indicated as cancer. Persons with cancer
who die of other causes are not counted in the death statistics in this publication.
CIN (cervical intraepithelial neoplasia): squamous cell carcinoma of the cervix is mostly
preceded, over a period of years, by a spectrum of asymptomatic abnormalities known as
cervical intraepithelial neoplasia (CIN) graded as CIN I (mild dysplasia), CIN II (moderate
dysplasia) and CIN III (severe dysplasia and carcinoma-in-situ). CIN usually occurs at least a
decade before cervical cancer. If CIN remains untreated, some women will develop cervical
cancer and others will progress to invasive cervical cancer, despite treatment (AIHW: Jelfs
1995).
Cone biopsy: biopsy in which an inverted cone of tissue is excised, as from the uterine
cervix.
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Colposcopy: an examination of the lower genital tract with a magnifying instrument called a
colposcope. This method of conservative evaluation allows the clinician to more accurately
assess the cytologic abnormality by focusing on the areas of greatest cellular abnormality and
by sampling them with a punch biopsy to attain diagnosis.
Cryosurgery: the destruction of tissue using extreme cold.
Dysplasia: abnormal cell growth.
Endocervical: the inside of the uterine cervix or the mucous membrane lining of the cervix.
Epidemiology: the quantitative study of the distribution and determinants of health-related
states and events in populations, and the application of this study to the control of health
problems.
Epithelium: the covering of internal and external surfaces of the body, including the lining of
vessels and other small cavities. It consists of cells joined by small amounts of cementing
substances. It is classified into types on the basis of the number of layers deep and the shape
of the superficial cells.
Exfoliate: to break away or remove.
HGA: high-grade abnormalities as defined for this report include CIN 12, CIN 2, CIN 3 or
adenocarcinoma-in-situ.
Histology: the microscopic study of the minute structure and composition of tissues.
Hysterectomy: refers to the surgical procedure whereby all or part of the uterus is removed.
Hysterectomy fractions: the proportion of women who have had their uterus removed by
hysterectomy.
HPV: Human papilloma virus.
ICD-10: International Classification of Disease—a coding system used to identify the primary
site of the malignancy. This classification is in its tenth revision.
Incidence: see new cancer case
Intraepithelial: the area within the layer of cell tissues forming the epidermis of a body
cavity. These cells comprise contiguous cells having minimum intercellular substance.
Invasive cancer: a tumour whose cells have a tendency to invade healthy or normal tissues.
LGA: low-grade abnormalities include atypia, warty atypia (human papilloma virus (HPV)
effect), possible CIN, equivocal CIN, CIN 1 or endocervical dysplasia not otherwise specified
(NOS).
Lymph node: masses of lymphatic tissue, often bean-shaped, that produce lymphocytes and
through which lymph filters. These are located throughout the body.
Malignant: abnormal changes consistent with cancer.
Metastasis: the process by which a disease is transferred from one part of the body to
another, for example via the lymphatic system or the bloodstream.
Mortality: see cancer death.
Neoplasia: the process by which tumours are formed.
New cancer case: a person who has a new cancer diagnosed for the first time. One person
may have more than one cancer and therefore may be counted twice in incidence statistics if
it is decided that the two cancers are not of the same origin. This decision is based on a series
of principles set out in more detail in a publication by Jensen et al. (1991).
NOS: not otherwise specified.
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NSW: New South Wales—a state of Australia on the eastern seaboard which has the largest
state capital city in Australia, Sydney, and a population of 6,575,217 (2001).
NT: Northern Territory—a territory in the north of Australia with a population of 197,768
(2001) and Darwin as its capital city.
Pap smear: a test prepared for the study of exfoliated cells from the cervix (refer to
Appendix A).
Post-partum: following childbirth.
Qld: Queensland—a state in the north-east of Australia with a population of 3,628,946 (2001)
and Brisbane as its capital city.
Radiation therapy: the treatment of disease with any type of radiation, most commonly with
ionising radiation, such as X-rays, beta rays and gamma rays.
RRMA: Rural, Remote and Metropolitan Areas Classification.
SA: South Australia—a state in the southern part of Australia with a population of 1,511,728
(2001) and Adelaide as its capital city.
Screening: the performance of tests on apparently well people in order to detect a medical
condition at an earlier stage than would otherwise be the case.
Sensitivity: the proportion of individuals with the disease whom the screening test labels
positive.
Squamous malignancy: Cervical cancer can be derived from several cells types. One of these
cell types is the squamous cell and most cervical cancers are derived from this cell type.
Stroma: the supporting framework of an organ.
Tas: Tasmania—an island state in the south-east of Australia with a population of 471,795
(2001) and Hobart as its capital city.
The Institute: The Australian Institute of Health and Welfare.
Vic: Victoria—a state in the south-east of Australia with a population of 4,804,726 (2001) and
Melbourne as its capital city.
WA: Western Australia—the largest state in Australia, located in the west with a population
of 1,901,159 (2001) and Perth as its capital city.
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